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ABSTRACT 
The global incidence of bone fractures, and subsequently that of non-healing ones, is 
expected to rise in the coming decades, mostly due to an increased risk of age-related 
conditions. Currently, the biomaterials field is moving towards the design of scaffolds 
mimicking the cell microenvironment to guide stem cells differentiation and recapitulate 
the development of target tissues. Biomimicry is a wide concept and several approaches 
have been adopted to produce cell-instructive scaffolds. Herein, we have explored the use 
of citric acid and lysyl oxidase, both of them related to bone nanostructure and mechanical 
performance, to develop scaffolds resembling the extracellular matrix of developing bone. 
First, elastin-like recombinamers (ELRs) hydrogels were achieved through a one-step 
chemical crosslinking reaction with citric acid, a molecule currently considered to be 
essential for the proper performance of bone tissue. By systematically studying the 
crosslinking reaction and its contribution to hydrogel properties, we were able to control 
the architecture and stiffness of citric acid-crosslinked hydrogels while preserving the 
integrity of adhesion sequences in ELRs. Interestingly, the use of citric acid conferred so-
produced hydrogels the ability to nucleate calcium phosphate.  
Mechanically-tailored citric acid-crosslinked hydrogels were shown to be able to support 
the growth of human mesenchymal stem cells and to lead to seemingly biocompatible 
degradation products. Despite in vitro differentiation studies weren’t conclusive as to their 
osteogenic potential, both mechanically-tailored and non-tailored citric acid-crosslinked 
hydrogels were shown to integrate into bone and to be partially degraded upon 
implantation in critical size defects in mouse calvaria. Even though cell invasion in 
mechanically-tailored scaffolds was seemingly lower than in non-tailored counterparts, 
both types of matrices allowed the formation of bone tissue, by intramembranous 
ossification, to a similar extent by the end of the study. At the time points selected for the 
in vivo study, both tailored and non-tailored hydrogels were found to be osteoconductive; 
osteoinduction was not observed in any of the cases. Mechanically-tailored hydrogels not 
being seemingly superior to control matrices at selected time points could to be due to (i) a 
high surface polymer density hindering cell invasion and thus delaying osteoinduction, or 
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to (ii) a non-osteoinductive combination of properties (chemical + physical) despite 
hydrogels possessing theoretically osteoinductive stiffness. These results point out that 
scaffolds must be seen as a whole given the high complexity of the in vivo cell niche, 
whose signals act synergistically to define cell behavior. Thus, more complex designs are 
required if recapitulation of bone development is to be targeted.  
Additionally, recombinant lysyl oxidase (LOX) from human aorta was successfully 
produced in Escherichia coli to high purity. Despite achieving LOX with copper cofactor 
amounts and activity higher than those found in the literature, overall activity was low and 
the insolubilization of ELRs was not achieved, suggesting that novel expression and 
purification systems not compromising enzymatic activity are required if LOX is to be 
used to produce scaffolds.  
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1.1  BONE: AN OVERVIEW 
1.1.1 The skeletal system 
The skeletal system, the framework of vertebrates, consists of 206 bones orchestrated to 
shape our body and protect our valuable, delicate internal organs. Bones have been long 
known for being the primary source of hematopoietic cells and a reservoir of salts to 
maintain systemic mineral homeostasis. Furthermore, recent discoveries have shown that 
bones act also as a source of endocrine hormones regulating metabolic homeostasis [1], 
pointing out that the skeletal system is an essential complex and multifunctional player in 
assuring systemic wellbeing.  
 
Figure 1. Classification of bones. Bones can be classified on the basis of their a) function, b) 
developmental origin, and c) mode of osteogenesis.  
The 206 human bones can be classified on the basis of their function, ontogenic origin, 
mode of osteogenesis and shape. From a functional point of view, the skeleton can be 
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divided into i) the axial part (skull and trunk), which supports and protects organs in the 
ventral and dorsal cavities and provides surface for muscle attachment and, ii) the 
appendicular part (upper and lower limbs), which allows movement (Figure 1a). From a 
developmental point of view, bones come from three different embryonic origins: the 
paraxial mesoderm (axial skeleton except for craniofacial bones), the lateral plate 
mesoderm (appendicular skeleton) and the ectodermal neural crest (craniofacial bones) [2] 
(Figure 1b). From a mode-of-osteogenesis point of view, bones can be divided into those 
formed by intramembranous ossification (i.e. direct bone formation; facial bones, 
mandibles, flat bones of the skull and clavicles) and those arising by endochondral 
ossification (i.e. bone formation through a transient cartilage template) [3] (Figure 1c). 
Finally, under a shape criterion, bones can be classified into those being i) long 
(length>width; e.g. femur), ii) short (length≈width; e.g. carpal bones), iii) flat (plate-like; 
e.g. calvaria) and iv) irregular (shape not fitting none of the above; e.g. vertebrae) [3]. 
1.1.2 Bone composition 
Bone is made up of cells, nerves, blood vessels and matrix, with the latter representing ca. 
the 90% of the total weight of the tissue. Bone matrix is a composite material comprising 
both organic (ca. 20% in weight) and inorganic (ca. 65% in weight) fractions that 
contribute to its exceptional mechanical behavior [4].  
The organic matrix provides flexibility, thus making the tissue able to withstand tension. It 
is composed of collagens (90% of the organic matrix), mainly type I, although small 
amounts of other types are also present. The additional 10% is due to non-collagenous 
proteins, proteoglycans (i.e. highly glycosylated proteins), glycoproteins, citric acid, and 
growth factors to a lesser extent [4–6]. The organic matrix represents the trails that guide 
the deposition of the inorganic matrix, responsible for bone’s resistance to compression. 
The inorganic matrix, commonly known as mineral phase, is also an ion reservoir for 
mineral homeostasis, containing approximately the 99% of the calcium, the 85% of the 
phosphorous, and the 40-60% of the sodium and magnesium in the human body [4].  
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1.1.3 Bone hierarchy: from macro to nano 
1.1.3.1 Bone macrostructure 
Prior to going through bone’s hierarchical organization, let’s briefly review the anatomy of 
a long bone. A long bone such as the femur can be divided into 3 anatomical parts: 
diaphysis (shaft), metaphysis and epiphysis (Figure 2a). The diaphysis, the shaft of a long 
bone is a sheath that protects the medullary cavity filled with fat (yellow bone marrow). 
Bone extends proximally and distally and eventually flattens and expands (metaphyses) to 
both ends (epiphyses).   
 
Figure 2. Anatomy of long bones. a) Structure of the femur as a model for long bones with 
detailed anatomical sites and parts; from [7]. b) Radiographic image of a human radius showing 
the distribution of  the volumetric percentages of compact and trabecular bones in sections from 
different anatomical sites; adapted from [8]. 
All the human bones contain two distinctly arranged forms of bony tissue: trabecular 
(cancellous or spongy) and compact (or cortical). Trabecular bone, a mesh of rod and 
plate-like struts found in the inside of bones, is a low-density tissue with 50-90% of its 
volume being pores [4] which accommodate blood vessels and the marrow, the primary 
post-natal site of hematopoiesis. In contrast, compact bone is a dense tissue with ca. 10% 
porosity found in the outer shell of bones that represents ca. the 80% of bony tissue, thus 
actively contributing to the load-bearing role of the skeleton [9]. In one particular bone, 
the proportion of trabecular and compact tissues varies among anatomical sites. While the 
diaphysis contains a thick layer of cortical bone and little amount of cancellous tissue, the 
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compact-to-trabecular ratio decreases distally and proximally (Figure 2b), with the 
metaphyses and diaphyses containing most of the cancellous bone and being filled with 
hematopoietic cells (red bone marrow). The proportion of both types of bone varies not 
only among bones and anatomical sites [8,10], but also among patients with different 
gender [11] or age [8]. Despite these particular differences, the organization of cortical and 
trabecular bony tissues at the microscale is a common trait to all bones. 
1.1.3.2 Bone microstructure 
The basic structural unit of mature cortical bone (i.e. lamellar bone) is the osteon, a 
cylindrical system consisting of concentric plate-like portions of bone matrix (concentric 
lamellae) with a central canal (Haversian canal) that contains blood vessels and nerves 
(Figure 3a). Lamellae consist of densely packed oriented collagen fibers surrounding 
matrix-free spaces (lacunae) containing embedded osteocytes (See section 1.1.4.1) with 
branched and elongated cell processes extending radially along canaliculi. These cell 
processes connect osteocytes to Haversian canals, the primary source of nutrients for 
osteocytes [4], but also to each other and to osteoprogenitors located in bone surfaces 
(lacuno-canalicular network) [12]. Osteocyte-to-osteocyte connections run even through 
adjacent concentric lamellae, whose collagen fibers display displaced orientation, an 
organization often considered to resemble that of plywood. Osteons are delimited by 
cement lines (5-μm thick mineralized boundaries [9]) and are often separated one from 
each other by remnants of old osteons, the so-called interstitial lamellae, and confined 
between circumferential lamellae, which demarcate the inner (inner circumferential 
lamellae) and outer (outer circumferential lamellae) perimeters of cortical bone.   
Outwardly, compact bone is covered by articular cartilage (hyaline cartilage) in those 
regions where the bone articulates with another one (Figure 3b), and wrapped in 
periosteum elsewhere. The periosteum comprises an inner layer containing 
osteoprogenitors and a fibrous outer layer, both of them containing collagen fibers running 
parallel to bone surface except in those regions where ligaments and tendons attach to 
bone, where fibers extend to compact bone (perforating or Sharpey’s fibers) [3]. The 
periosteum also contains blood vessels that penetrate bone and branch to nourish osteons 
and connect them through the so-called Volkmann’s (or perforating) canals, which run 
transversally to the longitudinal axis of osteons. This vascular system ensures no cell is 
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 Figure 3. Microscopic anatomy of compact and trabecular bone.  a) Detailed anatomy of a section from a long bone diaphysis; from [552]. b) 
Simplified anatomy of a diaphysis showing the particular outermost envelope in articulations; from [553]. c) Microstructure of trabecular bone; from 
[552]. 
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more than 300 μm away from a blood vessel [4]. 
Internally, compact bone is surrounded by the endosteum (it thus covers Haversian and 
Volkmann’s canals [3]), which is often one cell layer thick and comprises 
osteoprogenitors and bone-lining cells (See section 1.1.4.1). The endosteum also covers 
cancellous bone, whose structural unit is the hemiosteon (or bone packet), a crescent-
shaped structure that results from the partial resorption of osteons, but lacking the central 
canal (Figure 3c). The high porosity of trabecular bone provides a high surface area for 
bone to be in contact with blood vessels [9], an important fact for mineral homeostasis.  
1.1.3.3 Bone nanostructure 
Collagen fibers making up osteons and hemiosteons mainly comprise organized oriented 
collagen fibrils with interspersed mineral crystals (Figure 4a), although mineralization-
related molecules such as non-collagenous proteins [13] and citric acid [6] may be present 
to a lesser extent. The basic unit of collagen in bone is heterotrimeric tropocollagen (or 
collagen molecule), the assemblage of two type I collagen α1 chains and one α2 chain in 
the form of a triple helix about 300 nm long and 1.5 nm thick [5] (Figure 4b). Collagen 
molecules arrange laterally and longitudinally in a staggered manner [14], with 
longitudinally neighboring molecules shifted by ca. 40 nm (gap region) [15]. This shift 
gives microfibrils, which comprise 5 tropocollagen units with quasi-hexagonal 
arrangement [16], their particular pattern when stained with metal ions: alternating dark 
(overlap regions) and light (gap regions) bands, which together make up the 67 nm so-
called D period. Microfibrils have been suggested to interdigitate to give rise to fibrils 
[17], which would possess transverse channels (gap channels) deriving from the alignment 
of gap zones in neighboring microfibrils [18]; fibrils (ca. 0.5-mm diameter) further pack to 
make up fibers of ca. 5-mm diameter [19]. The detailed collagen hierarchy has been 
mainly derived from studies using turkey tendon which, although probably possessing a 
nanostructure slightly differing from that of bone, is studied as a model for the 
biomineralization of type I collagen in mineralizing tissues.  
The mineral fraction in bone is accepted to be made of carbonated hydroxyapatite 
(commonly termed hydroxyapatite; HA) crystals [4]. These crystals possess a plate-shaped 
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Figure 4. Nanostructure of bone tissue. a) Hierarchical bone organization, from the macro to 
the nanoscale; from [20]. b) Hierarchical structure of type I collagen fibrils depicting the 
staggered arrangement of tropocollagen to give rise to its characteristic D period; from [5]. c-e) 
Detailed schemes of staggered collagen molecules with hydroxyapatite plate-like crystals filling 
gap regions and intermolecular spaces; c-d from [5]; e from [21]. f) Scheme of bonds stabilizing 
the bone nanocomposite. Collagen molecules (green helices) are linked to each other through 
lysyl oxidase-catalyzed crosslinks (black and red bars). Water (blue lines) is located in between 
crystals and collagen molecules, which bind to each other through salt bridges and hydrogen 
bonds (yellow dots); from [5]. 
morphology and are about 5 nm thick, 30 nm wide and 50 nm long, although they can 
eventually grow up to few hundreds of nanometers in length [21]. Hydroxyapatite crystals 
have been found to run parallel to collagen, with their long crystallographic axis (or c-
axis) extending along the longitudinal axis of collagen molecules. Hydroxyapatite is 
considered to nucleate and grow within collagen fibers with the gap region (and 
subsequently, gap channels) being the primary site of mineral deposition (Figure 4c) 
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although it seems to occur also in the overlap region as well as in the intermolecular and 
extrafibrillar spaces [20] (Figure 4 d and e).  
Type I collagen has been long considered to be inert during biomineralization but, despite 
the underlying mechanism is yet to be resolved, some evidences have pointed out that 
collagen would play an important role in its own mineralization. The study of the amino 
acid sequence and 3D spatial arrangement of the collagen triple helix has led to finding 
regions with accumulation of either positively or negatively-charged residues (or the 
mixture of both) in the gap region that could accommodate Ca2+ and PO43- ions and thus 
serve as nucleation points. These charged regions are known to possess structural 
flexibility, which would allow for nucleation and crystal growth to occur [22]. Thus, 
factors affecting collagen chemistry and/or structure, such as genetic abnormalities [23] 
and enzymatic [24] and non-enzymatic crosslinking [5], are likely to alter mineralization 
and subsequently the mechanical properties of the tissue.  
Collagen fibers result from the dense packing of its hierarchical constituents. Although the 
processes ruling their mineralization remain unsolved, studies are slowly shedding light on 
how this may actually take place. Initially, calcium phosphate with unclear origin would 
precipitate in the form of amorphous calcium phosphate (ACP), which would then 
penetrate the collagen structure and transform into hydroxyapatite. The infiltration of ACP 
into collagen seems, at least partially, to be driven by the coordinated action of non-
collagenous proteins (NCPs) such as dentin phosphophorin, dentin matrix protein 1 and 
fetuin, which would mediate the surface and intrafibrillar deposition of ACP [13]. Despite 
the mechanisms underlying ACP maturation into HA remain elusive, recent evidences 
point out that it could be controlled and terminated by citric acid [6] in concert with NCPs 
[25] to achieve a mechanically optimum crystal size [26]. The collagen-HA 
nanocomposite is further mechanically optimized by lysyl oxidase-catalyzed crosslinking 
[24] and mineral-organic matrix salt bridges and hydrogen bonds [20] (Figure 4f), laying 
the groundwork for an exquisitely optimized tissue. 
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1.1.4 Cell types in bone 
 
Figure 5. Cell types in bone. Cells in bone arise from two types of stem cells, which determines 
their fate as bone-forming (MSCs-derived lineage) or bone-resorbing (HSCs-derived lineage) 
cells. Cells are depicted with a differentiation degree increasing from right to left; from [3].  
Bone is accepted to contain five main cell types from two different lineages (Figure 5). On 
one hand, osteoprogenitors, osteoblasts, osteocytes and bone-lining cells belong to the 
osteoblastic lineage [4] and represent particular differentiation stages from common 
precursors, mesenchymal stem cells (MSCs; section 1.1.5). On the other hand, osteoclasts 
belong to the hematopoetic lineage [4], deriving from hematopoietic stem cells (HSCs). 
Interestingly, the osteoblastic and hematopoietic lineages are related to bone formation 
and resorption, respectively, two processes spatially and temporally related and potentially 
cross-regulated (See section 1.1.8). Below, a brief description of bone cells is provided; 
specific cellular activities will be presented in detail in section 1.1.8. 
1.1.4.1 Osteoblastic lineage: towards bone formation 
The most primitive of the abovementioned cell types are osteoprogenitors. 
Osteoprogenitors arise from the osteogenic commitment of MSCs and are resting cells that 
reside in the internal and external surfaces in bone (i.e. periosteum and endosteum, 
including those regions surrounding Haversian and Volkmann’s canals) [3]. When 
stimulated, osteoprogenitors differentiate towards pre-osteoblasts, proliferative cells that 
start expressing genes responsible for extracellular matrix production [27]. Pre-osteoblasts 
further differentiate to become osteoblasts (they can probably also arise from pericytes 
[28]), which are commonly found lining bone surfaces [4]. Osteoblasts actively synthetize 
and deposit osteoid (i.e. unmineralized bone matrix) and probably induce and control its 
mineralization by secreting calcium phosphate vesicles, the so-called matrix vesicles [29], 
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non-collagenous proteins [30,31] and citric acid [32]. At the end of the matrix deposition 
and mineralization stage, most osteoblasts undergo apoptosis [33] and those having 
survived can turn into osteocytes or bone-lining cells (also known as resting osteoblasts). 
Bone-lining cells are located on the surface of quiescent bone, covering a ca. 2 μm-thick 
osteoid layer on top of the mineralized matrix [34]. These cells are thought to help create 
an isolated space for resorption to occur [35], to play a role in regulating the mineral influx 
and efflux between bone and the extracellular fluid, and to redifferentiate to secreting 
osteoblasts upon proper stimulation [36]. 
Osteocytes are terminally differentiated osteoblasts entombed in the bone matrix and the 
most abundant cell type in bone, representing up to the 90% of cells in the tissue [4]. They 
are accepted to act as mechanosensors, translating mechanical disturbances in the tissue 
after loading into biochemical changes signaling the need for bone formation or resorption 
[37,38]. Additionally, they seem to play a role (i) in the release of calcium during 
lactation, having the apparent ability to mobilize (i.e. osteocytic osteolysis) and replace 
mineral in the perilacunar and canalicular spaces [39] and (ii) in regulating the function of 
the rest of bone cell types [40].  
1.1.4.2 Hematopoietic lineage: towards bone resorption 
Osteoclasts are multinucleated cells that arise from the fusion of 3-12 circulating or 
marrow-derived mononuclear osteoclast progenitors [34]. Although osteoclasts have been 
long known as the specialized bone-resorbing cells contributing to bone’s capacity to be 
remodeled in response to mechanical loading, their active role seems to be above and 
beyond degrading the tissue. Evidences point out that osteoclasts might regulate the 
proliferation and differentiation of osteoprogenitors and thus the coupling of bone 
resorption and formation, contribute to HSCs mobilization, and play a role in regulating 
the activity of CD8+ T lymphocytes, responsible for the destruction of tumor cells [41], 
and collectively suggest that osteoclasts are potential regulators of the bone 
microenvironment.  
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1.1.5 Mesenchymal stem cells 
Stem cells are unspecialized entities with the capacity of self-renewal for long periods of 
time and able to give rise to a given number of tissue-specific cell types, which defines 
their potency (i.e. degree of commitment). On the basis of their potency, stem cells can be 
classified, from more to less committed, into uni, oligo, multi, pluri and totipotent, with 
multi and pluripotent stem cells being the center of stem cells research due to their 
potential in the treatment of human conditions, defects or injuries. Pluripotent stem cells 
are those able to differentiate into cell types from any of the three germ layers (e.g. 
embryonic stem cells; ESCs), while multipotent stem cells are able to turn into a limited 
number of cell types, often exclusively from one germ layer. Although much research 
focused on ESCs and iPSCs (induced pluripotent stem cells) has been and is actually being 
carried out, their clinical application is still hindered by their known tendency to induce 
the formation of teratomas and teratocarcinomas in vivo [42,43]. In contrast, multipotent 
stem cells are already being included in clinical setups. Examples of multipotent stem cells 
currently used in the clinics are HSCs, used to treat leukemia, and MSCs, included in 
clinical trials targeting the repair of a variety of tissues [44].  
MSCs are adherent spindle-shaped cells first termed colony-forming unit fibroblasts 
(CFU-Fs) given their capacity to generate clonogenic colonies [45]. These cells are known 
to be “capable of bone formation” [45] and  of undergoing adipogenic and chrondrogenic 
differentiation in vitro [46]. This feature has long characterized them so much so that the 
International Society for Cellular Therapy (ISCT) stablished the trilineage differentiation 
capacity, along with adherence to plastic and the expression of given surface antigens, as a 
minimum criterion for a cell to be considered a MSC [47]. The term “Mesenchymal stem 
cells” was coined given their capacity to give rise to connective tissues [48], which arise 
from the mesoderm-derived embryonic tissue mesenchyme. However, studies published in 
the last decade have shown MSCs to be able to differentiate into cell types such as 
astrocytes, neurons and oligodendrocytes [49,50], hepatocytes [51], cardiomyocytes [52] 
and insulin-producing cells [53]. In other words, MSCs’ differentiation potential seems to 
be beyond the endoderm, extending to all three germ layers. Whether this phenomenon is 
due to MSCs being (i) pluripotent, (ii) a heterogenic population regarding differentiation 
potential and /or (iii) able to transdifferentiate [54] is still a riddle. 
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Although MSCs have been classically considered to arise from the endoderm (and thus, 
they would reside in endoderm-derived tissues), experimental evidences suggest they may 
derive from multiple developmental origins [55]. These cells were first isolated from bone 
marrow [45], lately reported from adipose tissue [56] and a myriad of fetal [57] and post-
natal tissues [58,59], and now considered to reside in all the adult tissues [58]. However, 
differences regarding proliferation, differentiation potential, proteome and the expression 
of surface markers have been noticed when comparing MSCs isolated from different 
tissues [44,55,58]. This may well mean that the tissue of origin imprints some specific 
features such as a preferential cell fate [60,61] or that different populations exist in single 
preparations from  a specific source [62–64]. The latter seems more likely given the recent 
description of MAPCs (Multipotent adult progenitor cells) [65,66], MIAMI (Marrow-
isolated adult multilineage inducible) cells [67], USSCs (Unrestricted somatic stem cells) 
[68] and MASCs (Multipotent adult stem cells) [69] (sub)populations in MSCs 
preparations. These (sub)populations (i) may be a result of the surface markers criterion 
imposed by the ISCT being not restrictive enough to generate pure MSCs preparations or 
(ii) may be artifacts [70] derived from culture-induced genetic and epigenetic alterations 
[61]. How these (sub)populations are related to MSCs is still a mystery, and so it is the 
anatomical location of the latter. In this respect, evidences on their widespread distribution 
in adult tissues have led to suggesting that a ubiquitous source of MSCs would exist. 
Pericytes (or mural cells), perivascular cells that wrap microvessels and capillaries, have 
been suggested to be primitive precursors for MSCs. These cells have been shown to 
possess clonogenic potential and to express cell markers characteristic to MSCs in vitro 
and to generate bone, cartilage and adipose tissue phenotypes both in vitro and in vivo 
[28,55,58,59]. Recent evidences, though, point out that pericytes wouldn’t be the only 
precursor for MSCs, which may also derive from adventitial cells (i.e. cells found in the 
tunica adventitia, the outermost layer of larger vessels). Adventitial cells have been 
isolated from several tissues and found to be clonogenic, to differentiate into osteoblasts, 
adipocytes and chondrocytes in vitro, and to express MSCs markers in vivo [71]. 
Together, recent advances on the biology of pericytes and adventitial cells, collectively 
termed PSCs (Perivascular stem cells), have led to suggesting the perivascular space as the 
in vivo MSC niche and the source of “multipotent” cells for local tissue repair [55]. 
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MSCs are known to support the hematopoietic niche [72], to mobilize to sites of 
inflammation after injury [73] after the local release of chemokines [74], and to secrete 
trophic factors (cytokines and growth factors) that exert a vast number of paracrine effects 
[75–77]. Thanks to their microenvironment-induced secretory behavior, MSCs are capable 
of promoting immunomodulation [78,79], the protection of injured tissues from 
autoimmunity [80], and the recruitment of vascular cells [75] and progenitors [81] to the 
site of injury, among others. Together with the capacity to differentiate into several cell 
types, these functionalities point MSCs as a central population contributing both directly 
and indirectly to creating a regenerative microenvironment to achieve tissue repair. The 
use of MSCs in clinical trials has gained momentum lately thanks to their pro-regenerative 
profile and demonstrated therapeutic safety [82], which have led them to being included in 
studies targeting a wide spectrum of conditions [44,83,84].  
1.1.6 Bone formation 
As introduced in section 1.1.1, bones are formed by two modes of osteogenesis: 
intramembranous and endochondral. Although many details about intramembranous 
ossification are yet to be deciphered, it is known that it consists in the direct formation of 
bone. In this mode of osteogenesis, MSCs would aggregate in the form of preosteogenic 
condensations that would grow and would be invaded by blood vessels. The vascular 
invasion would lead to a proper microenvironment for ossification in the condensation 
core (i.e. ossification center), where cells would undergo osteogenic differentiation, 
secrete osteoid and get embedded in the matrix, thus reaching terminal differentiation (i.e. 
becoming osteocytes). The local secretion of osteoid would lead to the emergence of bone 
spicules (i.e. local aggregates of osteoid). Further mesenchymal cells would differentiate 
into osteoprogenitors that would secrete more osteoid, leading to the enlargement and 
occasional fusion of spicules (and thus to the emergence of trabeculae) by appositional 
growth [3,85], giving rise to trabecular bone. Intramembranous ossification not only takes 
place during embryonic development, but also during fracture repair.  
In contrast, endochondral ossification is more complex and well described, involving the 
formation of bone from a temporal cartilaginous framework. It starts with the emergence 
 INTRODUCTION  
16 
 
of prechondrogenic mesenchymal condensations at the site of skeletogenesis. Cells in the 
core of condensations proliferate and differentiate in an avascular microenvironment and 
start depositing cartilage matrix rich in type II collagen, giving rise to the cartilaginous 
anlage, a hyaline cartilage model that serves as a template for ossification (Figure 6a). 
Hyaline cartilage is covered by the perichondrium, a sheath of connective tissue and a 
source of osteo and chondroprogenitors [86], with the latter widening the anlage by 
deposition of further matrix (i.e. appositional growth) [3]. Additionally, chondrocytes in 
the inside of the anlage (i.e. interstitial growth) proliferate in a perichondrium-controlled 
fashion. When the anlage achieves a critical size, chondrocytes in the shaft stop 
proliferating, undergo hypertrophy, degrade the type II collagen-rich matrix, secrete 
matrix rich in type X collagen and trigger its mineralization (Figure 6b) [3,86]. 
Concurrently, cells near the ends of the anlage keep proliferating, thus enlarging it 
longitudinally; perichondrial cells close to hypertrophic chondrocytes undergo osteogenic 
differentiation giving rise to the intramembranous formation of a cortical sheath, the 
periosteum, around the diaphyseal region of the developing bone. Mineralized matrix 
deprives hypertrophic chondrocytes of nutrients and they start dying, leaving cavities in 
the matrix. Blood vessels then penetrate the developing bone through the periosteum, 
stablishing the primary ossification center, reaching the cavities and allowing osteoclasts 
to reach the hypertrophy region, where they erode the mineralized cartilage. Osteoblasts 
arrive at the erosion place and start depositing osteoid onto remnants of mineralized 
cartilage and trabeculae are formed (Figure 6c) [87]. As the primary ossification center 
expands distally and proximally, a primitive medullary cavity is created (deposited 
trabecular bone is partially resorbed), extending to both metaphyseal regions (Figure 6d). 
Cartilage keeps growing in the epiphyseal ends and blood vessels eventually penetrate the 
developing epiphyses, leading to the development of the secondary ossification centers, in 
which the cartilage-bone transition proceeds as previously stated, except for trabecular 
bone, which in this case is not resorbed (Figure 6e). At this point, cartilage has not been 
totally replaced by bone; two cartilaginous regions remain: i) the articular cartilage at the 
very end of epiphyses, meant to reduce friction in articulations, and ii) the growth (or 
epiphyseal) plate, a template for the post-natal longitudinal growth of bone located 
between the primary and secondary ossification centers (Figure 6f). 
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Figure 6. Endochondral ossification of a long bone. a-f) Detail on the stages of the cartilaginous anlage-to-bone transition. g) Scheme of depicting the 
different functional regions making up the epiphyseal growth plate. Adapted from [88]. 
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The growth plate recapitulates the events taking place during the development of 
ossification centers and can be divided into five different functional zones (Figure 6g). 
The most proximal is the reserve zone, a region characterized by the presence of quiescent 
chondrocytes. The former is followed by the proliferative zone, where chondrocytes in 
column-like arrangements actively proliferate and secrete matrix. Distal to the 
proliferative zone, the maturation and hypertrophy zone contains enlarged and 
metabolically active chondrocytes that secrete matrix and start mineralizing it. The next 
region is the zone of calcified cartilage, where chondrocytes undergo apoptosis due to 
nutrient deprivation. In the most distal end of the growth plate (i.e. the zone of 
ossification), invasion of blood vessels, osteoclastic resorption and bone deposition occur 
[3,88]. The growth plate remains active until skeletal maturity is achieved, when the 
production of new cartilage ceases and the diaphyseal and epiphyseal medullary cavities 
converge; the only remnant of the growth plate is then a bony layer known as epiphyseal 
line [3]. At this point, the only cartilage remaining in bones is articular cartilage. 
Regardless of the mode of ossification, the tissue is initially laid down in the form of 
immature (or woven) bone, which makes up the embryonic skeleton and those regions 
undergoing fracture repair [4]. Woven bone, characterized by a haphazard collagen 
distribution, irregular mineralization and high cellularity [4], is rapidly deposited and 
mineralized. Due to the random distribution of its collagen fibers, it is considered to 
possess poor mechanical properties [89], which denotes it is a temporal tissue (otherwise, 
the skeleton couldn’t fulfill its structural function). Indeed, woven bone is replaced with 
mature (or lamellar) bone - which is slowly laid down and more organized, and contains a 
lower number of osteocytes per unit volume [4] (more details on the structure of mature 
cortical and trabecular bone can be found in section 1.1.3.2) - in a process known as bone 
remodeling (see section 1.1.8). The speed at which lamellar bone is laid down is so low 
that a temporal tissue is required for the bone growth rate to be consistent with the growth 
rate of the animal/individual; woven bone is thus slowly converted to lamellar bone to 
finally meet the mechanical requirements of the tissue [89]. 
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1.1.7 Bone modeling: growth and mechanical adaption 
Bone is a highly dynamic tissue that senses and adapts to the mechanical requirements of 
the organism. The mechanism by which this adaptation takes place is called bone 
modeling [90] and it always occurs on preexisting bone on the periosteal, endocortical and 
trabecular surfaces; it is generally meant to increase bone mass and to shape bones (i.e. 
changing their geometry) mainly during childhood, although it may occur during 
adulthood [91]. Modeling may involve bone formation mediated by osteoblasts (formation 
modeling) and/or osteoclasts-driven resorption (resorption modeling). However, although 
formation and resorption may occur synchronously and in a coordinated manner to shape 
the tissue, these two processes are not coupled, meaning they take place on different 
surfaces. 
Modeling is triggered by mechanical strain; if the strain is high, formation modeling 
occurs in order for the tissue to withstand the mechanical solicitations; if the strain is low, 
resorption modeling takes place to remove “excess” bone. Regardless of the type of 
modeling, it contributes to three processes: radial growth, longitudinal growth and bone 
drift. 
 
Figure 7. Effects of modeling on bone structure. Examples depicting the contribution of 
formation and resorption modeling to a) the diaphyseal radial growth and b) the metaphyseal 
longitudinal growth of model long bones; c) illustrates bone drift due to modeling in murine ulna 
(left) and radius (right) of a growing mouse. Adapted from [91].  
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Radial growth consists in the coordination of formation and resorption to increase the 
diaphyseal diameter of long bones while keeping cortex thickness constant (resorption 
occurs in the endocortical surface, while formation takes place in the periosteal region; 
Figure 7a); it is gender and age specific [91]. During endochondral ossification, formation 
and resorption occur in the metaphyses to preserve the shape of bones during longitudinal 
growth; in this case, bone is resorbed in the periosteum, while new bone is deposited into 
the endocortical surface (Figure 7b). Bone drift is the process by which trabecular struts 
are moved and the distance cortex-central axis at a diaphyseal level is modified. In the 
latter case, depicted in Figure 7c, resorption occurs in two periosteal or endocortical 
surfaces, while formation takes place in one endocortical and one periosteal surfaces.  
1.1.8 Bone remodeling: mineral homeostasis and renewal 
Bone remodeling is the process by which bone is locally resorbed and reformed in a 
coupled manner to maintain the systemic mineral balance and to preserve the mechanical 
integrity of the tissue [37,91]. Remodeling associated with mineral homeostasis is thought 
to be nontargeted (i.e. non site-specific) since it can take place in any skeletal site as long 
as it doesn’t mechanically compromise the tissue. In contrast, remodeling related to the 
preservation of mechanical integrity is considered to be targeted (i.e. site-specific) given it 
is aimed to repair bone defects [92] such as microcracks. 
While modeling mostly takes place during growth, remodeling is a continuous process in 
which bone resorption and formation result from the temporally and spatially-coupled 
activity of osteoclasts and osteoblasts. In both cases, cellular events leading to bone 
resorption and/or formation are assumed to be regulated by osteocytes, considered to act 
as mechanosensors [37]. Briefly, mechanical loads are thought to induce movement of the 
insterstitial fluid in the lacuno-canalicular network, which produces shear stress on the 
membrane of osteocytes [93]. Osteocytes, then, would produce signals for the 
activation/inhibition of osteoclasts and osteoblasts [94–96], thus being important 
regulators of bone’s adaption to mechanical overuse or disuse through modeling. 
Osteocyte death is accepted to trigger targeted remodeling to repair microcracks derived 
from repeated mechanical loading (i.e. fatigue). Microcracks would disrupt the lacuno-
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canalicular network, thus depriving some osteocytes from nutrients and leading to cell 
death [37]. Osteocyte death is thought to induce bone resorption [97] by either the 
apoptosis-related release of pro-resorption signals or by the absence of osteoclast-
inhibiting signals produced under normal conditions; these signals (or the lack thereof), in 
concert with osteoclasts-inhibiting signals from healthy osteocytes, would lead to targeted 
remodeling events to occur only at damaged regions [98].  
 
Figure 8. The bone remodeling cycle. Osteoblasts, osteoclasts and bone lining cells team up to 
renew bone in a spatially and temporally coupled manner. Adapted from [100]. 
In bone remodeling, the cellular actions leading to coupled bone resorption and formation 
are conducted by the so-called basic multicellular unit (BMU), a cellular team comprising 
osteoclasts, osteoblasts and bone lining cells. The events occurring during bone 
remodeling make up the remodeling cycle (Figure 8), a sequential process in which 
cellular actions are tightly regulated (differences can be found in the bibliography as to the 
number of stages of the cycle; herein, the number of stages has been maximized to easily 
identify the main cellular events). When damage is produced, the need for remodeling is 
signaled through yet unclear mechanisms and bone lining cells degrade the outward 
unmineralized matrix layer in the tissue, exposing the mineralized matrix [99] (Figure 8, 
stage 0). The bone lining cells monolayer then detaches partially from the surface creating 
an isolated space for remodeling known as the bone remodeling compartment (BRC) [35]. 
The presence of blood vessels close to the BRC allows the arrival of mononuclear cells 
[101], which fuse together to make up mature osteoclasts (Activation phase; Figure 8,stage 
 INTRODUCTION  
23 
 
1). Osteoclasts then adhere to bone surface and become polarized, exposing the tissue to a 
highly specialized set of membrane domains for bone resorption (Resorption phase; Figure 
8, stage 2). Briefly, osteoclasts anchor to bone by means of peripheral actin rings (sealing 
zone) to create an isolated space for resorption [102]. Within this space, the apical 
membrane is known as the ruffled border, which contains a sophisticated machinery for 
the release of HCl and lysosomal enzymes such as cathepsin K, and for the uptake of 
matrix degradation products. HCl is used to lower the pH and induce the dissolution of 
HA; cathepsin K then degrades the organic fraction of the matrix along with 
metalloproteinases [102]. Osteoclasts move forward and degrade a few hundreds of 
microns. Behind the osteoclasts front, a subset of bone lining cells smooth the surface and 
deposit a thin layer of osteoid that once mineralized is known as cement line [9,91] 
(Reversal phase; Figure 8, stage 3). Finally, osteoblasts secrete new osteoid (Formation 
phase; Figure 8, stage 4) to fill the cavity excavated by osteoclasts (Howship’s lacuna) and 
terminally become either osteocytes or bone lining cells. When remodeling has finished, 
bone enters a quiescent state (Figure 8, stage 5) in which newly deposited osteoid 
mineralizes with time.  
 
Figure 9. Span of the osteoclastic activity in a remodeling cycle. Finite element models 
displaying the Howship’s lacunae created by osteoclasts in a) cortical, and b) cancellous bone. 
Adapted from [90]. 
Despite the cellular events in cortical and trabecular remodeling are essentially the same, 
differences exist as to the geometry of the remodeled bone portion (Figure 9). In cortical 
bone, osteoclasts dig a tunnel about 2 mm long and 200 µm wide [103], and are followed 
 INTRODUCTION  
24 
 
by osteoblasts depositing osteoid in centripetal layers (lamellae) and finally leaving a 
central void space (Haversian canal) [9], giving rise to an osteon. In cancellous bone, 
osteoclasts dig a trench across the trabecular surface about 200 µm long [104] and 60 µm 
deep [90]. Generally, the remodeling cycle can take up to 6 months [100], with the 
remodeling rate being affected by factors such as gender, age and physical activity [91]. 
Remodeling is regulated systemically by hormones such as parathyroid hormone (PTH), 
and locally by the osteoblasts-osteoclasts crosstalk through the OPG/RANKL/RANK 
(Osteoprotegerin/ receptor activator of necrosis factor kappa B ligand/ receptor activator 
of necrosis factor kappa B) axis [103].  
1.1.9 Bone healing: structural and functional re-establishment 
As previously stated, the major function of our bony framework is to shape our body and 
to protect our internal organs. Such an important role requires a robust mechanical 
performance to allow movement and to resist the many types of mechanical loads bones 
are subjected to on a daily basis. The strength of bone tissue is mainly due (i) to its 
biocomposite nature, which allows a homogenous distribution of the load to minimize the 
concentration of stresses on the brittle mineral phase [26], and (ii) to its structure. At the 
nanoscale, factors such as (i) the staggered arrangement of collagen fibrils, (ii) the degree 
of mineralization, and (iii) the large aspect ratio and distribution of mineral platelets have 
been seemingly optimized to make the tissue able to withstand high loads before failing by 
fracture [26,105,106]. At the microscale, the osteonal lamellae arrangement and the 
density and orientation of trabeculae clearly influence the mechanical properties of cortical 
[107–110] and trabecular bone [111], respectively. At the macroscale, the overall 
mechanical properties of the tissue are related to the total amount (mass and size) of bone 
as well as to its geometry [112]. Despite this hierarchical optimization, bones are 
susceptible to overloads and to the coalescence of microfractures, two of the most 
common causes of bone fracture along with osteoporosis, an age-related condition 
involving decreased bone density and propensity to recurrent fractures [113]. Whatever 
the cause underlying fractures, bone healing (or fracture repair) normally takes place 
through the so-called indirect (or secondary) fracture healing [114], a multistep process 
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involving inflammation, soft callus formation, hard callus formation, and remodeling 
(Figure 10). It proceeds as follows. 
 
Figure 10. Time course of indirect bone healing.  After injury, a hematoma is created at the 
fracture site, which becomes a strongly pro-inflammatory environment that induces the 
recruitment of MSCs (stage 1). MSCs then differentiate into chondrocytes, which create a 
fibrocartilage callus in concert with fibroblasts (stage 2). The soft callus undergoes endochondral 
ossification to create bone (stage 3), which is ultimately remodeled (stage 4).  Adapted from 
[120]. 
Shortly upon damage, a hematoma is formed due to the extravasation of blood from 
disrupted vessels. This hematoma arises in between and around fracture ends and contains 
inflammatory cells that release proinflammatory factors to induce the recruitment of 
MSCs [115], to prevent infection [116] and to promote angiogenesis (i.e. the formation of 
vessels from pre-existing ones) [117,118]. Additionally, macrophages and phagocytic cells 
remove necrotic tissue [119,120] to clear fracture ends. Platelet-derived factors induce the 
recruitment and chondrogenic differentiation of MSCs from the bone marrow, the 
periosteum and surrounding soft tissues as well as the proliferation of fibroblasts and 
endothelial cells [121] (Figure 10, stage 1). Fibroblasts and chondrocytes then give rise to 
a soft callus (or fibrocartilage), an initial fracture-stabilizing structure developed under the 
regulation of periosteum-secreted factors [122]. Concomitantly, the ends of the disrupted 
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subperiosteal bone are bridged by periosteal progenitors-mediated intramembranous 
ossification [123], further stabilizing the fracture (Figure 10, stage 2). Additionally, blood 
vessels invade the soft callus, which undergoes endochondral ossification (Figure 10, 
stage 3); during this process, the soft callus is gradually revascularized and substituted by 
mineralized matrix, thus becoming the so called hard (or bony) callus [119]. Ultimately, 
bone remodeling takes place to turn woven bone into mature, lamellar bone (Figure 10, 
stage 4). By the end of this process, bone has been structurally and functionally restored. 
Herein described events correspond to the process commonly taking place after an injury; 
restoration proceeds through direct healing in those rare cases in which the fracture is 
stably fixed and the gap between fracture ends is negligible (more details can be found in 
[114]).  
1.1.10 Failed fracture repair: delayed unions and non unions 
Fracture repair is affected by a myriad of systemic factors such as age, nutritional status, 
diseases, use of pharmacological drugs, smoking and alcohol abuse [124] and local factors 
such as fixation-related intrafragmentary motions and the length of the fracture gap 
[125,126]. Both systemic and local factors can result in impaired healing either in the form 
of delayed unions or even non unions of bone ends, with local factors being especially 
important for the clinical management of fractures. It has been proven that the use of 
fixation methods allowing micromotions is beneficial for secondary bone healing to occur 
[127], but their effect is minimized in the case of large gaps [126]. Gap size has been 
demonstrated to be a critical factor that can lead to incomplete and delayed healing, or to 
the lack thereof  [126] when it exceeds a threshold length above which bone can’t 
spontaneously heal (i.e. critical-sized defects).  
It is estimated that the 5-10% of fractures undergo delayed or non unions [128]. The latter 
have received much attention in the last decades and much effort is being made to find an 
effective and safe treatment to help the body regenerate large defects. Critical-sized 
defects have been classically treated by bone grafting (i.e. bone transplantation), either 
using bone from the same patient (i.e. autograft) or from another individual belonging to 
the same species (i.e. allograft). Autografts are the ideal option since the patient receives 
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its own tissue, which is highly osteoinductive and osteoconductive because of the presence 
of bone cells, bone matrix and signaling molecules [129]. However, the use of autografts 
requires multiple surgical procedures to harvest and subsequently implant the tissue, the 
available quantity of which may be insufficient in the case of large defects [130]. 
Allografts, normally from cadavers, overcome the limitations imposed by autografts, but 
may be a vehicle for disease transmission [130]. 
The number of people aged 60 or over is expected to dramatically increase globally by 
2050 [131]. In this context, the prevalence of osteoporosis is estimated to rise by 23% in 
the European Union (EU), which translates to an increment of 28% in the number of 
annual fractures in the region by 2025 [132]. These prospects, together with the high risk 
of recurrent fractures [113], foresee a globally increased need for bone grafts in the 
coming decades, urging scientists to develop approaches overcoming the limitations of 
autografts and allografts. 
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1.2 BIOMATERIALS AND TISSUE ENGINEERING 
1.2.1 Biomaterials: from substitution to regeneration 
The history of biomaterials started in the late 1940s, when the ophthalmologist Harold 
Ridley noticed that fragments of cockpit canopies in the eyes of pilots were well tolerated 
by the body. After performing some “biocompatibility” assays with the material the 
canopies were made of, poly(methyl methacrylate), he used it to produce intraocular 
lenses to replace cataractous lenses in the early 50s [133]. More or less concomitantly, Dr. 
Arthur Voorhees successfully implanted tubes made of Vinyon (polyvinyl chloride fibers) 
cloth to bridge dog aortas without signs of foreign body reaction [134]. These are 
examples of early biomaterials (known as first-generation biomaterials), where materials 
not specifically meant to be used in humans/animals were used to produce implants. By 
then, biomaterials were meant to functionally replace a tissue without eliciting toxicity to 
the host tissue (i.e. being bioinert) [135].  
The second generation of biomaterials was born in the 1980s. This generation, still aiming 
substitution, introduced two important concepts: bioactivity and biodegradability. The 
field moved from using materials eliciting a minimal host response to materials intended 
to induce specific responses once implanted (i.e. bioactivity). Early bioactive materials 
were bioglasses and ceramics, mainly HA, shown able to create a strong bond with host 
bone (i.e. osseointegration), thus providing structural and mechanical stabilization [136]. 
The field moved also towards the use of temporal implants that would be resorbed after 
their intended mission was completed, so only host tissue could be found at the site of 
implantation by the end of the process. Biodegradable polymers allowed the development 
of resorbable sutures made of polylactic and polyglycolic acids [135] and of temporal 
carriers for drug delivery such as polylactic acid systems for the release of contraceptives 
[137]. 
Third-generation biomaterials appeared with the new millennium aiming to induce highly 
specific cellular behaviors at the molecular level [138]. Biocompatibility, bioactivity and 
biodegradability are inherent to third-generation biomaterials, which should ideally be 
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injectable to minimize the pain related to implantation. They are mainly used to achieve 
tissue regeneration and to deliver cells and/or drugs. 
 
Figure 11. The evolution of biomaterials. Scheme depicts the three generations of biomaterials 
with their corresponding goal and main properties. 
By now, it is obvious the field has rapidly evolved and become more and more ambitious 
in the last decades (Figure 11). Biomaterials, first defined as “non-viable materials used in 
a medical device, intended to interact with biological systems” [139] are now described as 
“substances that have been engineered to take a form which, alone or as a part of a 
complex system, are used to direct, by control of interactions with components of living 
systems, the course of any therapeutic or diagnostic procedure, in human or veterinary 
medicine” [140]. With the purpose of achieving tissue regeneration, a current-generation 
biomaterial could be more specifically defined as a substance for the therapeutic 
reconstruction of the human body that selectively stimulates cell responses through 
chemical and physical signals (adapted from [140]). In the case of bone, biomaterials for 
tissue regeneration should stimulate MSCs to undergo osteogenic differentiation (i.e. 
osteoinduction) and be a platform (scaffold) for cell growth and bone development (i.e. 
osteoconduction) [141]. With this purpose, materials can be selectively engineered and 
processed to achieve scaffolds with desired structure, surface chemistry and mechanical 
properties to induce and guide the regenerative process. 
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1.2.2 Tissue engineering  
The evolution of biomaterials gave birth to tissue engineering, “an interdisciplinary field 
that applies the principles of engineering and the life sciences towards the development of 
biological substitutes that restore, maintain, or improve tissue function” [142]. Two types 
of tissue engineering strategies are currently being explored: those administering ex vivo-
expanded cells and those using or stimulating cell homing, the endogenous machinery for 
the recruitment of cells to the site of injury (i.e. in situ tissue engineering). Regardless of 
the type of strategy, bone tissue engineering involves the use of cells (mainly MSCs), 
growth factors, scaffolds and their combinations. 
MSCs can be used alone or in combination with scaffolds. Cell transplantation, 
whatsoever the cell source, requires an ex vivo expansion step, increasing costs, delaying 
interventions and potentially inducing phenotypic alterations such as reduced migration 
and engraftment potential, proliferation, differentiation potential and trophic (secretory) 
activity [143–149]. When used alone, MSCs are usually infused intravenously, resulting in 
potentially reduced viability upon injection [150] and low percentage of cells reaching 
target tissues [151,152], which can be bypassed by seeding or encapsulating them on 
scaffolds. Although pre-seeded/encapsulating constructs can improve cell engrafting to the 
target tissue and be a source of signals to recruit stem cells and progenitors to the defect 
site, problems related to ex vivo expansion remain unsolved.  
A first alternative to cell transplantation is the use of bone growth factors, molecules that 
interact with membrane-bound receptors to elicit the activation of signaling cascades 
important to bone development and repair. Growth factors, which have attracted much 
interest lately, are commonly used in combination with scaffolds or microparticles, either 
encapsulated/loaded or grafted [153]. Several bone growth factors such as bone 
morphogenetic proteins (BMPs) [154–157], transforming growth factors β (TGF-β) 
[155,156,158], insulin-like growth factors (IGFs) [159] and fibroblast growth factors 
(FGFs) [160] have proved useful to induce osteogenesis in vitro and/or in vivo. Among 
them, BMPs are the most popular since the U.S. Food and Drug Administration (FDA) 
approved the use of recombinant human BMP-2 (INFUSE, Medtronic) and BMP-7 (OP-1, 
Stryker) in 2004. Although many studies have demonstrated the potential of BMPs, 
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especially that of BMP-2, in bone tissue engineering, heterotopic ossification has been 
described in patients treated with BMP-7 [161] and BMP-2 [162], with the latter being 
associated to several serious side effects when used in patients suffering from spinal fusion 
[163]. In the wake of these events, BMP-2, long considered to be a gold standard for 
osteoinduction, in now under investigation, raising concern about the use of growth factors 
in bone tissue engineering.  
A second and more interesting alternative to cell therapy for bone tissue engineering is the 
use of scaffolds, commonly based on calcium phosphate cements (CPCs) and polymers. 
The former group, CPCs, emerged in the early 80s and has been thoroughly investigated 
ever since, becoming a promising family of biomaterials for bone regeneration. Several 
CPCs-based bone fillers are on the market [164], although their use is restricted to 
fractures in non load-bearing skeletal sites because of their poor mechanical performance 
[164–166]. CPCs are biocompatible and osteoconductive, can be injectable [167,168], and 
display composition and structure-dependent bioresorption  and osteoinduction [169–171].  
During the last decade, a new desired property has been added to those assumed for a 
third-generation biomaterial scaffold, biomimicry, which literally consists on the imitation 
of life or nature [172]. In the field of tissue engineering, it specifically consists on the 
imitation of the cellular microenvironment to finely drive cell behavior to recapitulate 
tissue development and ultimately achieve tissue regeneration. In the case of bone tissue 
engineering, biomimicry is the tool to develop osteoinductive constructs taking the 
extracellular matrix, the natural cellular scaffold, as a reference. The field is now moving 
towards the development of ECM-mimicking polymeric scaffolds with osteoinductive 
potential superior to that of CPCs. Biomimetic biomaterials represent the 4th generation of 
biomaterials [173]. 
1.2.3 The extracellular matrix: an archetype for scaffold design 
The extracellular matrix (ECM) has been classically defined as the tissue- and 
developmental stage-specific [174,175] nanofibrillar scaffold physically supporting cells. 
This natural scaffold is dynamically remodeled during development [176] and tissue 
adaptation [177–179] as well as in response to disease and injury [180], leading to features 
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such as composition and stiffness changing over time and space [181–183]. The ECM 
properties and cell behavior are reciprocally regulated: ECM’s composition, structure and 
stiffness depend upon cell-mediated synthesis and remodeling and, in turn, the matrix 
regulates cell processes such as adhesion, migration, proliferation and differentiation 
[176,184]. Thus, the ECM, once considered to be an inert scaffold, is now seen as a key 
player on tissue development and repair (and subsequently on tissue engineering) in light 
of its many functions in the cell niche (i.e. cell microenviroment) (Figure 12).  
Figure 12. Functions of the extracellular matrix. From [185]. 
The ECM composition is tissue-specific but, in general terms, the matrix is a complex 
mesh of structural fibrillar proteins such as collagen, elastin and fibronectin, anchored 
molecules such as growth factors, proteoglycans, and water [184,186]. Fibrillar proteins 
and proteoglycans allow cell adhesion and growth by being both a physical support and a 
source of sequences for cell adhesion [187] such as the (i) universal cell adhesion Arg-
 INTRODUCTION  
33 
 
Gly-Asp (RGD) tripeptide from glycoproteins such as fibronectin [188], vitronectin [189] 
and collagen I [190], (ii) the endothelial cells-specific Arg-Glu-Asp-Val (REDV) 
tetrapeptide from fibronectin [191], and (iii) the Ile-Lys-Val-Ala-Val (IKVAV) 
pentapeptide from laminin for neuron adhesion [192]. ECM constituents serve also as a 
source of signaling molecules after proteolytic processing [193–197] and as molecule 
presenters to facilitate the access of growth factors to their cellular receptors 
[185,197,198]. The charged nature of glycoproteins and proteoglycans in the ECM allows 
the binding and storage of growth factors such as BMPs, FGFs and vascular endothelial 
growth factors (VEGFs), which can be maturated [199], presented and/or released to 
create a growth factors gradient/patterning for a spatio-temporal control of cell behavior 
[180,185,200]. Charges in ECM components also attract counter-ions, inducing an 
osmotic pressure and the subsequent swelling of the matrix [201], which acts like a 
sponge. The nature and chemical state of ECM constituents thus determine its water 
content which, together with the physical properties of the components, defines the 
mechanical properties of the matrix as well as the integrity and mechanical performance of 
the tissue [186,202–204]. Last but not least, ECM molecules transmit tissue-applied loads 
to cells, thus mechanically connecting cells to their microenvironment [204].   
1.2.3.1 ECM-cell crosstalk  
The ECM and the intracellular space are mainly linked through integrins, a family of 
heterodimeric (α and β subunits) transmembrane receptors that mediate cell-cell adhesions 
as well as cell-to-ECM (inside-out) and ECM-to-cell (outside-in) signaling [205]. The 
cell-ECM connection is possible thanks to the association of integrins with adapter 
proteins that link them to the cytoskeleton and to other signaling-related proteins such as 
growth factor receptors [206]. Upon binding to the ECM, integrins are clustered and their 
intracellular domains bind adapter proteins such as vinculin, tallin and paxillin, which 
induces actin polymerization, giving rise to actin filaments [206,207]. Actin filaments 
organize into stress fibers and further integrin clustering is induced, strengthening the cell-
ECM binding and leading to the emergence of local protein complexes known as focal 
contacts (or focal adhesions) [208]. Focal contacts mechanically connect the ECM and the 
intracellular space (i.e. mechanosensing), and activate complex signaling cascades 
extending to the nucleus that regulate a myriad of cellular processes [206].  
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Several α and β subunits have been described and they can assemble into up to 24 
different combinations, each of which shows specific binding and signaling features 
[206,209]. The coordination of specific integrins, soluble molecules and growth factor 
receptors triggers signaling cascades leading to changes at a gene expression level, thus 
allowing the integration of signals coming from the cell microenvironment to regulate cell 
behavior [206,210,211]. Interestingly, outside-in signals induce cellular responses that, in 
turn, produce changes in the ECM (inside-out signals) that can be felt by cells that will 
respond accordingly. This integrin-mediated feedback mechanism [212,213] permits the 
existence of a highly dynamic microenvironment for cells to be able to respond rapidly to 
tissue requirements.  
1.2.3.2 Lessons from the ECM 
Multiple integrins can bind to a given ligand and, at the same time, multiple ligands can be 
recognized by a single integrin [205]. This redundancy is somehow striking given the 
outstanding optimization of the cell machinery. In this sense, authors have shown that the 
binding of different integrins to one particular ligand leads to different signals being 
transmitted [214] and have suggested that integrin specificity could be somehow cell-type 
specific [205].  Thus, a relatively narrow spectrum of integrins would allow for a wide 
range of specific signaling outcomes.  
It is well known that the composition of the ECM, by eliciting the binding of specific 
integrins, regulates cell morphology [215], migration [216,217], proliferation [197,218], 
differentiation [216,219,220] and survival [214,215,221,222] upon adhesion. Interestingly, 
adhesion through integrins is itself a checkpoint for adherent cells survival [223] as 
detachment leads to adherence-dependent apoptosis (i.e. anoikis) [224]. This is a 
mechanism to maintain homeostasis, preventing survival of detached cells that could 
adhere to inappropriate locations [206]; resistance to anoikis is assumed to be the reason 
why cancer cells can metastasize [225].  
The effect of the structural and mechanical properties of the ECM has been extrapolated 
from studies based on the use of non-natural substrates, which have revealed that physical 
properties of the substrate affect cell adhesion, morphology, migration, proliferation and 
differentiation [226–230].  And collectively, studies have shown that substrate structural, 
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chemical and mechanical properties condition integrin distribution [231–233], clustering 
[231–236] and specific binding [219,235–237] and, as previously stated, the signals being 
transduced [238] and thus the cellular outcome. It is seemingly reasonable, then, to design 
tailored scaffolds with characteristics mimicking those of target tissue’s natural ECM.  
1.2.3.3 In situ bone tissue engineering: integrating lessons from the ECM 
As stated in section 1.2.2, two main bone tissue engineering strategies involving the use of 
scaffolds are currently being explored: (i) the implantation of cells, either encapsulated or 
seeded, and (ii) the stimulation or exploitation of cell homing (i.e. in situ bone tissue 
engineering; Figure 13). Those strategies involving the implantation of cells and scaffolds 
or the stimulation of cell homing, commonly achieved by combining scaffolds and growth 
factors, won’t be further discussed given the limitations related to ex vivo cell expansion 
and to the use of growth factors. We’ll focus on the use of scaffolds meant to achieve bone 
regeneration by taking advantage of the natural cell homing signaling pathways. In short, 
this strategy consists on implanting scaffolds shortly after injury (ideally, by injection; 
Figure 13a) so MSCs being homed to the site of injury find a platform to adhere to (Figure 
13b). After adhesion, MSCs should be able to grow, and to differentiate in a scaffold-
controlled manner to rebuild the tissue (Figure 13c). For this control to be possible, 
scaffolds must be tailored to possess features inducing MSCs to undergo osteogenic 
differentiation (besides, of course, promoting MSCs adhesion).  
 
Figure 13. Schematic representation of in situ bone tissue engineering. a) After implantation, 
ideally by injection, b) progenitors homing to the insult site would colonize the scaffold, which 
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would instruct them to c) regenerate bone. During the process, the scaffold should be degraded 
by growing cells to achieve a scaffold-free native tissue.  
Separately, matrix structure [239–241], stiffness [242] and surface chemistry [237,243] 
have been proven useful to induce osteogenic differentiation of MSCs, and parameters 
such as ligand nature [219], density [244] and presentation [230] have been shown to 
influence the behavior of cells belonging to the osteoblastic lineage. Although studies have 
pointed out that tailored stiffness or topography of scaffolds would be sufficient to 
regulate stem cells fate [239,242], the debate about using scaffolds relying on a single 
parameter, mainly stiffness, acting as a master force driving differentiation is now open 
[245]. Combinatorial studies [246–248] have reported contradictory results as to the 
stiffness value at which stem cell differentiation is induced, suggesting that the results 
published by Engler and co-workers [242], and by extension those by Oh and coworkers 
[239], would be valid in the set of conditions used in their experiments and need to be 
taken as proofs of concept. Thus, the design of scaffolds for in situ bone tissue engineering 
is moving towards more complex setups accounting for the contribution of multiple matrix 
properties in order to achieve a superior level of biomimicry. 
1.2.3.4 Hydrogels: lessons learnt 
Scaffolds mimicking the ECM can be basically classified as either electrospun mats or 
hydrogels. Electrospinning has become very popular in the last decade since it allows the 
creation of mats of fibers with diameters close to that of ECM structural proteins. 
Electrospun mats can be tailored to possess surface chemistry permissive for cellular 
processes either by using specific polymers or by functionalization [249–256]. However, 
electrospinning commonly leads to scaffolds with low pore size [257], hindering cellular 
colonization, and affecting proliferation and matrix deposition [258]. Pore size and 
interconnectivity are also important for vascularization [259–261] and thus for the 
nutrition of cells growing within the scaffold.  
The abovementioned limitations may be overcome by using hydrogels, three-dimensional 
polymeric networks that can absorb large quantities of water thanks to their interconnected 
microscopic pores [262]. Their open network structure allows for gas (O2 and CO2) 
exchange and determines the diffusion of solutes (e.g. nutrients, metabolic wastes and 
soluble signaling molecules) [263] and swelling [264,265], and thus their mechanical 
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properties and degradability. Hydrogel network properties can be tailored by crosslinking, 
a chemical, physical or enzymatic reaction leading to the creation of bonds linking 
different polymer chains (interchain crosslinking) or regions (intrachain crosslinking). 
Thus, crosslinking allows tuning hydrogel architecture, mechanical properties and 
degradability [266–268], which evidences the tailorable nature of hydrogel physical 
properties. Hydrogels can be prepared from a myriad of natural polymers [269–275] as 
well as from synthetic polymers [276–282], further evidencing hydrogels are highly 
versatile platforms that allow the tailoring of multiple parameters to achieve implants with 
properties resembling those of the ECM.  
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1.3 ELASTIN-LIKE POLYMERS 
1.3.1 Genetically-engineered protein-based polymers 
When designing hydrogels for a given application, selecting the polymer to be used is the 
first step to take. On one hand, synthetic polymers are commercially available and stable 
in a wide range of conditions, and allow the fabrication of hydrogels with tuned 
mechanical properties and chemical modifications, but they may show reduced 
biocompatibility and biodegradability [283]. In contrast, natural polymers are 
biodegradable, possess a chemistry allowing chemical modifications and interactions with 
cellular receptors, and both themselves and their degradation byproducts are 
biocompatible [283,284] (Table 1). On the other hand, natural polymers may display 
batch-dependent features, may elicit immunogenic responses and be a vehicle for disease 
transmission, and may lose their properties during processing (E.g. protein denaturation) 
[283–285]. These limitations, especially critical in the case of ECM structural proteins 
obtained from animal sources, can be overcome by using their engineered counterparts. 
Advantages Drawbacks 
Biocompatibility Limited commercial availability 
Inherent biodegradability Batch-to-batch differences 
Biocompatible degradation byproducts Potential immunogenicity 
Sequences for cellular receptors Possible loss of biological properties 
Functional groups usable for modifications Risk of disease transmission 
Table 1. General features of natural polymers. 
In the last years, the concept of protein engineering has gained momentum in the 
biomaterials field. The synthesis of engineered proteins was initially carried out by 
chemical synthesis [286] but has gradually moved into recombinant synthesis by using 
genetically modified biological bioreactors, mainly Escherichia coli. By this latter 
methodology, the amino acid sequence and polypeptide (from now on, polymer) length 
can be easily modified by changing the nucleotide sequence and the length of the 
codifying DNA sequence, allowing for a precise design of the polymer and its properties 
[287]. This strategy allows producing polymers with monodisperse molecular weight of 
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up to hundreds of kDa, a constantly increasing limit [288,289]. Interestingly, the 
molecular tailoring of DNA sequences allows the cost-effective production of polymers 
with increased molecular complexity and functionalities not displayed in natural polymers 
[288] at high yields [290].  Engineered polymers designed and produced by recombinant 
DNA technology are known as genetically-engineered protein-based polymers (GEPBPs), 
including polymers based on natural proteins suchs as resilin [291], elastin [288,292,293], 
and Nephila clavipes spider silk [294,295].  
1.3.2 Elastin-like polymers: main properties 
Among GEPBPs, elastin-like polymers (ELPs) stand out as a powerful tool given their 
versatility and interesting properties. These polymers are based on the sequence of 
mammalian elastin [296], a protein from the ECM conferring elasticity to tissues like skin, 
large blood vessels and muscles, and to organs such as the lungs [297,298]. Elastin 
includes crosslinking (rich in alanine and lysine) and hydrophobic (rich in proline, glycine 
and hydrophobic amino acids such as valine and alanine) regions [299]. The latter seem to 
be a common trait to elastomeric proteins [292] and to play an essential role in 
determining their physical properties [300]. Hydrophobic regions such as PGGV, 
PGVGV, PGVGVA and GGLGV have been found repeated along the sequence of 
mammalian elastin, and the protein in different animal species displays differences as to 
the predominant hydrophobic region [299] and the number of repetitions. As an example, 
the VPGVG pentapeptide is repeated three, eleven and fifteen times in human, bovine and 
chicken elastin, respectively [301]. Assuming the contribution of hydrophobic regions to 
elastin physical properties, these regions are the basic building blocks of ELPs. Two main 
types of ELPs have been developed: (i) those developed by Tamburro and coworkers 
(building block: XxGGYyG, where Xx and Yy correspond to hydrophobic residues) 
[292], and (ii) those developed by Urry and coworkers (building block: VPGXG, where X 
is known as visiting residue, a position that can be occupied by any amino acid except 
proline [302]).  
VPGXG-based ELPs have been extensively studied and used in the form of 
poly(VPGVG), considered to be a model ELP. This model polymer was subjected to 
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several biological in vitro and in vivo tests and it was shown to be biocompatible [303], a 
feature assumed to be a common trait for all VPGXG-based ELPs, given that the organism 
would be unable to distinguish them from native elastin [287]. The model polymer was 
also found to be inherently anti-fouling [296], so ELPs meant to be included in tissue 
engineering strategies need to be designed to include cell adhesion sequences such as 
RGD [304] and REDV [305,306]. Further bioactivity can be achieved by the inclusion of 
sequences such as (i) the SN15 fragment of human salivary statherin [307] or (ii) the 
VGVAPG hexapeptide, a natural target sequence for elastase [306] that can act as a 
chemoattractant for monocytes, fibroblasts, keratinocytes and vascular smooth muscle 
cells upon enzymatic processing [195]. Although ELPs would be degradable by generic 
proteases, sequences like VGVAPG can be included to adjust their biodegradability to that 
required for a given application, which gives an idea of the great versatility of these 
polymers.  
ELPs are not only biocompatible, biodegradable and potentially multifunctional polymers 
but also smart, self-aggregating and thus segregating from the aqueous phase (i.e. 
coacervation) in response to external stimuli. This feature seems to be common to 
elastomeric proteins with hydrophobic domains [299]. Self-aggregation has been 
described for elastin, the hydrophobic domains of which would organize leading to the 
formation of filamentous coacervates made up by fibrous structures of about 5 nm [308] in 
response to temperature increases; this phenomenon has been also described for VPGXG-
based ELPs [309].  
1.3.3 ELPs: the inverse transition phenomenon 
Proteins are known for undergoing a transition from an ordered to a disordered state 
(denaturation) in response to increases in temperature. Both elastin and ELPs undergo the 
inverse process (disorder to order; Figure 14), which led to coining the term “inverse 
transition temperature” (ITT) for ELPs [309].   
In a solution below the ITT, the polymer chains remain disordered in the form of random 
coils, with water surrounding the hydrophobic domains of the polymer [309]. When 
temperature is raised, the non-polar solvation layer is broken [310] and the polypeptide 
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chains undergo hydrophobic folding, with each PVGXG pentamer leading to a type II β 
turn. This leads to polypeptide chains folding in the form of β spirals that hydrophobically 
aggregate to make up nanometric particles that segregate from the solution [309]. This 
aggregation would involve weak bonds such as van der Waals forces and hydrogen bonds 
that allow the creation of 3D structures [287] and the reversibility of the process when 
temperature is decreased below the ITT [296]. Interestingly, a single PVGVG pentamer is 
enough for the phase transition to occur [311], thus stablishing a sequence-functionality 
relation that explains this striking property of elastin and ELPs. It is noteworthy to 
mention that the self-aggregation process is affected by a myriad of parameters which 
should be considered when using ELPs as raw materials for the creation of scaffolds or 
drug delivery systems (Table 2). 
 
Figure 14. Proposed mechanism for the coacervation of ELPs. From [287].  
Up to date, ELPs have been used in many applications, such as (i) drug delivery [313,315–
320], (ii) development of cell harvesting systems [321], (iii) improvement of the efficiency 
of recombinant protein purification [322], (iv) prevention of postoperative adhesions 
[323,324], (v) soft tissue augmentation for correcting urinary incontinence [325], and (vi) 
bone [326–328], (vii) cartilage [329–331], (viii) vascular [332,333], (ix) nervous system 
[334] and (x) ocular surface regeneration [335]. 
1.3.4 ELPs: crosslinking 
As previously mentioned, ELPs are able to coacervate in response to increases in 
temperature, with the coacervation process being reversible and affected by many external 
parameters that can compromise the stability of ELPs-based scaffolds. In order to produce 
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hydrogels stable over a wide range of conditions, ELPs have been crosslinked by means of 
a myriad of methods (Table 3), being chemical crosslinking the most commonly used. 
Parameter Reference 
Mean polarity [309,312] 
Molecular weigth [306,312,313] 
Sequence composition [314] 
Amino acid in the visiting residue position [313] 
Working concentration [311,313] 
Amino acid distribution along the sequence [312] 
Salt type and concentration, and presence of organic solvents [296,311] 
Solution pH [306,309] 
Pressure [311] 
Table 2. Parameters affecting the inverse aggregation phenomenon. 
Modern (i.e. recombinant) ELPs are generally designed to be enriched in lysine residues 
as a source of primary amines (ε-NH2) to be used for crosslinking purposes (an additional 
trait inherited from elastin [336]) and are thus commonly crosslinked by using lysine-to-
lysine chemical methods. Among the chemical species used in lysine-to-lysine chemical 
crosslinking, glutaraldehyde stands out as a highly reactive compound that gets 
incorporated into the nascent polymeric network. Although this compound is widely used 
[337], concern has been raised about its use to produce hydrogels for tissue engineering, 
which may be inherently cytotoxic due to the exposure of highly reactive pendant groups 
[338] or to glutaraldehyde depolymerization during the degradation of the scaffold [339]. 
Another lysine-to-lysine integrative crosslinker is genipin, a natural molecule with 
increasing interest in the biomaterials field that can lead to cytotoxicity upon scaffold 
degradation [340].  
In order to avoid cytotoxicity related to the release of toxic crosslinking products during 
scaffold degradation, non-integrative methods such as enzymatic crosslinking have been 
developed. ELPs have already been crosslinked with bacterial transglutaminase, which 
despite not being a lys-to-lys method, is an approach to how the ECM in bone is 
crosslinked; however, it is still far from producing the particular crosslinks responsible for 
bone ECM mechanical properties (see section 1.5.1). Another example of non-toxic 
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crosslinking method is catalyst-free click-chemistry, which consists on reticulation 
mediated by highly specific modular reactions that yield non-toxic crosslinking products 
[341,342]. Despite click chemistry is an interesting approach, it requires the time-
consuming chemical modification of polymers to introduce the reactive groups of interest 
[342]. This, along with crosslinking, can be achieved by using water-soluble carbodiimide, 
which induces the formation of cytocompatible crosslinks and can be easily removed from 
the so-produced scaffolds.  
Method Crosslinker Reference 
Physical Coacervation  [325,330] 
 Gamma irradiation [303,343,344] 
Chemical Glutaraldehyde [292,300,305,306,345] 
 β-[tris(hydroxymethyl)phosphino]propionic acid (THPP) [331,346,347] 
 Dicumyl peroxide (DCP) [344] 
 Hexamethylene diisocyanate (HDI) [348,349] 
 N-Cyclohexyl-N′-(2-morpholinoethyl)carbodiimide metho-
p-toluenesulfonate (CMCI) 
[286,350] 
 N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) [344] 
 Disuccinimidyl glutarate (DSG) [292] 
 Bis(sulfosuccinimidyl) suberate (BS3) [351–353] 
 Disuccinimidyl suberate (DSS) [351] 
 Tris-succinimidyl aminotriacetate (TSAT) [354] 
 Pyrroloquinoline quinone (PQQ) [293,355] 
 Genipin [326,355] 
 Tetrakis(hydroxymethyl) phosphonium chloride (THPC) [356] 
 Catalyst-free click chemistry [342] 
Enzymatic Microbial transglutaminase [329,333,357] 
Table 3. Methods proven useful to crosslink ELPs. 
1.3.4.1 Water-soluble carbodiimide 
EDC, a water-soluble zero-length crosslinker belonging to the family of carbodiimides, is 
a widely used reagent to crosslink proteins; it catalyzes the formation of amide (peptide) 
bonds by inducing the condensation of carboxyl groups (-COOH) with primary amines    
(-NH2) [358]. Interestingly, both EDC and its main byproduct are water-soluble, and 
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peptide bonds can be degraded by generic proteases, which suggests that EDC is useful to 
produce biodegradable hydrogels with minimally compromised biocompatibility.   
 
Figure 15. Reaction mechanism of EDC-mediated activation of –COOH groups. The 
formation of amide bonds can occur through direct (blue route) and indirect mechanisms (green 
route). The reaction can evolve to the formation of non-desired unreactive species (orange 
route), which can be avoided by adjusting some reaction parameters or by producing NHS esters 
(red route). 
The reactions involved in the EDC-catalyzed formation of peptide bonds, along with side 
reactions, are depicted in Figure 15. EDC reacts with carboxyl groups (i.e. activation) to 
give rise to O-acylisourea, an intermediate specie that can suffer nucleophilic attack by an 
–NH2 group to produce a peptide bond (blue route). O-acylisourea can also (i) lead to the 
formation of acid anhydride, an unstable specie that can react with primary amines and 
produce peptide bonds (green route), or (ii) irreversibly stabilize into N-acylurea, a non-
reactive specie (orange route).The latter can be avoided by performing the reaction in 
solvents with low dielectric constant at low temperatures [359] or using N-
hydroxysuccinimide (NHS), which reacts with O-acylisourea to form a more stable 
intermediate to react with primary amines [360]. Parameters such as solvent polarity 
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[361], presence of water [362,363] and pH [358,364] are important for the stability of 
EDC and O-acylisourea [358,362] and may determine the main route through which the 
reaction evolves; others like the EDC:NHS molar ratio [360,365], EDC:COOH and 
COOH:NH2 molar ratios [365] and reaction time [358,362,365] mainly influence the yield 
of the reaction. The outcome of the EDC-mediated activation of –COOH groups depends 
on many reaction parameters, so optimization is required in order to achieve and control 
crosslinking. Interestingly, EDC can be used not only to catalyze crosslinking, but also to 
engraft –COOH or –NH2-terminated molecules to provide polymers with new 
functionalities.  
As previously noted, ELPs are generally designed to display –NH2 groups for 
crosslinking. It is noteworthy to mention that they are also commonly short on –COOH 
groups [366] so EDC-mediated crosslinking would hardly take place unless carboxyl 
group-donor molecules are used. In these conditions, a donor molecule would act as a 
bridge connecting polypeptide chains, thus getting physically integrated into the network. 
Examples of donor molecules are nitriloacetic, suberic and glutaric acids, which have been 
already used in the form of commercially available NHS esters (TSAT, BS3, DSS and 
DSG; Table 3) to crosslink ELPs. Suberic and glutaric acids possess two –COOH groups, 
both of them required to condense with primary amines for crosslinking to occur. 
Polycarboxylic acids (i.e. they contain >2 –COOH groups) such as nitriloacetic acid are 
more versatile molecules, allowing to achieve higher degrees of crosslinking and thus to 
tune hydrogel features such as mechanical properties and degradability [267,367]. 
Additionally, under controlled conditions, polycarboxylic acids can partially react to both 
crosslink the polymer and to introduce carboxylates on surface, which may help driving 
cell differentiation [237,243] or inducing scaffold mineralization [368,369]. Thus, 
polycarboxylic acids activated with carbodiimides can be potentially used both to achieve 
crosslinking and to provide the network with new functionalities.  
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1.4 CITRIC ACID 
1.4.1 Citric acid in bone 
Citric acid is a central molecule in Krebs cycle, a set of enzymatic mitochondrial reactions 
coupling nutrients degradation with energy production. As such, this tricarboxylic acid is 
distributed along the body but it seems to be particularly abundant in bone. Authors have 
reported citric acid to represent the 1.42% of ground ox and sheep bones [370], 1% of dog 
bones [370], 0.5-1% of wet weight in dog, beef and rabbit bones [371] and the 5.5% of the 
organic fraction in bone from several animal species [6], quantities much higher than those 
found in any other tissue. It’s for this reason that bone is considered to be the main citric 
acid deposit in the body, containing up to the 70% and 80% of the total citric acid in adult 
mice [370] and humans [372], respectively. Citric acid accumulation in bone seems not to 
be accidental, as illustrated by its synthetic enzymatic activities being overexpressed 
compared to that responsible for its degradation [373,374]. Collectively, these studies 
from the 30s, 40s, 50s and 60s evidenced that citric acid, recently suggested to be 
produced by osteoblasts [32], plays a role in bone mineralization, although by then this 
role was unknown.  
1.4.2 Citric acid and biomineralization 
In 2010, Hu, Rawal and Schmidt-Rohr [6] published a study focused on the relation 
between citric acid and hydroxyapatite. After removing endogenous citrate, the authors 
exposed cow, chicken and fish bone to solutions containing radiolabelled citric acid and 
found the tricarboxylic acid closely bound to mineral phase, covering 1/6 of its surface 
(Figure 16a) and representing the 0,42% of the mineral phase weight. These authors 
concluded that citrate, with a spacing of its carboxylate groups matching that of calcium 
ions along the c-axis in HA crystals, would bind to the mineral phase of bone and prevent 
the binding of further calcium phosphate, thus stopping its growth. 
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Figure 16. Models of the citrate-HA interaction. a) Diagram of citrate (with oxygen from 
carboxylates depicted in red) bound to two HA surfaces (with calcium ions depicted in dark 
blue). Calcium ions in the (1010)1 surface are spaced by c/2=0.34 nm, which matches the 
distance spacing the central and terminal carboxylates of citrate; in the (1010)2 surface, calcium 
ions are spaced by c=0.688 nm, which matches the distance between the terminal carboxylates 
of citrate. Blue-filled circles: calcium atoms; green: phosphorus atoms; pink dots: OH- ions; red 
circles: carboxylates in citric acid. From [6]. b) Diagram depicting the model for 
biomineralization proposed by Xie and Nancollas. According to this model, citrate and non-
collagenous proteins would collaborate to drive the directional growth of HA crystals. Adapted 
from [25]. 
Some authors have reported charge anisotropy along the facets of the HA crystals [375–
377], so citrate binding and thus the introduced charges, wouldn’t be homogeneous along 
the crystalline surface. Through electrostatic repulsion, this would result in the conditioned 
aggregation of crystals, which would undergo oriented growth, mainly in their 
longitudinal axis [378]. In a recent model for bone mineralization (Figure 16b), Xie and 
Nancollas [25] proposed that crystal growth would be dependent on the distance between 
contiguous calcium ions, so crystal thickening would be stopped when this distance 
matches that spacing the carboxylates of citrate. In the model of Hu, Rawal and Schmidt-
Rohr, bound citrate would be almost parallel to the HA surface, thus exposing methylene 
groups (-CH2) to make the surface less hydrophilic and thus more compatible with 
hydrophobic residues from collagen [6] in the osteoid. Finally, the growth of HA crystals 
along their long axis would be controlled and stopped by NCPs in order for the crystals to 
achieve an optimum size [25,26], thus conferring fracture strength and tolerance to flaws 
on the crystals, and a proper stiffness on the composite material that is bone. Interestingly, 
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the role of citric acid in biomineralization seems to extend beyond bone, as suggested by 
studies showing a coordination of citrate and NCPs to control the shape and size of 
calcium oxalate monohydrate crystals, the main component of kidney stones [379,380]. 
Collectively, these evidences point out citrate as an important global regulator of in vivo 
biomineralization. 
1.4.3 Citric acid and in vitro calcium phosphate nucleation 
In the 40s, calcium, phosphate and citrate were found able to form complexes when at 
proper concentrations in alkaline conditions [381,382], a phenomenon that is likely to 
underlie the binding of citrate to HA crystals to stop their growth and that points out that 
citrate might act as calcium phosphate-nucleating molecule.  
Using surfaces functionalized with several functional groups, Tanahashi and Matsuda 
demonstrated that negatively charged surfaces are good substrates for HA nucleation. 
Although phosphates showed an obviously favored nucleation capacity, carboxylates were 
found able to nucleate HA almost at the same rate as phosphates after an induction period 
[383], suggesting citrate could act as a nucleating molecule. This was demonstrated by 
Rhee and Tanaka after exposing bovine collagen matrices to 1.5x simulated body fluids 
(SBF). HA was found only when 1.5x SBF was supplemented with citric acid [384] and 
the process was found to be dependent on the Ca2+-to-citrate molar ratio on the 
supplemented solution [385]. Interestingly, HA precipitated in the presence of citrate was 
found to display X-ray diffraction peaks broader than those from normal HA, which 
would be due to citrate inducing the formation of crystals with either low crystallinity or 
low size. Although both phenomena have been described when preparing CPCs in the 
presence of citric acid [386–388], citrate has been reported to be especially effective on 
reducing crystal size down to the nanoscale [389–392]. Together with Rhee and Tanaka’s 
work, these studies suggest that citric acid is useful to both induce HA nucleation and to 
stop crystal growth.  
1.4.4 Citric acid in the biomaterials field 
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Citric acid is a molecule with an increasing interest in the biomaterials field, where it has 
been basically used (i) as a raw material for the development of biodegradable polymers, 
(ii) an additive in the preparation of scaffolds, and (iii) a crosslinking agent. 
In the early 2000s, Yang and co-workers developed poly(diol citrate) [393], a 
biodegradable polyester elastomer based on citric acid and already used in the 
development of vascular implants [394–398], fixation devices for bone fractures [399], 
composites for bone regeneration [400–402] and gene delivery systems [403]. These 
elastomers have been doped with urethane bonds [404], and modified with amino acids 
[405], maleic acid [406] and sebacic acid [407], thus increasing the number of potential 
applications of these polymers. More recently, glycerol and citric acid-based 
biodegradable polyesters for drug delivery have been developed [408].  
Citric acid, as an additive, has been used as a porogen in combination with carbonate salts 
in the development of porous scaffolds based on poly(L-lactic acid) [409], glycolic acid 
and lactic acid [410], poly(propylene fumarate) [411], ELPs [348] and CPCs [412]. In the 
case of CPCs, citrate has been also used to achieve scaffolds with improved injectability 
[413,414], compression strength [413,414], and biocompatibility and osteoconduction. 
[390,391].  
Citrate has also been used as a crosslinker, given that it is a natural and biocompatible 
molecule possessing three carboxyl groups feasible to be used in reticulation reactions. 
However, carboxyl groups lack reactivity, so crosslinking with citric acid needs to be 
induced. First, the formation of peptide bonds by the condensation of –COOH from citric 
acid and primary amines from prolamines and collagen [415–417] has been achieved by 
applying high temperatures (usually, in the 125-150ºC range), conditions clearly 
detrimental if natural proteins or GEPBPs are to be crosslinked. A second and more gentle 
strategy is based on the use of NHS esters of citric acid upon chemical activation with 
carbodiimides. NHS-esterified citric acid has been produced by chemical synthesis, a 
time-consuming option involving the use of organic solvents, and employed to produce 
hydrogels [418,419] to be used as tissue adhesives [420], vascular stents [421,422] or 
scaffolds for vascular tissue engineering [423]. Interestingly, the in vivo role suggested for 
citrate in biomineralization has not yet been considered when using it for reticulation 
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purposes. This points out that citric acid can be used as a novel bioactive crosslinker 
providing lysine-displaying polymers with calcium phosphate nucleation potential. 
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1.5 LYSYL OXIDASE 
1.5.1 Lysyl oxidase: an overview 
Lysyl oxidase (or LOX; EC 1.4.3.13) is a copper-dependent amine oxidase responsible for 
the in vivo crosslinking of elastin and type I collagen. This protein, first described in 
embryonic chick bone, catalyzes the specific oxidative deamination of ε-NH2 (Figure 17) 
from lysine present in collagen and elastin [424], as well as from hydroxylysine in 
collagen [425].  
 
Figure 17. LOX-catalyzed oxidative deamination of lysine and hydroxylysine residues. R1: 
H in lysine; R1:OH in hydroxylysine. 
LOX belongs to the lysyl oxidases family, together with lysyl oxidase-like (LOXL) 
proteins 1-4. All the members of the family show a highly conserved C-terminus (it 
suggests LOXL proteins would also possess enzymatic activity [426,427]; Figure 18) and 
divergence in the N-terminus, which is thought to be related to LOX/L-to-protein 
interactions, as evidenced by studies showing that the N-terminal of LOX and LOXL 
mediate substrate recognition [428]. 
Increasing evidences point out that LOX and LOXL proteins possess a spatially and 
temporally-regulated expression and oxidize specific substrates. Lysyl oxidases have been 
shown to possess tissue-specific expression patterns [426,429–433] which, together with 
their temporally-regulated expression, may have an effect on their functions, as evidenced 
by studies pointing out that these enzymes can possess a tumor suppressor role and can 
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also be involved in cancer progression, vascularization and metastasis [434,435]. 
Although the substrate specificity of LOXL proteins is still unclear, studies focused on the 
spatial expression of lysyl oxidases are shedding light on their putative substrates. For 
example, LOX and LOXL have been shown to co-localize with type I and III collagens, 
respectively [436], and LOX-2 co-localizes with type IV collagen in several tissues [426], 
which suggests that lysyl oxidases would have preferential substrates. However, a given 
protein can be oxidized by different lysyl oxidases, as in the case of elastin, which can be 
processed both by LOX and LOXL, with LOX showing a higher oxidative activity for 
elastin [426] and assumed to be the main member of the family crosslinking this protein. 
 
Figure 18. Schematic representation of domains within LOX and LOXL proteins. From 
[434].  
Human LOX is synthetized in the form of a 47 kDa preproenzyme that, after undergoing 
removal of the signal peptide and N-glycosilation, is secreted in the form of a 50 kDa 
proenzyme [437] (Figure 19). Once in the extracellular space, the proenzyme undergoes 
proteolysis carried out by C-proteinases [438–440], mainly BMP-1 and mTLL-1 
(mammalian Tolloid-like 1) [440], leading to the 32 kDa non-glycosilated, active version 
of the enzyme [438,441] and to a 18 kDa N-glycosilated pro-peptide. Interestingly, the 
propeptide has been shown to mediate substrate recognition [442], to inhibit osteoblast 
proliferation [443] and to be a tumor suppressor [442,444–447] and it is a candidate 
oligopeptide to be used in the treatment of cancer. 
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Figure 19. Synthesis of active human LOX. Adapted from [434]. 
For LOX to be active, it requires the presence of two cofactors: Cu2+ and lysyl-
tyrosylquinone (LTQ). During the proenzyme stage, a Cu2+ atom is incorporated into the 
active site by complexation with histidine residues [448–451]. The incorporation of the 
metallic atom induces a self-catalytic reaction leading to the formation of a covalent bond 
linking a tyrosine residue with the side chain of a lysine residue, thus leading to the 
formation of LTQ [452].  
The LTQ cofactor gets reversibly modified during oxidative deamination, which follows a 
ping-pong mechanism. During the first half of the reaction, an ε-NH2 from a lysine or 
hydroxylysine residue binds to the active site through LTQ, it becomes oxidized and it is 
then released while the LTQ is now in an “aminated” (reduced) state; in the second half of 
the reaction, the enzyme is reconstituted to its initial (oxidized) state [336,453]. The 
modified residue possesses now an aldehyde group and it is known as allysine or 
hydroxyallysine depending on whether the oxidized residue was lysine or hydroxylysine, 
respectively. The modified residue can then react with another modified residue (aldol 
condensation) or with an unmodified residue to form a Schiff base, which can undergo 
Amadori rearrangement leading to a ketoimine. Divalent crosslinks further react with 
single residues to form pyrroles and pyridinolines mature trivalent crosslinks in collagen, 
or tetravalent desmosine and isodesmosine in elastin; both divalent and more complex 
crosslinks coexist both in collagen [24] (Figure 20a) and elastin [454] (Figure 20b). 
Crosslinking of fibrillar collagens is essential for their structural role [455] and, 
interestingly, collagen in tough tissues displays great content in trifunctional crosslinks 
[455], suggesting a mechanical role for multivalent crosslinks also assumed for 
desmosines in elastin. Thus, LOX-catalyzed crosslinking is likely to be essential in 
determining the mechanical performance of elastic tissues such as blood vessels. 
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Figure 20. LOX-catalyzed crosslinks in collagen and elastin. a) Divalent and mature 
crosslinks found in collagen; adapted from [455]. c) Main crosslinking products found in elastin; 
i) lisinonorleucine, ii) merodesmosine (precursor for desmosines [456]), iii) demosine, and iv) 
isodesmosine; Adapted from [457].  
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1.5.2 Factors affecting LOX activity 
During decades, scientists have been intrigued as to the capacity of LOX to crosslink both 
elastin and collagen despite sequences contiguous to lysine residues are quite different in 
both proteins [458]. Early studies on the specificity of the enzyme showed it is active 
against short aliphatic diamines, but its activity seemed to be limited in these conditions, 
given that short compounds would end up inactivating the enzyme [459], especially when 
two lysine residues are close to each other [460,461]. In the case of elastin, positively-
charged residues close to lysine residues would permit a proper interaction between the 
substrate and the active site (it would be acidic, just like the protein itself [458]) for 
oxidative deamination to take place. Globally, the net charge of the substrate would have 
also an effect on LOX activity, showed to be boosted when the substrate to crosslink has 
an isoelectric point (pI) higher than 8 [458]. However, the most important parameter 
seems to be the side chain volume of those amino acids flanking lysine residues: the more 
voluminous the side chain, the lower the oxidation rate [458,461]. This is consistent with 
the fact that lysine residues in tropoelastin are commonly located in domains rich in 
alanine (i.e. crosslinking domains) [462], the amino acid with the second shortest side 
chain. Interestingly, this parameter not only affects reaction kinetics, but it has also an 
effect on the type of crosslink generated during the reaction. Residues with voluminous 
side chain are commonly found contiguous to –KAAK- domains, which would prevent the 
oxidation of  the closest lysine; -KAAAK- domains are generally flanked by alanine 
residues so lysines can be effectively oxidized [454] (Figure 21). Additionally, the three-
dimensional configuration of the substrate plays a role in determining the type of crosslink 
generated. For example, desmosine and isodesmosine are formed exclusively when the 
protein is in a coiled state so –KAAK- and –KAAAK- sequences are close to each other. 
Elastin also contains –KP- domains, where lysine is spaced by one or more proline 
residues [463], which are not involved in the formation of tetravalent crosslinks. To sum 
up, LOX activity is affected by the length, sequence, charge and spatial configuration of 
the substrate.  
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Figure 21. Crosslinks occurring in domains 10, 19 and 25 in coiled tropoelastin. From [454]. 
1.5.3 LOX and ELPs 
Using collagen [425] and tropoelastin [464], scientist have demonstrated that these 
proteins are crosslinked with maximum efficiency when aggregated in the form of 
fibrillary collagen and coacervated elastin. In the case of tropoelastin, coacervation would 
be required for a proper alignment of molecules [465]. Kagan and co-workers investigated 
the specificity of the enzyme for ELPs poly(X-Pro-Gly-Gly), poly(Val-Pro-Gly-X-Gly) 
and poly(Ala-Pro-Gly-X-Gly-Val), where X is valine or lysine, and the valine-to-lysine 
ratio is 4:1 [466]. When incubating the polypeptides with purified LOX, they detected the 
formation of allysyl residues in all cases, but crosslinks were just found in the case of the 
pentapeptide-based polymer, which was thought to be due to differences regarding their 
capacity to coacervate. When repeating the experiment with the poly(VPGXG) polymer at 
55ºC, they found an increased formation of allysyl and crosslinking products. This would 
be due to a displaced equilibrium favoring the coacervated form of the polymer and thus 
the intra- and interchain interactions. Additionally, the authors of the study concluded that 
the pentapeptide most of modern ELPs are based on would possess a proper 
hydrophobicity to allow enzyme-polymer interactions and crosslinking to take place. 
LOX-catalyzed crosslinking is thus an interesting strategy to design highly biomimetic 
hydrogels having (VPGXG)-based ELPs as raw materials.  
ELPs-based polymeric matrices for tissue engineering have already been produced by 
enzymatic crosslinking [329,333,357]. However, these approaches are based on the use of 
transglutaminase, which catalyzes the formation of covalent bonds between lysine and 
glutamine residues in type II [467,468], type III B [469], and type V and IX [470] 
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collagens and for which no activity against elastin has been demonstrated in vivo. Up to 
date, just two studies have reported the successful use of LOX to insolubilize (i) ELPs 
when studying the specificity of the enzyme [466] and (ii) polymers based on adhesive 
proteins of mussel foot to study the adhesion mechanisms of these animals [461]. In the 
vascular tissue engineering field, vascular smooth muscle cells have been supplemented 
with hyaluronic acid and Cu2+ [471,472] or bovine LOX [473] in order to successfully 
increase the cellular deposition of insoluble elastin. To our knowledge, LOX has not yet 
been used to produce scaffolds for tissue engineering and is a novel method to produce 
scaffolds highly resembling the extracellular matrix of selected tissues. 
Up to date, LOX has been mainly obtained and purified from animal sources such as 
bovine aorta [458–461,466,473–479], human placenta [480], mussel foot [461], bovine 
articular cartilage [475], bone from chick embryo [424], cartilage from chick embryo 
[481], piglet skin [482] and aorta from chick embryo [475]. Despite the protocols to obtain 
active LOX from animal tissues are quite established, especially using bovine aorta as a 
source, the purification process is complex and time-consuming and, additionally quantity 
and activity-related batch-to-batch issues are inherent. Given that the active form of the 
enzyme doesn’t possess any post-translational modification (N-glycosilation is lost during 
proteolysis of the proenzyme), it is feasible to produce it in good yields using Escherichia 
coli as a bioreactor [483–485]. This would allow the in vitro use of the enzyme to produce 
nature-inspired scaffolds for tissue engineering.  
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1.6 CHALLENGES IN BONE TISSUE ENGINEERING 
Global aging and the increased incidence of age-related pathologies are expected to lead to 
a rise in the number of fractures in the coming decades [131,132]. With allo and autografts 
being a gold standard, yet a limiting factor for the treatment of non-healing fractures 
[130], synthetic scaffolds making the most of the natural regenerative cascades and 
helping the body reconstruct the damaged tissue hold great promise. Fourth-generation 
(i.e. biomimetic) biomaterials aim to recapitulate the cellular events taking place during 
development by specifically stimulating stem and progenitor cells. With this purpose, the 
ECM is taken as a reference for the design and development of hydrogels for bone tissue 
engineering, which are now aimed to provide MSCs with complex combinations of 
signals to drive their differentiation towards osteogenic phenotypes. 
In the last decades, much effort has been made to develop polymers with nature-inspired 
chemical motifs to create synthetic matrices. More recently, authors have demonstrated 
that physical cues such as stiffness and topography from the extracellular matrix also 
affect cell behavior [239,242]. However, scaffolds focusing on single signals, either 
chemical or physical, fail to reproduce the complex microenvironment surrounding cells, 
whose behavior depends on the integration of multiple specific signals. Despite scaffolds 
with such a complexity level are far from being available, great efforts are being made to 
develop matrices with increasing complexity and with a greater control of their particular 
parameters.  
Early combinatorial studies have shown that cell behavior strongly depends on the 
synergistic effect of matrix parameters [246–248], evidencing that an exquisite scaffold 
design is required to induce the formation of native tissue. While much work has been 
done to achieve polymers with tailored chemistry, either by chemical/recombinant 
synthesis [306,307,486] or by functionalization [247], tailoring physical properties of 
hydrogels is still challenging. 
Two of the most studied physical cell-instructing features are stiffness and structure. 
Stiffness has been successfully modified by adjusting the amount of crosslinker used to 
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prepare scaffolds [246,247]; structure is commonly tailored by means of techniques such 
as electrospinning or lithography, or by using chemical additives such as porogens. 
However, electrospinning and lithography usually suffer porosity [257] and thickness 
limitations [487], respectively, thus leading to scaffolds with tailored topography (2.5D) 
rather than tailored bulk structure (3D). The use of porogens is effective at creating 
matrices with open pores to allow cell colonization (and thus the formation of tissues in 
3D) [348], but fail to provide cells with specific structural features. New strategies to tailor 
scaffold architecture are then required in order to produce hydrogels with increased 
complexity able to finely control cell behavior. 
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2.1 RATIONALE AND SPECIFIC AIMS OF THE THESIS 
2.1.1 Rationale 
In this thesis, we explore the usefulness of crosslinking as a tool to produce hydrogels with 
chemical and physical signals to induce the osteogenic differentiation of MSCs. With this 
purpose, two nature-inspired crosslinking methods have been considered for the 
production of cell-free scaffolds for in situ bone tissue engineering.  
2.1.2 Specific aims 
1. Selecting biologically-relevant molecules feasible to be used to crosslink elastin-like 
polymers into cyto and biocompatible scaffolds. 
2. Developing and characterizing citric acid-crosslinked hydrogels with tailored physical 
properties. 
3. Characterizing the in vitro and in vivo biological performance of citric acid-crosslinked 
hydrogels. 
4. Producing, purifying and characterizing recombinant human lysyl oxidase for the 
production of hydrogels for tissue engineering. 
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3 CHAPTER 2 - FABRICATION OF TAILORED SCAFFOLDS FOR BONE 
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PREFACE 
 
This chapter represents the systematic study that allowed the design of citric acid-
crosslinked hydrogels with cell-instructive features. After optimizing the generic chemical 
crosslinking reaction, the effect of specific reaction parameters on hydrogels properties 
was systematically assessed. Understanding and controlling the crosslinking reaction 
allowed the production of tailored structurally and mechanically-tailored hydrogels 
displaying functional groups for scaffold mineralization and peptide sequences available 
for cell adhesion.  
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3.1 MATERIALS AND METHODS 
3.1.1 Elastin-like recombinamers (ELRs) 
ELRs were provided by BIOFORGE group. Three different ELRs were used, all of them 
being based on the repetition of the VPGXG peptapeptide (Figure 22). HRGD6 polymer  
contains the RGD tripeptide and lysine residues for cell adhesion and crosslinking, 
respectively [304]; REDV polypeptide contains REDV for the adhesion of vascular cells, 
lysines for crosslinking and VGVAPG, the target sequence for elastase [306]; IK24 ELR  
contains crosslinking residues [488]. 
 
Figure 22. Schematic representation of HRGD6, REDV and IK24 ELRs. Light green: cell 
adhesion sequences; light blue: target sequence for elastase; green: crosslinking residues. 
3.1.2 Glutaraldehyde-crosslinked hydrogels 
3.1.2.1 Sample preparation 
40 mg/ml HRGD6-glutaraldehyde (from now on, HRGD6-glut) hydrogels were prepared 
at a 1:3 lysine:aldehyde group ratio. The polymer was dissolved in ultrapure water 
overnight at 4ºC and mixed with 5% glutaraldehyde in ultrapure water at a 1:1 volume 
ratio. Reaction mixes were vortexed thoroughly, dispensed on 6-mm polydimethylsiloxane 
(PDMS; Sylgard 184 Elastomer kit, Dow Corning) molds and let to react for 7:30 at 4ºC. 
Then, unreacted aldehydes were reduced by incubating hydrogels on ice for 2 h with 1% 
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NaBH4 in phosphate-buffered saline (PBS), and washed several times with PBS. 54 mg/ml 
HRGD6 samples (RGD-G) were prepared as abovementioned, reduced on ice with 5% 
NaBH4 in PBS for 2 hours, and thoroughly washed with PBS.  
3.1.2.2 Autofluorescence: selection of candidate chemical treatments 
HRGD6-glut hydrogels were prepared as previously stated (but not reduced with NaBH4) 
and assessed for nonspecific fluorescence. Samples for the reduction of autofluorescence 
were also prepared as abovementioned and subjected to six candidate chemical treatments 
(Table 4).  
Treatment  Function Reference 
NaBH4 Reduction of aldehydes and Schiff bases [489,490] 
NH4Cl Blockage of aldehydes [491] 
Glycine Blockage of aldehydes [489] 
Schiff’s reagent + NaBH4 Blockage of aldehydes+quenching of fluorescence [492] 
Trypan blue Quenching of fluorescence [493] 
Toluidine blue Quenching of fluorescence [494] 
Table 4. Treatments used to reduce autofluorescence. 
Toluidine blue (TolB), trypan blue (TryB), NH4Cl  and glycine treatments consisted on 
incubating samples with 0.1% TolB in PBS, 0.4% TryB (Sigma) or 50 mM NH4Cl in 
PBS, respectively, for 3h at RT. After incubation, samples were washed several times with 
PBS. NaBH4 treatment consisted on incubating hydrogels with 0.1% NaBH4 in PBS for 2 
h on ice. Samples were then washed several times with PBS. Schiff’s reagent + NaBH4 
treatment consisted on incubating hydrogels with Schiff’s reagent (Sigma) for 3h at RT. 
Samples were then washed for 5 minutes 3 times with sulfurous water (5 ml 10% Na2S2O5  
in ultrapure water + 5 ml HCl + 100 ml ultrapure water for a final volume of 110 ml) and 
subjected to NaBH4 treatment as previously stated. Control (untreated) samples were 
crosslinked and washed several times with PBS.  
To qualitatively assess the effect of chemical treatments, treated and untreated samples 
were visualized under an Eclipse TE200 inverted microscope (Nikon, Japan) and 
MetaMorph Microscopy Automation & Image Analysis Software (Molecular Devices, 
version 5.0r1). A 4x objective, a gain of 2 and a binning of 1x1 were used; images in blue, 
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green and red channels were acquired with 150 ms, 100 ms and 50 ms exposure, 
respectively. To assess the emission spectra of treated and untreated samples, hydrogels 
were placed on glass slides and visualized under a Leica TCS SP5 confocal microscope 
(Leica, Germany) and LAS-AF software (Leica; version 2.4.1 build 6384) in xyλ mode. 
Hydrogels were excited with different laser lines and emission was recorded with 
wavelength increases of 7 nm, a pinhole of 53.1 µm (1 airy unit) and a constant gain. 
Excitation and emission wavelengths are summarized in Table 5.  
Excitation wavelength Emission wavelength 
405 nm 415-695 nm 
458 nm 465-699 nm 
488 nm 495-792 nm 
514 nm 520-789 nm 
561 nm 570-797 nm 
633 nm 640-797 nm 
Table 5. Summary of excitation and emission wavelengths used to study the effect of 
chemical treatments on hydrogel autofluorescence. 
3.1.2.3 Optimization of candidate chemical treatments to reduce autofluorescence 
HRGD6-glut hydrogels were prepared as previously stated in 16-well Lab-Tek glass 
chamber slides (Nunc) and tested for the effect of toluidine blue and trypan blue 
treatments before cell seeding (post-treatment seeding) and after cell staining (pre-
treatment seeding). In both cases, samples were incubated with either toluidine blue or 
trypan blue for 3 hours at RT; pre-seeding treatment samples were washed until no 
apparent dye release was noticed; post-treatment seeding samples were washed to remove 
excess dye limiting light exposure in order to avoid the bleaching of specific fluorescence. 
Rat MSCs (rMSCs) were cultured in 75 cm2 flasks at 37°C in a 5% CO2 atmosphere. Cell 
expansion was carried out in complete medium: AdvDMEM (Gibco) supplemented with 
15% FBS (Gibco), 2 mM L-glutamine (Gibco), 100 U/ml Penicillin and 100 μg/ml 
Streptomycin (Gibco). Cells were detached at a confluence of about 80% with Tryp-LE 
Express (Gibco) and the number of viable cells was determined after staining with Trypan 
blue. 2.5·103 viable cells were seeded on each sample and kept in culture for 24 hours. 
Samples were then treated with fixative solution (3% paraformaldehyde and 40 mM 
sucrose in PBS) for 10 minutes at 4°C, washed three times with cold 0.15% glycine in 
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PBS (PBS-gly), permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for 5 minutes and 
stained with 4 μg/ml 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI; Sigma) for 2 
minutes for nuclei observation. Samples were visualized under an Eclipse TE200 inverted 
microscope by using MetaMorph software.  
3.1.3 Citric acid-crosslinked hydrogels 
3.1.3.1 Reaction setup 
3.1.3.1.1 Reaction optimization 
As previously mentioned, the dielectric constant (ε) of the solvent can affect the route 
through which the carbodiimide-catalyzed reaction evolves. Thus, the suitability of using 
different solvents was assessed by testing the solubility of citric acid (11.8 mM), IK24 
ELR (80 mg/ml), NHS (76.95 mM) and EDC (192.38 mM) in N-hexane (Panreac), diethyl 
ether (Aldrich), tetrahydrofuran (Sigma), 96% ethanol (Panreac), 8:2 ethanol:water, and 2-
(N-Morpholino)ethanesulfonic acid (MES, Sigma) buffer. 
To test the effect of the pH of reaction mixes on crosslinking occurrence, different samples 
were prepared. IK24 polymer was dissolved in 0.109 M MES buffer containing citric acid; 
EDC and NHS were independently dissolved in MES buffer. Citric acid-IK24, EDC and 
NHS solutions were mixed at 1:1:1 volume ratio (polymer concentration: 26.7 mg/ml) at a 
constant 2:2:1 EDC:NHS:COOH molar ratio and 1:1.06, 1:3.25, 1:5.44 and 1:9.3 
NH2:COOH molar ratios to produce 1:1, 1:3, 1:5 and 1:10 samples, respectively. Reaction 
mixes with adjusted and non-adjusted pH were incubated at 37ºC for 2 h and assessed for 
gelation occurrence. Additionally, samples 1:1 were prepared at a 2:-:1 EDC:NHS:COOH 
molar ratio (NHS was substituted by MES buffer) to assess whether EDC alone could lead 
to crosslinking. The pH of all reaction mixes was measured by properly mixing all 
reagents except IK24 polymer, assumed not to contribute to the pH of the solution.  
To test the effect of polymer concentration on hydrogel consistency, IK24 hydrogels were 
prepared at EDC:COOH 1.88:1 and COOH:NH2 1:1 molar ratios in MES buffer. 26.7 
mg/ml samples were prepared by mixing citrate-polymer, EDC, and MES solutions at a 
1:1:1 volume ratio; 40 mg/ml samples were prepared by mixing citrate-polymer and EDC 
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solutions at a 1:1 volume ratio. pH was adjusted to ca. 6 and reaction mixes were 
incubated at 37ºC for 2 hours. 
In order to check whether the crosslinking method developed with IK24 could be applied 
to HRGD6 polymer, 40 mg/ml IK24 and HRGD6 hydrogels at EDC:COOH 3.33:1 and 
COOH:NH2 1:1 molar ratios were prepared. Polymers were independently dissolved in 
citrate-containing MES buffer at 4ºC and mixed with EDC solutions. pH was adjusted to 
ca. 6 and reaction mixes were incubated at 37ºC for 2 hours.  
The pH evolution of selected samples was monitored to make sure that reaction mixes are 
properly buffered to keep a crosslinking-permissive pH during the reaction. HRGD6 
polymer, citric acid and EDC were mixed in a microtube to achieve reaction mixes with a 
40 mg/ml polymer concentration, and EDC:COOH 9.3:1 and COOH:NH2 3.25:1 molar 
ratios in MES buffer. pH was adjusted to ≈ 6 and the microtube tube was partially 
immersed in a jacketed water bath at 37ºC. pH was monitored using a Crison 50 28 
microelectrode and a Crison GLP 22+ pHmeter (Crison, Spain). 
To check whether REDV, an ELR containing a high number of acidic residues, is feasible 
to be crosslinked by means of herein developed reaction, REDV was assessed for 
crosslinking in the absence of citric acid. Thus, REDV was dissolved in MES buffer and 
mixed with EDC solutions to achieve reactions mixes with 1:1, 2:1 and 3:1 EDC:COOH 
molar ratio and a 2.48:1 COOH:NH2 molar ratio at a 40 mg/ml polymer concentration and 
pH ≈ 6.  
3.1.3.1.2 Effect of acid/base temperature 
To test the effect of the temperature of the acid/base used to adjust pH on the kinetic 
variability of crosslinking, HRGD6 polymer, citric acid and EDC were mixed to achieve 
reaction mixes with a 40 mg/ml polymer concentration, and EDC:COOH 9.3:1 and 
COOH:NH2 3.25:1 molar ratios in MES buffer. pH was adjusted to ≈ 6 with HCl either at 
4ºC or RT and reaction mixes were poured into 96-well plates at RT. Absorbance 
evolution was recorded at 37°C and λ=750 nm for 62.5 minutes using an Infinite M200 
Pro multimode reader and i-control software (Tecan, Switzerland), and collected data were 
treated with Origin (OriginLab, version 8.0724). Four kinetic parameters were analyzed: 
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(i) latency time (i.e. the time lapse between the beginning of the incubation and the initial 
increase in turbidity), (ii) reaction length (i.e. the time lapse between the onset of 
variations in turbidity and the time by which dAbs/dt returns to basal levels), (iii) 
maximum velocity (Vmax, max dAbs/dt), and (iv) maximum absorbance (Amax). Latency 
time, reaction length and Vmax were obtaining by using the Spectroscopy Peak Analyzer 
tool in Origin after performing mathematical derivation of the absorbance data. 
3.1.3.1.3 Effect of substrate temperature 
To test the effect of the temperature of the substrate on the kinetic variability of 
crosslinking, reaction mixes with a 40 mg/ml polymer concentration, and EDC:COOH 
9.3:1 and COOH:NH2 3.25:1 molar ratios in MES buffer were prepared. pH was adjusted 
to ≈ 6 and reaction mixes were poured into 96-well plates at either 4ºC, RT or 37ºC. The 
absorbance evolution was recorded and kinetic parameters were obtained as previously 
stated. 
3.1.3.1.4 Autofluorescence of citric acid-crosslinked hydrogels 
40 mg/ml HRGD6 hydrogels were prepared at EDC:COOH 1.88:1, COOH:NH2 2.16:1.06 
molar ratios (pH ≈ 6) and washed with PBS to remove excess reagents. Autofluorescence 
was visually assessed under an Eclipse TE200 inverted microscope using MetaMorph 
software and emission spectra were acquired using a Leica TCS SP5 confocal microscope 
as previously stated.  
To test the effect of trypan blue on reducing the autofluorescence of citric acid-crosslinked 
hydrogels, samples were prepared as abovementioned and incubated with 0.4% trypan 
blue for 3 h at RT. Hydrogels were thoroughly washed until no apparent dye release was 
noticed, sterilized with 70% ethanol under UV irradiation for 1 hour and washed several 
times with PBS. 5·103 rMSCs were seeded on samples, which were kept in culture for 24 
hours. Cells were fixed and permeabilized as previously stated and stained with Acti-Stain 
488 phalloidin (Cytoskeleton) in the conditions suggested by the manufacturer, and with 4 
μg/ml DAPI for 2 minutes. Hydrogels were then mounted with Mowiol 40-88 (Sigma-
Aldrich), sealed with nailpolish and observed by confocal microscopy with a stepsize of 
670 nm and a pinhole of 1 airy unit.  
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3.1.3.2 Effect of molar ratios on hydrogels properties 
3.1.3.2.1 Sample preparation  
HRGD6 polymer was crosslinked with citric acid through an EDC-catalyzed reaction in 
0.109 M MES buffer. Seven different hydrogels, each one characterized by a particular 
combination of EDC:COOH and COOH:NH2 molar ratios, were prepared (Table 6). 
Setups were encoded in the form EXCY, where EX denotes the molar excess (X) of EDC 
with respect to –COOH groups and CY denotes the molar excess (Y) of -COOH with 
respect to -NH2 groups. In all cases, HRGD6 polymer was dissolved overnight at 4ºC in 
MES buffer containing citric acid monohydrate; similarly, EDC was dissolved overnight 
at 4ºC in MES buffer. Polymer-citrate and EDC solutions were mixed at a 1:1 volume 
ratio (polymer concentration: 40 mg/ml) and pH was adjusted to ≈ 6 by adding cold NaOH 
or HCl. Crosslinking reactions were carried out at 37°C for 1 h on substrates at RT and 
stopped by incubation with 0.1 M Na2HPO4 at room temperature for 3 hours. Samples 
were then washed by performing 5 swelling/shrinking incubation cycles in ultrapure water 
at 4°C (swelling)/37°C (shrinking) to allow excess EDC and reaction by-products to be 
released. 
Code EDC:COOH COOH:NH2 
 E2C1       1.88:1 1.06:1 
 E3C1       2.82:1 1.06:1 
 E5C1        4.7:1 1.06:1 
 E9C1        9.3:1 1.06:1 
 E9C2         9.3:1 2.16:1 
 E9C3         9.3:1 3.25:1 
 E9C5         9.3:1 5.44:1 
Table 6. Summary of the conditions used to prepare citric acid-crosslinked hydrogels.  
3.1.3.2.2 Gelification and kinetics 
Reaction mixes for all seven different hydrogels were prepared as abovementioned and 
poured into 96-well plates. Absorbance evolution was monitored at 37ºC and kinetic 
parameters were quantified as previously mentioned. 
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3.1.3.2.3 Unreacted –NH2 groups 
Hydrogels were prepared in 96-well plates and incubated with 100 µl of a 10.55 mM 
2,4,6,-trinitrobenzenesulfonic acid (TNBS, Sigma) solution in 9:1 0.1 M NaHCO3:0.1 M 
Na2CO3 (pH 8.93) in the dark at 4°C with gentle stirring for 30 hours. 200 µl of 6 M HCl 
were added to completely hydrolyze samples over a 75 hours period and resulting 
solutions were diluted 1/10 in ultrapure water. Absorbance was read at λ=342 nm and 
glycine was used to prepare standard curves to stoichiometrically quantify unreacted 
primary amines. 
3.1.3.2.4 Swelling 
Hydrogels were prepared on PDMS films and incubated consecutively in ultrapure water 
at 37°C, room temperature and 4°C for 24 hours. Following each incubation, excess water 
was carefully blotted and samples were weighted. Hydrogels were finally dried at 37ºC 
and weighted again. Swelling ratio, weight increase percentage due to water absorption, is 
defined by  
 
where Ws and Wd correspond to weight in the swollen and dried states, respectively.  
3.1.3.2.5 Thermal stability 
Hydrogels were prepared on PDMS molds with 6 mm-diameter holes, dried at 37°C and 
analyzed by thermogravimetry with a TGA/DSC1-Star system thermobalance (Mettler-
Toledo, Switzerland). Measurements were performed in a nitrogen atmosphere (50 
cm3/min) from 40°C to 800°C at a heating rate of 5°C/min.  
3.1.3.2.6 Resistance to enzymatic degradation 
A pilot study was performed to adjust the enzyme concentration to be used on degradation 
experiments. Briefly, E9C5 hydrogels were prepared in 96-well plates and incubated with 
4.7·10-1, 4.7·10-2, 4.7·10-3 and 4.7·10-4 U/ml porcine pancreatic elastase (Worthington 
Biochemical Corporation), corresponding to 100 µg/ml, 10 µg/ml, 1 µg/ml and 0.1 µg/ml, 
respectively, in PBS for 1 h at 37ºC under agitation. This concentrations were selected as 
 CHAPTER 2 
 
75 
 
consulted studies used the protein at concentrations in the 0.1 µg/ml – 300 µg/ml range 
[495–497]. Absorbance evolution at 750 nm was recorded as previously stated. 
After optimizing enzyme concentration, E2C1, E9C1 and E9C5 setups were selected to 
simplify the degradation study. Hydrogels were prepared in 96-well plates and incubated 
with 2.82·10-3 U/ml porcine pancreatic elastase in PBS at 37ºC for 1, 3 and 7 days. 
Hydrogels not exposed to elastase were used to set sample weight at day 0. At every time 
point, samples were washed with ultrapure water, dried at 37ºC and weighted.  
3.1.3.2.7 Structure 
Samples to be assessed by confocal microscopy were prepared on 16-well glass chamber 
slides and stained with 0.4% Trypan blue for 3 hours at room temperature. Several 
washing steps with PBS were performed until no apparent dye release was noticed. 
Hydrogels were fixed as previously mentioned, mounted with Mowiol 40-88 (Sigma-
Aldrich) and sealed with nailpolish. Images were adquired at an emission wavelength 
range of 579-657 nm and a stepsize of 80 nm by using a TCS SP5 confocal microscope 
and LAS-AF software. The size of polymer aggregates was measured with Fiji [498]. 
Hydrogels to be observed by Field Emission Scanning Electron Microscopy (FESEM) 
were prepared in PDMS molds, washed with water several times to remove salts, 
lyophilized and sputtered with graphite. FESEM images were obtained by using a NOVA 
NANOSEM 230 microscope (FEI, United States) at a 3.00 kV voltage and 5.2 mm 
working distance.  
3.1.3.2.8 Percentage polymer-occupied volume 
Sections obtained by confocal microscopy were used to quantify PV/TV (Polymer volume 
fraction; i.e. polymer-occupied volume/total volume). PV/TV was quantified with Volume 
Fraction tool (BoneJ [499] plugin v.1.3.11 for Fiji) using the surface algorithm with a 
surface resampling value of 2 and a specific threshold for each set of images. 3D 
reconstructions of quantified volumes were analyzed to assess volume calculations were 
performed using proper thresholding. 
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3.1.3.2.9 Surface stiffness 
All seven different hydrogels were prepared as previously stated to test the effect of molar 
ratios on surface stiffness. All samples were prepared in 6 mm-diameter PDMS molds and 
kept in PBS at 37°C until use. Molds were mounted on glass slides using double-sided 
tape and ten force curves per sample were acquired in Force Mode using IGOR Pro 
sofware (Wavemetrics, version 6.2.2.2A) and a MFP-3D stand alone unit (Asylum 
Research, United States). Measurements were made in PBS at 37°C using chromium and 
gold-coated, pyramidal silicon nitride cantilevers (NanoWorld) with a nominal spring 
constant of 0.08 N/nm and assuming Poisson’s ratio to be 0.5. A custom-made script 
considering cone-shaped tip was used to calculate Young’s modulus by means of Hertz 
model.  
3.1.3.3 Effect of reaction conditions on hydrogels cytotoxicity and RGD integrity 
3.1.3.3.1 Cytotoxicity 
rMSCs were expanded as previously mentioned and 104 viable cells/well were seeded on 
24-well plates and allowed to adhere for 4 hours. Non-adhered cells were washed out with 
PBS and attached cells were quantified with 10% Alamar blue (TREK Diagnostic 
Systems) in complete medium to verify homogenous adhesion in all wells. Cells were then 
washed with PBS and wells were subsequently replenished with complete medium.  
Selected hydrogels were tested for cytotoxicity by indirect contact. Samples prepared in 
PDMS molds were sterilized with 70% ethanol under UV irradiation for 1 hour, washed 
thrice with PBS and kept in the buffer at 37°C until use. Polyethylene terephthalate (PET) 
Millicell Inserts (Millipore) with a 0.4 µm pore size were placed into wells and 300 µl of 
culture medium were added to each insert. Hydrogels were then washed twice with PBS to 
remove remaining ethanol and transferred to inserts. Negative controls (TCPS) consisted 
on inserts containing just complete medium; positive controls consisted on the use of 
complete medium supplemented with 1% phenol (Sigma-Aldrich) in both the wells and 
the inserts. 
After a 42.5 hours incubation period at 37°C and 5% CO2, cytotoxicity by indirect contact 
was assessed by cell quantification with Alamar blue and cell morphology examination. 
For cell shape visualization, cells were washed with DPBS (Gibco), stained in the dark 
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with 2 µM Calcein AM (Sigma-Aldrich) for 20 minutes at 37°C and washed with the 
buffer to remove excess dye. Images were acquired using an Eclipse TE200 inverted 
microscope and MetaMorph Microscopy Automation & Image Analysis Software.  
3.1.3.3.2 Cell adhesion 
Samples were prepared on 16-well Lab-Tek glass chamber slides, stained with Trypan 
blue and washed until no apparent dye release was noticed. rMSCs were expanded as 
previously stated, seeded at a final density of 2.5·103 viable cells/sample and kept in 
complete medium for 24 hours. Samples were fixed with paraformaldehyde, 
permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for 5 minutes, blocked with PBS-
gly supplemented with 6% bovine serum albumin (BSA; Sigma) for 45 minutes and 
stained in the dark at room temperature for vinculin and nuclei observation. Briefly, cell 
staining consisted on: (i) incubation with mouse anti-vinculin primary antibody (Sigma) at 
a 1/400 dilution in PBS-gly supplemented with 3% BSA (PBS-gly-BSA 3%) for 1h, (ii) 
incubation with Alexa 488-conjugated goat anti-mouse secondary antibody (Molecular 
Probes) at a 1/300 dilution in PBS-gly-BSA 3% for 1h, and (iii) incubation with 4 μg/ml 
DAPI (Sigma) for 2 minutes. Hydrogels were then mounted, sealed and observed by 
confocal microscopy. Volocity 3D Image Analysis Software (Pelkin Elmer, version 6.2.1) 
was used to obtain 3D reconstructions. 
3.1.3.4 Design and characterization of tailored hydrogels 
3.1.3.4.1 Surface stiffness  
An EDC:COOH 9.3:1, COOH:NH2 1.06:1 combination of molar ratios was selected to 
test the influence of polymer concentration on stiffness. Samples were prepared at 40, 54, 
80 and 160 mg/ml polymer concentrations and stiffness was quantified as previously 
stated. 
3.1.3.4.2 Structure of mechanically-tailored hydrogels 
Hydrogels were prepared at a polymer concentration of 54 mg/ml using the EDC:COOH 
9.3:1, COOH:NH2 1.06:1 combination of molar ratios (from now on, RGD-C samples), 
incubated with 0.1 M Na2HPO4 for 3h at RT and washed with PBS by performing 
swelling/shrinking cycles. Samples to be observed by confocal microscopy were stained 
with Trypan blue, and mounted and visualized as previously stated. Hydrogels to be 
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visualized by FESEM were subjected to serial dehydration in ethanol and critical point 
drying with CO2. A voltage of 5 kV and a working distance of 6 mm were used to acquire 
images. The diameter of polymeric trabeculae was quantified using Fiji. 
3.1.3.4.3 In vitro mineralization 
To assess citrate-related calcium phosphate nucleation capacity, citric acid-crosslinked 
hydrogels with tailored stiffness (RGD-C) were compared to samples crosslinked with 
glutaraldehyde (RGD-G). RGD-C and RGD-G hydrogels were prepared as previously 
stated in 6 mm-diameter PDMS molds and thoroughly washed to remove remaining 
reagents, by-products and salts. 
Simulated body fluids (SBF) were prepared as specified in the literature [500]. Samples 
were incubated with filtered, pre-warmed SBF at 37ºC for 1, 7, 14 and 28 days; SBF was 
replaced every 3 days. At endpoints, hydrogels were washed 3 times with ultrapure water 
and kept at 37ºC until the end of the experiment.  
RGD-C samples were subjected to serial dehydration in ethanol and critical point drying 
with CO2; RGD-G samples were frozen with liquid N2 and lyophilized for two days. 
Hydrogels were then graphite-sputtered and analyzed using a Quanta 200 Scanning 
Electron Microscope (SEM; FEI) equipped with a Genesis Energy Dispersive X-Ray 
Spectroscope (EDS) system (EDAX, United States). A voltage of 20 kV and a working 
distance of 10 mm were used. 
3.1.3.4.4 Statistical analysis  
Data were analyzed by means of t-test or one-way ANOVA with Dunnett’s post hoc test. 
All analyses were performed using Prism (GraphPad, version 6.01). Results were 
considered significant when p≤0.05 unless otherwise specified.  
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3.2 RESULTS 
3.2.1 Glutaraldehyde-crosslinked hydrogels 
3.2.1.1 Autofluorescence: selection of candidate chemical treatments 
Collagen and elastin are known to possess autofluorescence [501,502], and this 
phenomenon is thought to stem from Schiff bases in the crosslinks present in these 
structural proteins [503–505]. Schiff bases are also considered to be behind the 
autofluorescence induced by glutaraldehyde upon reaction with primary amines [490,505]. 
Thus, in the case of glutaraldehyde-crosslinked ELRs hydrogels, treatments aiming to 
reduce Schiff bases, to block unreacted aldehyde groups to prevent them from leading to 
newly-formed Schiff bases or to unselectively quench fluorescence are potentially useful 
to reduce background signal.  
Fluorescence microscopy revealed that aldehyde-blocking treatments (glycine and NH4Cl) 
didn’t substantially reduce autofluorescence (Figure 23d-f and j-l). NaBH4 led to reduced 
signal in the green (ca. 495-570 nm) and red (ca. 620-750 nm) channels (Figure 23g-i), 
while NaBH4 and Schiff’s reagent led to globally reduced fluorescence (Figure 23m-o). 
Toluidine blue almost completely suppressed autofluorescence in all three channels 
(Figure 23p-r), while trypan blue suppressed signal in blue and green channels and 
reduced it in the red channel (Figure 23s-u).  
Lambda scans showed that all treatments led to reduced intensity in the blue (ca. 450-495 
nm) and green channels; emission in the red channel was at least slightly reduced by all 
treatments (Figure 24). Aldehyde-blocking reagents, glycine and NH4Cl, led to 
preferentially reduced signal in the blue and green channels (Figure 24b and d), while the 
reduction of Schiff bases mainly led to reduced signal in the red channel (Figure 24c), 
although a decreased signal in blue and green was also noticed. Interestingly, combining 
aldehyde blockage and Schiff base reduction led to reduced signal in all three channels 
(Figure 24e). Fluorescence quenching suppressed the signal in blue and green channels 
and reduced fluorescence in the red channel (Figure 24f and g). 
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Figure 23. Gross autofluorescence of glutaraldehyde-crosslinked HRGD6 hydrogels. The 
signal in control hydrogels (a-c) was compared to that in samples treated with  glycine (d-f), 
NaBH4 (g-i), NH4Cl (j-l), Schiff’s reagent + NaBH4 (m-o), toluidine blue (p-r), trypan blue (s-u). 
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Figure 24. Emission spectra of glutaraldehyde-crosslinked hydrogels. Control hydrogels (a) 
and samples treated with glycine (b), NaBH4 (c), NH4Cl (d), Schiff’s reagent + NaBH4 (e), 
toluidine blue (f) and trypan blue (g) were excited at 405 nm (black), 458 nm (grey), 488 nm 
(green), 514 nm (blue), 561 nm (red) and 633 nm (brown) wavelengths. 
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3.2.1.2 Optimization of candidate chemical treatments to reduce autofluorescence 
Toluidine blue and trypan blue were selected as candidate treatments to reduce nonspecific 
fluorescence. Given that both compounds are generic fluorescence quenchers and can 
potentially reduce specific fluorescence, the suitability of applying them prior to cell 
seeding and after cell staining with DAPI was studied. Toluidine blue didn’t effectively 
reduced background fluorescence in any of the cases (Figure 25a and c). Although trypan 
blue in pre-treatment seeding improved the signal-to-noise ratio, the background signal 
remained quite high (Figure 25b). In contrast, when applied before cell seeding, trypan 
blue led to highly reduced background signal and allowed the proper visualization of cell 
nuclei (Figure 25d and e). Thus, trypan blue was selected to be used to reduce the 
autofluorescence of samples previous to cell seeding.  
3.2.2 Citric acid-crosslinked hydrogels 
3.2.2.1 Reaction setup 
3.2.2.1.1 Reaction optimization 
The solubility of the reagents of interest was assessed in several solvents. N-hexane and 
diethyl ether were discarded given that citric acid didn’t dissolve in these solvents (Table 
7); IK24 didn’t dissolve in tetrahydrofuran nor in ethanol and partially dissolved in 8:2 
ethanol:water, so these solvents were also discarded. All reagents dissolved in 0.109 M 
MES buffer, which was selected as the solvent for the crosslinking reaction. 
Solvent Citric acid IK24 NHS EDC ε 
N-hexane No - - - 1.88 
Et2O No - - - 4.3 
THF Yes No Yes Yes  7.5 
Ethanol Yes No Yes Yes  24.55 
Ethanol:water 8:2 Yes NC Yes Yes  ? 
0.109 M MES buffer Yes Yes Yes Yes  ? 
Table 7. Summary of reagent solubility in different solvents. Et2O: diethyl ether; THF: 
tetrahydrofuran; NC: not completely. 
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Figure 25. Assessment of candidate treatments for autofluorescence reduction. Toluidine 
blue (a and c) and trypan blue (b and d) were applied after cell nuclei staining (a and b) and 
before cell seeding (c and d). Cell nuclei were stained with DAPI. Scale bar: 100 µm. 
When studying the effect of pH on crosslinking occurrence in the case of reaction mixes 
with non-adjusted pH, crosslinking was just achieved for 1:1 and 1:3 samples, which had 
pH 5.6 and pH 6.02, respectively (Figure 26a, i). 1:5 and 1:10 mixes just led to 
crosslinking after adjusting the initial pH down to ca. 5.8 (Figure 26a, ii). Interestingly, 
when the pH of 1:3 mixes was decreased to 5.7, obtained hydrogels displayed a decreased 
integrity. These results suggest that (i) a pH in the range of 5.6-6 is permissive for 
crosslinking of IK24 polymer with citric acid and that (ii) a pH of 6 would lead to 
hydrogels with improved consistency. When studying the effect of using EDC or 
EDC+NHS, both 1:1 reaction mixes prepared at 2:2:1 and 2:-:1 EDC:NHS:COOH molar 
ratios led to reticulation (Figure 26b), suggesting that EDC is sufficient to achieve 
crosslinking in herein used conditions (i.e. the reaction evolves through the route leading 
to amide bond formation). 
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Figure 26. Summary of tests for crosslinking optimization. (a, i) Reaction mixes with non-
adjusted pH; (a,ii) reaction mixes with adjusted pH. (b) Reaction mixes containing EDC+NHS 
or just EDC. (c) Hydrogels prepared at 26.7 mg/ml (left) and 40 mg/ml (right) IK24 
concentrations. (d) IK24 (left) and HRD6 (right) hydrogels prepared at 40 mg/ml polymer 
concentration. (e) pH evolution during the gelation of 40 mg/ml HRGD6 hydrogels prepared at 
EDC:COOH 9.3:1 and COOH:NH2 3.25:1 molar ratios.   
The effect of increasing polymer concentration on hydrogel consistency was qualitatively 
assessed. A 40 mg/ml IK24 concentration led to hydrogels with increased consistency and 
easier to handle when compared to their 26.7 mg/ml counterparts (Figure 26c). The overall 
optimized conditions were proven useful to produce 40 mg/ml HRGD6 hydrogels (Figure 
26d). In these conditions, the pH of the solution remained in a permissive range (pH 6.02-
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5.85) during the crosslinking reaction (Figure 26e), which confirmed that MES buffer is a 
proper solvent to perform the herein optimized reaction. 
Hydrogels were not achieved in the case of REDV polymer, which contains a high number 
of acidic residues and has a low ITT [306]. Even in the absence of citric acid and at low 
EDC:COOH molar ratios, the material rapidly precipitated upon mixing the reagents (the 
higher the EDC:COOH ratio, the faster the precipitation), so reaction mixes couldn’t be 
properly homogenized nor dispensed into molds. In light of this phenomenon, REDV was 
discarded as a polymer to be crosslinked with citric acid and EDC. 
3.2.2.1.2 Effect of acid/base temperature 
The effect of the temperature of the acid/base used to adjust the pH of reaction mixes on 
the kinetic variability of crosslinking was studied. The pH of reaction mixes prepared at 
4ºC was adjusted with HCl either at 4ºC or RT. When compared to mixes whose pH was 
adjusted with HCl at RT, those adjusted with the acid at 4ºC showed increased variability 
in the case of reaction length (Figure 27b). However, using HCl at 4ºC led to highly 
consistent latency time, Vmax and Amax values. In light of these results, solutions at 4ºC 
for pH adjustment were selected to be used ever since. 
 
Figure 27. Effect of the temperature of acid/base on kinetic variability. (a) Latency time, (b) 
reaction length, (c) Vmax, and (d) Amax were studied. 
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3.2.2.1.3 Effect of substrate temperature 
Reaction mixes prepared at 4ºC and poured into substrates at 4ºC, RT and 37ºC. Substrates 
at 37ºC led to considerable variability for all four kinetic parameters, while those at 4ºC 
and RT led to quite homogenous results (Figure 28). Substrates at RT were chosen for 
simplicity. 
 
Figure 28. Effect of substrate temperature on kinetic variability. (a) Latency time, (b) 
reaction length, (c) Vmax, and (d) Amax were studied. 
 
Figure 29. Autofluorescence of citric acid-crosslinked hydrogels (a) Autofluorescence in 
blue, green and red channels. (b) Emission spectrum, (c) rMSCs on hydrogels pre-treated with 
trypan blue; blue: nuclei; green: actin. Scale bar: 20 µm.  
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3.2.2.1.4 Autofluorescence of citric acid-crosslinked hydrogels 
Citric acid-crosslinked hydrogels were prepared in optimized conditions and tested for the 
presence of autofluorescence. Tested samples fluoresced in all three channels (Figure 
29a), as confirmed by emission spectra (Figure 29b), suggesting that ELRs are 
autofluorescent. Staining samples with trypan blue prior to cell seeding suppressed the 
autofluorescence in the blue and green channels, allowing the visualization of DAPI-
stained cell nuclei and green phalloidin-stained actin filaments (Figure 29c). 
3.2.2.2 Effect of molar ratios on hydrogels properties 
3.2.2.2.1 Gelification and kinetics 
Hydrogels became gradually opaque during reticulation (Figure 30a). This phenomenon 
made possible the monitoring of absorbance changes at a wavelength of 750 nm, at which 
none of the components showed remarkable light absorption. The increase in absorbance 
followed a sigmoidal curve that was mathematically derived to calculate latency time, 
reaction length, Vmax and Amax. These parameters were calculated to decipher how the 
relative abundance of reactive species (EDC and, -COOH and -NH2 groups) involved in 
the reaction kinetically affect polymer aggregation. With this purpose, seven different 
hydrogels were prepared using particular combinations of EDC:COOH and COOH:NH2 
molar ratios. Reaction length, Vmax and Amax didn’t show any trend as to the effect of 
molar ratios (Figure 38, Supplementary data). In contrast, latency time (Figure 30b) was 
found to be clearly influenced by the relative abundance of reactive species: increasing 
any of the two molar ratios led to a reduction in latency time (EDC:COOH, from 
568.33±91.45 s to 371.11±6.97 s; COOH:NH2, from 371.11±6.97s to 120.77±26.37 s). 
Figure 30. Study of citric acid-crosslinked hydrogels gelification. (a) Changes in absorbance 
ocurring during crosslinking reaction tracked at 750 nm (black) and mathematical derivative 
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(gray), from which kinetic parameters were extracted. Inset: citric acid-crosslinked hydrogel at 
reaction completion; U.A.: Units of absorbance. (b) Latency time calculated for all seven 
different samples. Plotting area was colored to clearly distinguish the separate contribution of the 
two molar ratios. *p value≤0.05 with respect to E2C1 samples; **p value≤0.05 with respect to 
E9C1 samples. 
 
Figure 31. Effect of molar ratios on functional group consumption, and on the swelling and 
thermal stability of hydrogels. (a) Quantification of unreacted primary amines after 
crosslinking with citric acid and EDC; **p value≤0.05 with respect to E9C1 samples. (b) 
Equilibrium swelling ratio of hydrogels incubated at different temperatures. (c, top) Mass loss 
profile of pure citric acid (dotted line) and HRGD6 polymer (solid line) when subjected to 
temperatures up to 800ºC. (c, bottom) Mass loss profile of citric acid-crosslinked hydrogels.   
3.2.2.2.2 Unreacted –NH2 groups 
The number of primary amines remaining unreacted after reticulation was quantified by 
using TNBS [506]. Although HRGD6 polymer was designed to display ε-amino groups 
from lysine residues to be used for crosslinking purposes, α-amino groups from the N-
terminus of polymeric chains may also participate in the EDC-mediated reaction. Thus, 
results presented herein correspond to the sum of unreacted α- and ε-amino groups. 
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As shown in Figure 31a, increasing the EDC-to-COOH ratio did not have an effect on the 
percentage of primary amines involved in the reticulation reaction (all samples displayed 
ca. 46% free –NH2), suggesting that EDC is efficient even at a 2-fold molar excess respect 
to carboxyl groups for a fixed COOH:NH2 ratio. In contrast, increasing the COOH:NH2 
ratio led to a remarkable decrease in the amount of unreacted amines, leading to an almost 
total consumption of –NH2 groups in samples E9C5 (6.01±4.48% free –NH2). 
3.2.2.2.3 Swelling  
Swellability was studied by incubating samples at different temperatures and comparing 
their weight both in the swollen and dried states. Hydrogels crosslinked with citric acid 
seem to retain ELR’s smart behavior [309], displaying characteristic swellability when 
incubated at different temperatures (Figure 31b). Generally, the lower the temperature the 
higher the mean swelling ratio, although just subtle differences were noticed in the case of 
E9C1, E9C2, E9C3 and E9C5 samples.  
When it comes to molar ratios, it was found that the tendency was similar in the case of 
the three temperatures tested. Briefly, increasing EDC:COOH from 1.88:1 to 2.82:1 led to 
an initial increase in the amount of absorbed water while further increase in EDC:COOH 
entailed a marked reduction of water absorption. On the other hand, COOH:NH2 caused a 
subtle decrease in swelling ratio when increasing from 1.06:1 to 2.16:1, at which an 
asymptotic value was reached. None of the molar ratios was found to seemingly affect 
swelling. 
3.2.2.2.4 Thermal stability 
The thermal stability of samples prepared in different conditions was studied by 
thermogravimetry, which has been shown to provide qualitative information about the 
nature [404,507] and density [397,508,509] of covalent bonds in a given polymeric 
network, besides allowing the semiquantification of those species present in analyzed 
samples. After subjecting hydrogels to temperatures up to 800ºC, the weight evolution was 
monitored and mathematically derived to obtain degradation temperature (temperature at 
which maximum mass loss/ºC is achieved) and citric acid content. Citric acid and HRGD6 
polymer showed degradation temperatures of 216ºC and 331º, respectively (Figure 31c, 
top). In all cases, hydrogels showed one-step degradation with maximum mass loss/ºC at 
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331ºC (Figure 31c, bottom), rendering the estimation of the weight percentage of citric 
acid in hydrogels impossible. None of the molar ratios seemed to have an effect on the 
thermal stability of citric acid-crosslinked hydrogels. 
3.2.2.2.5 Resistance to enzymatic degradation  
To investigate differences between samples regarding resistance to enzymatic degradation, 
hydrogels were incubated with porcine pancreatic elastase. A pilot study was performed to 
find a proper setting allowing for a fast degradation, yet slow enough to detect differences 
between conditions. Elastase at 4.7·10-1, 4.7·10-2 and 4.7·10-3 U/ml led to an excessively 
fast degradation, while 4.7·10-4 U/ml led to a really slow mass loss (Figure 32a). Thus, 
2.82·10-3 U/ml was chosen to be used in degradation studies. 
 
Figure 32. In vitro enzymatic degradation with porcine pancreatic elastase. (a) Pilot test 
performed to select a proper amount of elastase to be used in degradation experiments; 4.7·10-1 
(black), 4.7·10-2 (grey), 4.7·10-3 (brown) and 4.7·10-4 (light brown) U/ml were tested. (b) 
Degradation profiles of selected hydrogels after in vitro exposure to porcine pancreatic elastase; 
(left) E2C1 and E9C1 samples; (right) E9C1 and E9C5 samples. *p value≤0.01. 
In order to simplify the experiments and to provide a proof of concept, 3 out of the 7 
different hydrogels were chosen to be used in this part of the study: E2C1, E9C1 and 
E9C5. E2C1 samples were found to degrade quickly, losing ca. 50% of their mass within 
the first day and being completely dissolved by day 3 (Figure 32b, left). In contrast, E9C1 
hydrogels showed reduced degradation at day 1 and sustained mass loss along the 
experiment, by the end of which ca. 75% of the material had been digested. E9C5 samples 
showed a significantly reduced mass loss rate from day 3 to day 7, at which ca. 55% of the 
material had been enzymatically processed (Figure 32b, right). 
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3.2.2.2.6 Structure 
The effect of molar ratios on hydrogel architecture was studied both by confocal 
microscopy and FESEM. Observation of the structure by confocal microscopy was 
possible thanks to treating hydrogels with trypan blue, a fluorescence quenching 
compound [493] known to fluoresce in red [510–513]. This treatment allowed the 
visualization of three different architectures (globular, globulo-fibrillar and dense) and 
structural changes regarding polymer aggregation, aggregate size and matrix density.  
 
Figure 33. Structure of citric acid-crosslinked hydrogels prepared using different 
combinations of EDC:COOH and COOH:NH2 molar ratios. The architecture of hydrogels 
prepared using specific combinations of molar ratios visualized under confocal microscopy (a-h) 
and FESEM (a2-h2). Images a-h are representative confocal microscopy slices displaying the 
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characteristic architecture of citric acid-crosslinked hydrogels prepared in different reaction 
conditions. a,a2: E2C1; b, b2: E3C1; c, c2: E5C1; d-e, d2-e2: E9C1; f, f2: E9C2; g, g2: E9C3; h, 
h2: E9C5. Insets in images a-d illustrate changes in the size of polymer aggregates induced by 
using increasing COOH:NH2 molar ratios while keeping the EDC-to-COOH ratio constant. 
Confocal microscopy scale bar: 20 µm; inset scale bar: 3 µm. FESEM scale bar: 5 µm. 
Polymer in E2C1 samples assembled in the form of globules with a diameter of ca. 3 μm 
(Figure 33a). Increasing EDC:COOH to obtain E3C1 samples led to a transitional 
structure in which large aggregates and nascent elongated entities (trabeculae) formed by 
smaller aggregates (diameter of ca. 1.5 μm) were observed (Figure 33b). E5C1 and E9C1 
samples displayed architectures enriched with fiber-like structures where polymer 
aggregates had a diameter of ca. 1.3 µm and 1.2 µm, respectively (Figure 33c and d). 
Although it was not possible measuring the size of aggregates in E9C2, E9C3 and E9C5 
samples, increasing COOH:NH2 seemingly led to a reduction of the aggregate and 
trabeculae size down to the nanoscale (Figure 33f-h). This latter phenomenon was 
accompanied by an increase in hydrogels density. 
FESEM was used to confirm what was observed by confocal microscopy. No globules 
were observed in any of the samples. However, changes in the density of the structure and 
in polymer aggregation were confirmed. Increasing EDC:COOH molar ratio led to mesh 
constituents transitioning from irregular-shaped (Figure 33a2) to thin connecting fiber-like 
entities or trabeculae (Figure 33b2-d2). Increasing the COOH-to-NH2 ratio led to 
obtaining hydrogels with dense structures displaying sublimation-derived pores typical of 
lyophilized hydrogels [514] (Figure 33f2-h2). 
3.2.2.2.7 Percentage polymer-occupied volume 
In order to confirm the apparent effect of excess –COOH with respect to –NH2 on scaffold 
density, sections obtained by confocal microscopy were processed to quantify the volume 
occupied by HRGD6 polymer. The EDC:COOH ratio was found not to affect PV/TV; in 
contrast, COOH:NH2 had a strong effect on reducing the void volume (from 31.56±0.69% 
to 74.09±7.33% of polymer-occupied volume; Figure 34a) in such a way that the higher 
the COOH-to-NH2 ratio, the more dense the scaffold. 3D reconstructions of calculated 
volumes were compared to the original 3D sections to ensure proper calculations were 
performed; images can be seen in Figure 34b). After pairing PV/TV and swelling ratio 
mean values for all hydrogels, the way polymer is distributed along the sample was found 
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to strongly affect swellability. Briefly, an increase in the low-range PV/TV was associated 
to a decrease in the swelling ratio (i.e. the denser the hydrogel, the lower the equilibrium 
water content), reaching an asymptote at a PV/TV value of ca. 40%, beyond which 
swelling ratio remained unaffected (Figure 34c). These results suggest that the few tens of 
microns analyzed by confocal microscopy are likely to be representative of the bulk 
structure of herein described hydrogels. 
Figure 34. Study on the effect of EDC:COOH and COOH:NH2 molar ratios on polymer 
volume fraction. (a) Quantification of the percentage polymer-occupied volume (PV/TV) in 
hydrogels prepared under different conditions. *p value≤0.01 with respect to E9C1 samples. (b) 
Comparison of 3D reconstructions of calculated polymer-occupied volume (top) to 3D 
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reconstructions of sections obtained by confocal microscopy (bottom). Scale bar: 20 µm. (c) 
Mean values for PV/TV paired to mean value for swelling ratio at 4ºC (black), RT (gray) and 
37ºC (light gray). 
3.2.2.2.8 Surface stiffness 
An interesting question to answer was whether the apparent differences regarding 
crosslinking yield and structure between samples would influence their mechanical 
properties at a surface level. As it is shown in Table 8, stiffness was seemingly unaffected 
by molar ratios, none of which proved useful to mechanically tailor citric acid-crosslinked 
hydrogels. Additionally, none of the samples was shown to possess a Young’s modulus 
value in the range of interest (25-40 kPa [242]). 
Sample Young’s modulus (kPa) 
E2C1 1.81 ± 1.56 
E3C1 10.37 ± 6.53 
E5C1 3.32 ± 1.87 
E9C1 7.85 ± 5.51 
E9C2 3.13 ± 1.75 
E9C3 7.26 ± 3.26 
E9C5 5.19 ± 4.46 
Table 8. Young’s modulus of citric acid-crosslinked hydrogels prepared at a 40 mg/ml 
polymer concentration. 
3.2.2.3 Effect of reactions conditions on hydrogels properties and RGD integrity 
3.2.2.3.1 Cytotoxicity 
Cytotoxicity (by indirect contact) experiments were performed to test hydrogels for the 
release of excess EDC and its toxic by-product, N-acylurea. Again, E2C1, E9C1 and 
E9C5 samples were selected to simplify the experiment. Cells were seeded on tissue 
culture polystyrene (TCPS), let to adhere for 4 hours and quantified. Results were 
normalized to cell number in the negative control. No differences in cell number were 
observed (Figure 35a), assuring that all the wells used in the experiment had 
approximately the same initial cell density, thus avoiding artifacts due to uneven adhesion. 
Cells were exposed to different agents for 42.5 h and quantified again. After 
normalization, it was found that E2C1 and E9C1 samples led to an increased number of 
cells when compared to that in TCPS. In contrast, E9C5 hydrogels produced a decrease in 
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cell number of about 70%. No cell survival was observed in those wells treated with 
culture medium supplemented with 1% phenol. After staining with Calcein AM, cells 
exposed to culture medium and samples E2C1 and E9C1 were found to display normal 
morphology (Figure 35b); exposure to E9C5 induced morphological alterations. No cells 
were observed in those wells treated with 1% phenol. 
 
Figure 35. Effect of molar ratios on cytotoxicity and cell adhesion, and effect of polymer 
concentration on hydrogels stiffness. (a) Citotoxicity assessment of selected hydrogels by 
indirect contact. Cell numbers were quantified after adhesion (black bars) and after a 2-days 
exposure period (gray bars), and normalized to those in the control surface (TCPS) for each time 
point. (b) Morphology of rMSCs exposed to hydrogels and to control surface for 2 days; scale 
bar: 20 µm. (c) rMSCs on selected samples after preliminary 24-hour cultures. Green: vinculin; 
blue: nuclei. Scale bar: 20 µm. (d) Effect of polymer concentration on stiffness (filled dots) and 
Young’s modulus of E9C1 samples prepared at a 54 mg/ml polymer concentration (empty 
square). *p value≤0.001 with respect to TCPS. 
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3.2.2.3.2 Cell adhesion 
Cell adhesion experiments were performed to test hydrogels for RGD integrity. rMSCs 
were seeded on the surface of hydrogels and kept in culture for 24 hours. 
Immunocytochemical staining revealed that cells adhered to hydrogels regardless of their 
architecture (Figure 35c) and produced filopodia able to penetrate those matrices with an 
open structure (Figure 39, Supplementary data). Cells displayed normal morphology in all 
cases, although focal contacts were just observed in those samples with a dense matrix 
structure, in which nuclei were not visualized due to the strong autofluorescence of E9C5 
samples in the λemission= 430-476 nm range (blue channel).  
3.2.2.4 Design and characterization of tailored hydrogels  
3.2.2.4.1 Surface stiffness 
Given that molar ratios were found not useful to achieve target Young’s modulus, the 
effect of a third variable, polymer concentration, was explored. The E9C1 setup was 
chosen to study how polymer concentration influences stiffness at a surface level. The use 
of different amounts of polymer led to obtaining a logarithmic function from which the 
polymer concentration needed to achieve hydrogels with target Young’s modulus was 
extrapolated (Figure 35d). A Young’s modulus in the 25-40 kPa range is considered to be 
osteogenic; a modulus of 34 kPa was specifically targeted given that it has been already 
shown to induce the expression of osteogenic markers [242]. E9C1 hydrogels with a 
polymer concentration of 54 mg/ml -corresponding to a theoretical stiffness of 34.83 kPa- 
exhibited an experimental value of 36.13±10.72 kPa. 
3.2.2.4.2 Structure of mechanically-tailored hydrogels 
Mechanically-tailored RGD-C hydrogels (i.e. E9C1 samples prepared at a polymer 
concentration of 54 mg/ml) were analyzed by confocal microscopy and FESEM. Sections 
obtained by confocal microscopy revealed that RGD-C samples retained the fiber-like 
architecture seen in their 40 mg/ml counterparts (Figure 36a, i). Polymer globules in 
RGD-C hydrogels organized in the form of fiber-like entities (trabeculae) with a diameter 
of 952.64 ± 210.57 nm (Figure 36a, ii).  Under FESEM, RGD-C samples were found to 
possess a reduced number of globules and to be shaped by trabeculae with a diameter of 
106.30 ± 30.75 nm that locally arranged with varying degrees of alignment (Figure 36b, i 
and ii). 
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Figure 36. Structure of mechanically-tailored hydrogels. Study of the structure of 54 mg/ml 
hydrogels under (a) confocal microscopy and (b) FESEM. i) Detailed visualization and ii) size 
distribution of fiber-like entities in hydrogels with tailored stiffness. Confocal microscopy scale 
bar: 20 µm; FESEM scale bar: 1 µm. 
 
Figure 37. In vitro mineralization of RGD-C hydrogels by using SBF 1x. (a) Detail on the 
sparse mineral deposits found along the experiment. Scale bar: 20 µm. (b) Representative EDS 
profile showing the presence of calcium phosphates. (c) Calcium/phosphate ratio of mineral 
deposits found at different time points. 
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3.2.2.4.3 In vitro mineralization 
RGD-C hydrogels were tested for citric acid-related mineralization capacity using SBF 1x. 
RGD-G samples were included in this experiment in order to account for HRGD6-derived 
nucleation capacity, if any. No calcium phosphates were found on glutaraldehyde-
crosslinked hydrogels at any time point (Figure 40, Supplementary data). In contrast, 
sparse mineral deposits with a Ca/P ratio of ca. 1.8 were detected in RGD-C hydrogels at 
all time points (Figure 37).  
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3.3 DISCUSSION  
The studies described in the present chapter were performed with the aim of designing 
biomimetic hydrogels for in situ bone tissue engineering. The chemistry of carbodiimides 
was selected to induce the crosslinking of ELRs by activated citric acid. Reaction 
optimization studies demonstrated that hydrogels with good integrity were achieved when 
prepared at a 40 mg/ml polymer concentration and at a pH≈6 in MES buffer, which 
properly buffered the system for crosslinking to occur (Figure 26). Additionally, it was 
demonstrated that EDC allowed the proper formation of amide bonds (without the need of 
displacing the reaction with NHS) and that crosslinking with citric acid can be achieved in 
a polymer-independent manner as long as polypeptides are rich in lysine residues and poor 
in acidic amino acids. Additionally, in order for the reaction to be kinetically consistent, 
cold acid/base needs to be used to adjust the pH of reaction mixes (Figure 27), which 
should be poured into substrates at RT (Figure 28). 
HRGD6 elastin-like recombinamer was crosslinked with citric acid by means of EDC-
mediated catalysis. EDC and citric acid have already been combined to produce hydrogels 
involving the multistep, time-consuming chemical synthesis of N-hydroxysuccinimide 
esters of citric acid that can be then used to crosslink polymers containing free primary 
amines [418]. In the present chapter, a one-step, organic solvent-free reaction to achieve 
citric acid-crosslinked hydrogels in mild conditions was designed. 
As previously mentioned, the carbodiimide-mediated activation of –COOH groups to 
achieve the formation of peptide bonds is known to be affected by different parameters 
such as pH, reaction time, and EDC:COOH  and COOH:NH2  molar ratios. Once general 
reaction parameters were set, the effect of the relative abundance of reactive species on 
hydrogels properties was studied. With this purpose, seven setups characterized by 
particular combinations of EDC:COOH and COOH:NH2 molar ratios were prepared 
(Table 6) at 4ºC and pH≈6, and let to react for 1 h at 37ºC. Under these conditions, the 
reticulation reaction was characterized by an increase in turbidity following a sigmoidal 
curve (Figure 30a), a phenomenon already described for decellularized extracellular 
matrix [515] and a variety of polysaccharides and proteins such as coagulin [516], fibrin 
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[517] and agarose [518]. A typical analysis of this phenomenon involves dividing the 
reticulation curve into three main stages: (i) lag phase or induction period (herein, latency 
time), (ii) network growth stage and (iii) pseudo-equilibrium stage [518]. 
HRGD6 polymer has the ability to self-aggregate in response to changes in temperature 
and pH, displaying an inverse transition temperature of 32ºC in PBS at pH=7.4, although 
ITT would be somewhat lower at the pH used herein [304]. During latency time, the 
temperature of the solution gradually rises along the incubation period. When the solution 
reaches the ITT, polymer molecules undergo conformational rearrangement leading to 
intermolecular hydrophobic aggregation [311], giving rise to supramolecular aggregates 
with size increasing up to few micrometers over time [366]. In the presence of a 
crosslinker, aggregates are linked to each other, thus conferring hydrogels their 
characteristic nano-microarchitecture (network growth and pseudo-equilibrium stages). On 
this basis, it was hypothesized that the length of latency time, found to be affected by both 
molar ratios (Figure 30b), would have a direct effect on the size of polymer aggregates 
building up citric acid-crosslinked hydrogels, in such a way that the shorter the latency 
time, the smaller the aggregates shaping the network. 
The amount of –NH2 groups remaining unreacted after crosslinking was quantified for all 
seven hydrogels and found to be remarkably affected by the COOH-to-NH2  molar excess 
(Figure 31a). Specifically, the higher the COOH:NH2 molar ratio, the higher the amount of 
–NH2 groups involved in the reaction, boosting the number of crosslinking points and thus 
reducing polymer chain mobility and inter-chain void space [265]. This phenomenon 
didn’t directly affect thermal resistance nor swelling, although the latter was found to be 
influenced by PV/TV (Figure 34b) in such a way that (i) the higher the PV/TV, the lower 
the swelling and that (ii) PV/TV ≥ 40% leads to minimized swelling. As shown in Figure 
31a, Figure 34a and Figure 34b, PV/TV (i.e. hydrogel density) increases as the number of 
unreacted groups diminishes, suggesting that the degree of crosslinking, along with 
latency time, define the architecture of citric acid-crosslinked hydrogels, whose PV/TV 
defines their swelling degree.  
The structure of scaffolds prepared using different reaction conditions was studied (Figure 
33). As revealed by confocal microscopy, the EDC:COOH molar ratio affects (i) polymer 
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aggregation, which ranged from purely globular to globulo-fibrillar (i.e. globules 
organized in the form of fibrous structures), and  (ii) aggregate size, which is also 
seemingly affected by the COOH-to-NH2 molar excess. Additionally, the COOH:NH2 
ratio influences hydrogel density (as confirmed by FESEM observations and PV/TV 
calculations), an increase in which is likely to be the consequence of reduced aggregate 
size and of increased globule interconnectivity. Together, these results support the 
hypotheses that latency time and crosslinking degree dictate the organization of HRGD6 
polymer thus defining the architecture of herein described hydrogels. Furthermore, they 
point out that the architecture of citric-acid crosslinked hydrogels can be tuned by using 
specific combinations of EDC:COOH and COOH:NH2 molar ratios.  
FESEM failed to reveal the nano-microstructure (globules) seen by confocal microscopy, 
which was presumably lost during sample preparation for their visualization under 
electron microscopy (Figure 33 and Figure 36). This phenomenon proved the usefulness 
of red-shifting samples’ autofluorescence with trypan blue to visualize hydrogels’ intact 
structural features when no nanometric resolution is required. This is a cheap, fast and 
easy method to visualize hydrogel architecture, to perform structural calculations such as 
PV/TV or to visualize how cells interact with scaffolds (Figure 38, Supplementary data) in 
short duration cultures without the need of going through fluorophore grafting protocols. 
The resistance to in vitro degradation of selected samples (E2C1, E9C1 and E9C5) was 
assessed. The amount of unreacted –NH2 groups and PV/TV for E2C1 and E9C1 samples 
are not significantly different (Figure 31a and Figure 34a). However, E9C1 hydrogels 
showed improved resistance to enzymatic degradation (Figure 32b, left). Structurally, 
when increasing EDC:COOH, there was an apparent reduction in the occurrence of 
dangling polymeric ends accompanied by an increase of trabeculae interconnectivity 
(Figure 33a2-d2), which would be the reason for the increased stability of E9C1 hydrogels 
compared to that of E2C1 ones. E9C5 samples displayed improved resistance to 
degradation in comparison to E9C1 gels (Figure 32b, right), which would be due to (i) a 
higher polymer network connectivity [519] derived from a much higher consumption of –
NH2 groups [367] (Figure 31a), and (ii) a consequently increased PV/TV (Figure 34a) 
further limiting enzyme accessibility and ultimately slowing down degradation. Given that 
network and structural features are dependent on the reaction conditions used to prepare 
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structurally tailored scaffolds, it is noteworthy that the degradation of citric acid-
crosslinked HRGD6 hydrogels can’t be independently tuned.  
Hydrogels were tested for cytocompatibility by indirect contact with rMSCs.  E2C1, E9C1 
and E9C5 samples were selected to simplify indirect cytotoxicity assays. After a 42.5 
hour-exposure period, cell number in wells exposed to E2C1 and E9C1 samples was 
significantly higher than that in control wells (Figure 35a). This phenomenon could be due 
to the release of unbound or partially bound citric acid, which would be incorporated into 
the cell through the Na-coupled citrate transporter; once in the cytosol, citrate would be 
turned into lipids to meet the requirements for MSCs proliferation-related 
membranogenesis [520]. In contrast, E9C5 samples led to a highly reduced viability and 
altered cell morphology (Figure 35b), most likely due to the slow release of N-acylurea, 
the toxic and water-soluble by-product of EDC. This would be due to an incomplete 
removal of N-acylurea during the washing steps because of reduced diffusion in dense 
E9C5 hydrogels, leading to the slow release of the by-product during the experiment.  This 
cytotoxic effect was not noticed when rMSCs were seeded on E9C5 hydrogels (Figure 
35c), most likely due to the extra washes applied after pre-staining with trypan blue. Cell 
adhesion experiments revealed that rMSCs were able to adhere to all seven hydrogels, 
suggesting that –COOH groups from aspartic acid’s side chain are not involved in the 
EDC-mediated reaction in the conditions used herein, so RGD tripeptides remain 
unaffected and functional for cells to attach to them.  
The effect of the relative reactive species abundance on hydrogels mechanical properties 
was studied. Given molar ratios were found not useful to tune stiffness (Table 8), the 
influence of polymer concentration was explored. To do so, the E9C1 setup was chosen 
since it led to obtaining cytocompatible hydrogels possessing fiber-like microstructure and 
ca. 45% of free primary amines, a functional group shown to induce and maintain the 
osteogenic differentiation of MSCs [237,243]. After preparing E9C1 hydrogels at different 
polymer concentrations, 54 mg/ml was extrapolated (Figure 35d) as the concentration 
needed to achieve samples with a target Young’s modulus value of 34.83 kPa. 
Experimentally, RGD-C hydrogels were shown to possess a Young’s modulus of 
36.13±10.72 kPa and to retain its 40mg/ml counterpart’s fiber-like structure (Figure 36a). 
Interestingly, these results point out that the structure and surface stiffness of citric acid-
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crosslinked hydrogels can be separately tuned by modifying the combination of molar 
ratios and the polymer concentration used to prepare them, respectively.  
RGD-C hydrogels were shown to nucleate calcium phosphate when incubated with SBF 
1x. Although sparse at all time points, mineral deposits were found even by day 1 and kept 
a quite stable Ca/P ratio along the experiment (Figure 37). The presence of mineral phase 
in RGD-C but not in RGD-G hydrogels points out that unreacted –COOH groups from 
citric acid provide HRGD6 polymer with apatite-nucleating capacity [383], suggesting 
that RGD-C hydrogels would be able to bond to damaged bone. Additionally, the early 
formation of apatite in vitro suggests that hydrogel-to-bone bonding would occur shortly 
upon implantation [500], helping the scaffold to stay in place and thus reducing the risk of 
incomplete defect closure due to scaffold misplacement.  
The production of hydrogels for bone regeneration exhibiting calcium phosphate-
nucleation capacity has gained momentum in the last years due to hydroxyapatite’s 
osteogenic potential [521,522]. Mineralizing hydrogels can be achieved by  means of 
strategies such as the post-gelation partial hydrolysis to expose –COOH groups [368], 
functionalization with carboxylate-terminated spacers [369], or the use of polymers, either 
recombinantly [307,523] or chemically-synthetized [486], containing hydroxyapatite-
binding motifs. Post-gelation treatments and functionalization usually require the use of 
chemicals that can compromise the biocompatibility of the construct, while those 
hydrogels with internal nucleation motifs possess a polymer-dependent mineralization 
capacity. In contrast, our hydrogels are produced in mild conditions and display citric 
acid-dependent mineralization capacity. Citric acid, herein used both as a non-toxic 
crosslinker and a calcium phosphate-nucleating molecule, possesses carboxylates spaced 
by a distance matching that spacing calcium ions in hydroxyapatite and thus has been 
suggested to be both a natural HA-stabilizing and nucleating molecule [6]. Interestingly, it 
can be used in combination with EDC to produce hydrogels as long as the polymer to be 
crosslinked possesses a proper balance of –COOH and –NH2 groups, making this method 
a versatile strategy to achieve mineralizing hydrogels for bone regeneration. Globally, we 
have shown that crosslinkers are a useful tool to tune hydrogel physical properties as well 
as to provide polymers with new functionalities such as calcium phosphate nucleation 
capacity. 
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3.4 SUPPLEMENTARY DATA 
 
Figure 38. Additional kinetic parameters for the study of the effect of molar ratios on 
polymer aggregation. (a) Reaction length, (b) Vmax, and (c) Amax for all seven setups.  
 
Figure 39. Cell-scaffold interactions visualized by staining scaffolds with trypan blue. (a) 
Front and (b) tilted view of a rMSC with filopodia entering a E3C1 hydrogel. Green: vinculin; 
blue: nuclei. 
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Figure 40. SEM pictures of RGD-G hydrogels incubated with SBF 1x. Scale bar: 20 µm. 
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PREFACE 
The present chapter represents the study of the biological performance of mechanically-
tailored citric acid-crosslinked hydrogels both in vitro and in vivo. First, the effect of citric 
acid, a degradation product of our matrices, on stem cell proliferation and differentiation 
was studied. Second, tailored hydrogels were subjected to in vitro and in vivo experiments 
to determine their osteogenic potential in comparison to their non-tailored counterparts.   
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4.1 MATERIALS AND METHODS 
4.1.1 Citric acid as a soluble factor 
4.1.1.1 Cytotoxicity 
Human mesenchymal stem cells (hMSCs; Lonza) were expanded in complete medium 
(Advanced DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml Penicillin 
and 100 μg/ml Streptomycin), and detached at a confluence of about 80% with Tryp-LE 
Express. The number of viable cells was determined after staining with Trypan blue and 
104 viable cells in complete medium were seeded in 24-well plates and kept in culture for 
24 h. Non-adhered cells were washed out with PBS and wells were subsequently 
replenished with complete medium. PET Millicell Inserts with a 0.4 µm pore size were 
placed into wells and 300 µl of complete medium supplemented with 0.15, 0.75 or 1.25 
mM citric acid were added to each insert. Negative controls consisted on inserts 
containing complete medium; positive controls consisted on the use of complete medium 
supplemented with 1% phenol in both the wells and the inserts. After a 42.5 hours 
incubation period at 37°C and 5% CO2, cytotoxicity by indirect contact was assessed by 
cell quantification with Alamar blue and live/dead staining. For cell shape visualization, 
cells were washed with Dulbecco’s buffered-saline (DPBS), stained in the dark with 2 µM 
Calcein AM (Sigma) and 4 µM propidium iodide (Fluka) for 20 minutes at 37°C and 
washed with the buffer to remove excess dye. Images were acquired using an Eclipse 
TE200 inverted microscope and MetaMorph Microscopy Automation & Image Analysis 
Software. For cell quantification, cells were incubated with complete medium 
supplemented with 10% Alamar blue; absorbance at 570 nm was read using an Infinite 
Pro200 microplate reader (Tecan, Switzerland). 
4.1.1.2 Cell culture for proliferation and differentiation assays 
hMSCs were expanded as abovementioned. 104 viable cells were seeded in 24-well plates 
in either complete (normal) medium or differentiation medium (complete medium 
supplemented 50 µg/ml ascorbic acid, 10 mM β-glycerolphosphate and 10 nM 
dexamethasone) with or without citric acid (Table 9). Cells were kept in culture for up to 
21 days at 37ºC, 5% CO2 and culture medium was replaced twice a week.  
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Medium [Citric acid] (mM) 
Complete 0 
Complete 0.15 
Complete 0.75 
Complete 1.25 
Osteogenic 0 
Osteogenic 0.15 
Osteogenic 0.75 
Osteogenic 1.25 
Table 9. Summary of conditions used to test the effect of citric acid on hMSCs proliferation 
and osteogenic differentiation. 
4.1.1.3 Proliferation 
Proliferation was quantified at days 1, 3, 7 and 14. At every time point, culture medium 
was discarded and cells were incubated for 24 h with the corresponding medium 
supplemented with 10% Alamar blue. Medium containing Alamar blue was transferred to 
96-well plates and aborbance was read at 570 nm. Wells were then replenished with the 
corresponding medium and kept in culture.  
4.1.1.4 In vitro osteogenic differentiation 
4.1.1.4.1 Alkaline phosphatase 
At every time point, cells were lysed by incubation with mammalian protein extraction 
reagent (M-PER; Life Technologies) and subjected to three freezing/thawing cycles at -
80ºC/RT.  
Samples were transferred to microtubes and centrifuged at 2,500 g for 10 minutes at 4ºC 
using an Eppendorf 5415 R centrifuge. Cell debris were discarded and cell number was 
quantified by using a Cytotoxicity detection plus kit (Roche) according to manufacturer’s 
instructions. Briefly, cell lysates were incubated with reaction solution at a 1:1 volume 
ratio. Mixtures were incubated for 20 minutes at RT and absorbance was read at 490 nm 
using a reference wavelength of 600 nm.  
For alkaline phosphatase (ALP) expression quantification, lysates were incubated with the 
p-Nytrophenyl phosphate (pNPP) substrate at a 1:1 volume ratio. Reagents were 
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homogenized for few seconds and incubated at 37ºC for 40 minutes; absorbance was read 
at 450 nm. ALP expression results were normalized to cell number.  
4.1.1.4.2 Osteopontin 
Osteopontin (OPN) expression was assessed at days 3, 14 and 21 both by 
immunofluorescence and Enzyme-linked immunosorbent assay (ELISA). For 
immunofluorescence, cells were treated with fixative solution (3% paraformaldehyde and 
40 mM sucrose in PBS) for 10 minutes at 4°C and washed three times with cold 0.15% 
glycine in PBS (PBS-gly). Cells were then permeabilized with 0.1% Triton X-100 (Sigma-
Aldrich) for 5 minutes, blocked with PBS-gly supplemented with 6% bovine serum 
albumin (BSA; Sigma) for 45 minutes and stained in the dark at room temperature for 
actin, nuclei  and OPN visualization. Briefly, cell staining consisted on: (i) incubation with 
rabbit anti-OPN primary antibody (Abcam) at a 1/600 dilution in PBS-gly supplemented 
with 3% BSA (PBS-gly-BSA 3%) for 1h, (ii) incubation with Alexa 488-conjugated goat 
anti-rabbit secondary antibody (Molecular Probes) at a 1/300 dilution in PBS-gly-BSA 3% 
for 1h, (iii) incubation with rhodamine-phalloidin (Life technologies) for 30 minutes, and 
(iv) incubation with DAPI for 2 minutes. Cells were then mounted with Mowiol 40-88 
(Sigma-Aldrich) and sandwiched with 15 mm diameter circular glass coverslips. Samples 
were visualized under a DM-IRBE inverted microscope (Leica) by using the MetaMorph 
Microscopy Automation & Image Analysis Software. 
For the quantitative assessment of OPN expression, cell number was quantified using the 
Cytotoxicity detection plus kit as abovementioned. OPN was quantified from supernatants 
by means of the Human osteopontin platinum ELISA kit (eBioscience) according to 
manufacturer’s instructions. Briefly, wells were washed twice using wash buffer and 
samples were loaded into wells and incubated for 2 h at RT to allow the binding of the 
protein. Wells were thoroughly washed by incubating six times with wash buffer and 
incubated with biotin-conjugated anti-human OPN antibody for 1 h at RT under mild 
agitation. Wells were washed to remove excess antibody and incubated with streptavidin-
conjugated horseradish peroxidase (HRP) for 1 h at RT under mild agitation. Wells were 
washed again and incubated with tetramethyl-benzidine substrate solution for 30 minutes 
at RT and the reaction was stopped with 1 M phosphoric acid. Absorbance was read at 450 
nm using a reference wavelength of 620 nm. Data were analyzed by means of 
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Readerfit.com online software (Hitachi) by using a 5 parameter logistic nonlinear 
regression model. Results were normalized to cell number. 
4.1.1.4.3 Osteocalcin 
For the quantitative assessment of osteocalcin (OCN) expression, cell number was 
quantified using the Cytotoxicity detection plus kit as previously stated. OCN was 
quantified in duplicates from supernatants by means of a MicroVue bone osteocalcin EIA 
kit (Quidel) according to manufacturer’s instructions. Briefly, cell lysates were transferred 
into wells and incubated with anti-OCN antibody for 2 h at RT. Wells were washed twice 
and incubated with ALP-conjugated goat anti-mouse antibody for 60 minutes at RT. 
Excess antibody was removed by washing two times and wells were incubated with pNPP 
substrate for 35 minutes at RT. Stop solution was then added and the absorbance was read 
at 450 nm. Data were analyzed by means of Readerfit.com online software (Hitachi) by 
using a 4 parameter logistic nonlinear regression model. OCN expression was normalized 
to cell number. 
4.1.1.4.4 Mineralization 
Mineralization was assessed at days 3, 14 and 21 by Alizarin red staining. Cells were 
washed with PBS to remove cell debris and fixed with absolute ethanol (Panreac) for 2 h 
at -20ºC. Wells were washed with PBS to remove ethanol and incubated with 40 mM 
alizarin red (Sigma) in water (pH 4.2) for 10 minutes at RT under mild agitation. Excess 
alizarin red was removed by washing with ultrapure water and non-specifically bound 
calcium was removed by washing with PBS. Specifically-bound calcium was solubilized 
by incubation with solubilization buffer (0.1 mg/ml cetylpyridinium chloride in 10 mM 
sodium dihydrogen phosphate, pH 7) for 20 minutes at RT. Supernatants were transferred 
to 96-well plates and absorbance was read at 570 nm. Calculations were performed using a 
standard curve prepared using Alizarin red in solubilization buffer and considering that 
one alizarin red molecule binds two calcium ions. 
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4.1.2  Tailored hydrogels 
4.1.2.1 Hydrogels preparation 
HRGD6 citric acid-crosslinked hydrogels were prepared using EDC:COOH 9.3:1 and 
COOH:NH2 1.06:1 molar ratios (code E9C1) at either 54 mg/ml (tailored hydrogels) or 40 
mg/ml (non-tailored hydrogels) polymer concentrations. Briefly, HRGD6 polymer was 
dissolved at 4ºC overnight in MES buffer containing citric acid; EDC was also dissolved 
in MES buffer at 4ºC. Polymer-citrate and EDC solutions were mixed at a 1:1 volume 
ratio and pH was adjusted to ca. 6 by adding cold HCl. Mixes were homogenized and 
reaction mixes were poured into substrates (96-well plates or 16-well glass chamber 
slides) and let to react for 1 h at 37ºC. The reaction was stopped by incubation with 0.1 M 
Na2HPO4 at room temperature for 3 hours. Samples were then washed by performing 5 
swelling/shrinking incubation cycles in ultrapure water at 4°C (swelling)/37°C (shrinking) 
to allow excess EDC and reaction by-products to be released. 
4.1.2.2 In vitro biological characterization 
4.1.2.2.1 Cytotoxicity 
104 viable hMSCs were seeded in 24-well plates with complete medium and let to adhere 
for 24 h. Wells were washed with PBS to remove non-adhered cells and E9C1 hydrogels 
prepared at 54 mg/ml polymer concentration were assessed for cytotoxicity. 
Briefly, hydrogels were prepared in 6 mm PDMS molds as abovementioned. Samples 
were sterilized with 70% ethanol under UV irradiation for 1 hour, washed thrice with PBS 
and kept in the buffer at 37°C until use. PET Millicell Inserts with a 0.4 µm pore size were 
placed into wells and 300 µl of complete medium were added to each insert. Hydrogels 
were then washed twice with PBS to remove remaining ethanol and transferred to inserts. 
TCPS and complete medium supplemented with 1% phenol were used as positive and 
negative controls, respectively. After a 42.5 h incubation period, cell were quantified with 
Alamar blue and subjected to live/dead staining as previously mentioned.  
4.1.2.2.2 Proliferation 
hMSCs proliferation on hydrogels was assessed both quantitatively and qualitatively. 40 
mg/ml and 54 mg/ml HRGD6 hydrogels were prepared in 16-well glass chamber slides 
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and sterilized as abovementioned. Scaffolds were seeded with 2·103 viable cells and kept 
in culture for 1, 7, 14 and 21 days in either complete medium or osteogenic medium. For 
qualitatively assessing proliferation, samples were washed with PBS, fixed with 
paraformaldehyde as previously described, stained with 1% osmium tetroxide, and 
subjected to serial dehydration in ethanol and to critical point drying in CO2. Hydrogels 
were then graphite-sputtered and visualized under a Quanta 200 Scanning Electron 
Microscope (SEM; FEI) at a 10 mm working distance and a 20 kV voltage.  
For the quantitative assessment of cell proliferation in complete medium, hydrogels 
prepared in 96-well plates were degraded at days 1, 3, 7, 14 and 21 by using 2 mg/ml 
porcine pancreatic elastase in PBS for 3 h at 37ºC. After hydrogel degradation, M-PER 
was added to a 1:1 volume ratio and samples were subjected to three freezing/thawing 
cycles at -80ºC/RT. Cell lysates were used to quantify cell number by using the 
cytotoxicity detection plus kit as previously stated. 
4.1.2.2.3 In vitro osteogenic differentiation 
In vitro differentiation was assessed by quantifying (i) the expression of ALP from cell 
lysates, and (ii) the expression of OPN and OCN from cell supernatants. Quantification 
were performed as previously stated and results were normalized to cell number. 
4.1.2.3 In vivo biological characterization 
4.1.2.3.1 Sample preparation 
E9C1 reaction mixes were prepared at 40 mg/ml and 54 mg/ml polymer concentrations 
and to a final volume of 17.5 µl. Mixtures were poured into circular PDMS molds with a 
diameter of 3.5 mm and let to react at 37ºC for 30 minutes to avoid sample drying. 
Samples were then incubated with 0.1 M Na2HPO4 to stop the crosslinking reaction and 
washed by performing 5 swelling/shrinking cycles. Sterilization consisted on incubating 
samples with 70% ethanol for 1 h under UV irradiation subsequently washing hydrogels 
several times with PBS. Samples were kept at 37ºC until use.  
4.1.2.3.2 Scaffold implantation 
7-week-old CB17/lcr-Prkdcscid/lcrlcoCrl (Severe combined immunodeficiency; SCID) 
female mice (Charles River) were anesthetized with IsoVet® (Braun) and the surgical site 
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was cleaned with povidone-iodine (Braun). Calvariae were exposed by performing sagittal 
midline incisions and cutting periostea. Two 3.5-mm critical size defects were created on 
the parietal of each animal by using a sterile drill bit (Dremel), avoiding damaging the 
dura mater (Figure 41a). Surgical sites were cleaned with sterile phosphate-buffered saline 
and hydrogels were placed in the defects (Figure 41b). The incisions were closed by using 
absorbable sutures and animals were administered with subcutaneous analgesic (0.05 
mg/ml buprenorphine; Schering-Plough). Mice with empty defects were used as negative 
controls. All animals were kept in a pathogen-free environment throughout the experiment 
and sacrificed by cervical dislocation. Skulls were then harvested, fixed with 10% 
formalin (Sigma) for 48 h and kept at 4ºC in 70% ethanol until use. A summary of the 
treatment groups can be seen in Table 10. 
 
Figure 41. Implantation of 40 mg/ml and 54 mg/ml hydrogels in mouse calvaria. a) 
Defects with a diameter of 3.5 mm were created on parietal bone in mice. b) Hydrogels 
fitting the diameter of defects were implanted.  
Time Treatment Number of defects 
Day 0 Empty 6 
6 weeks Empty 6 
 54 mg/ml 6 
 40 mg/ml 6 
12 weeks Empty 6 
 54 mg/ml 6 
 40 mg/ml 6 
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Table 10. Summary of the treatment groups used in the in vivo experiment. 
4.1.2.3.3 Micro-computed tomography  
Micro-computed tomography (µCT) was performed using a Skyscan 1076 in-vivo µCT 
(Bruker, USA). Images were acquired using a 0.5 mm Al filter in high resolution mode 
(pixel size: 9 µm) at 50 kV, 199 µA and 10 W with a rotation step of 0.5º and with a total 
rotation of 180º. Reconstruction was performed in the conditions specified in Table 11; all 
parameters were set for all samples except post-alignment, which was set for each sample. 
Images of 0.25 g/cm3 and 0.75 g/cm3 bone mineral density (BMD) standards (Bruker) 
were acquired and reconstructed as abovementioned. 
Parameter Conditions 
Beam hardening correction 45  
Smoothing Gaussian filter, 3 
Ring artifact reduction 6 
Contrast limits 0-0.1 
Post-alignment As required 
Hounsfield units (HU) calibration OFF 
Format JPEG 
Table 11. Summary of the conditions used to perform reconstructions. 
Reconstructed data sets were reoriented using Dataviewer software (Bruker). The diameter 
of defects in animals sacrificed after surgery was calculated using CTAn software 
(Bruker) and a cylinder-shaped volume of interest (VOI) with 3.51 mm diameter and 1.82 
mm height was created. Whole-set histograms were adjusted to 48-218 grey levels and 
BMD calibration was carried out as recommended by the manufacturer. Calculations were 
performed using the 3D quantification tools included in CTAn; non-defected areas in 
calvaria frontal bone at 12 weeks post-implantation were used as a reference. Coronal and 
axial 3D images of the VOI were taken using a custom transfer function in CTVox 
software (Bruker).  
4.1.2.3.4 Histology 
Calvariae were partially decalcified by incubation with rapid decalcifier (Casa Álvarez) 
for 2.5 h at RT and washed three times in PBS for 20 minutes. Samples were then 
subjected to three different stainings.  
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Regressive hematoxylin and eosin staining. Samples were incubated with Harris 
hematoxylin (Sigma) for 2.5 minutes and thoroughly washed with tap water. 
Differentiation was carried out by incubation with 0.3% acid alcohol for 1 minute and 
stopped by washing samples with tap water. Samples were then incubated with ammonia 
water (bluing solution) for 1 minute, washed with tap water and incubated with eosin Y 
(Sigma) for 1 minute; eosin staining was differentiated by incubation with 95% ethanol for 
15 seconds. Dehydration and clearing consisted on (i) incubation with 100% ethanol for 
30 seconds, (ii) incubation with 100% ethanol for 1 minute, and (iii) and two 3-minutes 
incubation with xylene (Sigma). Samples were then mounted with Eukitt (Panreac) and 
sandwiched with coverslips. 
Goldner’s trichrome. Samples were incubated with Weigert’s iron hematoxylin (Sigma), 
washed with tap water and differentiated in 1% acid alcohol for 5 seconds. After being 
washed with tap water and rinsed in distilled water, samples were incubated with solution 
A (1.56 mM Ponceau 2R, 0.43 mM acid fuchsin and 0.196 mM azophloxine in 0.2% 
acetic acid) for 5 minutes and rinsed in 1% acetic acid. Glass slides were then incubated 
with solution B (44.2 mM orange G and 21.08 mM phosphomolybdic acid in distilled 
water) for 3 minutes and rinsed in 1% acetic acid. Samples were then incubated with 
solution C (2.52 mM light green in 0.2% acetic acid) for 5 minutes and treated with 1% 
acetic acid for 5 minutes. Dehydration, clearing and mounting were performed as 
abovementioned. 
Alcian blue. Glass slides were incubated with alcian blue solution (7.7 mM alcian blue 
8GX in 3% acetic acid, pH 2.5) for 30 minutes, washed with tap water and rinsed in 
distilled water. Samples were counterstained with nuclear fast red (Sigma) for 5 minutes 
and washed with tap water. Dehydration, clearing and mounting were performed as 
previously stated.  
4.1.2.3.5 Statistical analysis 
Data were analyzed by means of t-test or one-way ANOVA with Tukey’s post hoc test. 
All analyses were performed using Prism (GraphPad, version 6.01). Results were 
considered significant when p≤0.05 unless otherwise specified.  
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4.2 RESULTS 
4.2.1 Citric acid as a soluble factor 
4.2.1.1 Cytotoxicity 
A cytotoxicity by indirect contact experiment was performed to assess whether the 
selected citric acid concentrations were toxic for hMSCs. After a 42.5-h exposure to 
complete medium supplemented with citric acid, cell number was quantified and 
normalized to that in control wells (i.e. complete medium without citric acid). Cell 
quantification revealed that none of the selected concentrations were toxic (Figure 42a). 
These results were confirmed by live/dead staining (Figure 42b), which showed that 
almost all cells exposed to citric acid were viable (green cells), with only few cells being 
dead (red cells). No cells were observed in wells exposed to medium containing phenol. 
 
Figure 42. Cytotoxicity of complete medium supplemented with citric acid. a) Cell 
quantification after a 42.5-h exposure period. Live/dead staining of cells exposed b) 0 mM, c) 
0.15 mM, d) 0.75 mM, and e) 1.25 mM citric acid. Scale bar: 10 µm. *p value≤0.0001. 
4.2.1.2 Proliferation 
Proliferation assays were performed to assess whether the presence of citric acid affects 
hMSCs proliferation. Cells were cultured for up to 14 days in complete medium and 
quantified with Alamar blue; cell number at a given time was normalized to that in control 
wells (i.e. 0 mM citric acid). Cell number at day 1 seemingly increased as higher citric 
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acid concentrations were used, although just wells exposed to 1.25 mM citric acid 
displayed significantly increased cell number (Figure 43). Despite the presence of citric 
acid seemingly led to increased adhesion efficiencies, the cell number in control wells 
equaled those exposed to citric acid throughout the experiment, at the end of which all 
conditions led to similar cell numbers.  
 
Figure 43. hMSCs proliferation in citric acid-supplemented complete media. *p value≤0.05. 
 
Figure 44. ALP expression in hMSCs cultured in culture media containing citric acid. 
hMSCs were cultured either in a) complete medium or b) osteogenic medium. *p value≤0.05; 
***p value≤0.01; ****p value≤0.0001. 
4.2.1.3 ALP expression 
hMSCs were cultured in either complete or osteogenic media to assess whether the 
presence of citric acid might either induce osteogenic differentiation or potentiate the 
effect of differentiation medium. As shown in Figure 44a, low ALP expression was found 
in all conditions and at all times when cells were cultured in complete medium; ALP  
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Figure 45. Immunostaining for OPN expression in hMSCs cultured in complete medium. 
Scale bar: 100 µm. 
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Figure 46. Immunostaining for OPN expression in hMSCs cultured in osteogenic medium. 
Scale bar: 100 µm. 
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Figure 47. OPN expression in hMSCs cultured in culture medium containing citric acid. 
hMSCs were cultured either in a) complete medium or b) osteogenic medium. 
levels in control medium (0 mM) were significantly higher than those in citric acid-
containing media at day 14, but by day 21, ALP levels in cells cultured with citric acid 
equaled those in control cells. ALP expression was found to peak at day 7 in osteogenic 
media and to be increased in cells cultured with either 0 mM or 0.75 mM citric acid 
(Figure 44b). From day 7 on, ALP expression decreased and a second peak was found at 
day 21 in cells cultured with 0.75 mM citric acid.  
4.2.1.4 OPN expression 
OPN expression in hMSCs cultured in culture media with or without citric acid was 
assessed by immunofluorescence and ELISA. Despite immunofluorescence didn’t reveal 
substantial changes throughout the experiment in OPN expression in cells in complete 
medium, cells cultured in the presence of citric acid seemingly expressed higher levels of 
the marker by day 21 (Figure 45). Quantification by ELISA showed that OPN expression 
decreased throughout the experiment and revealed higher expression at day 21 in cells 
cultured with citric acid when compared to that in control cells, although differences were 
not statistically significant (Figure 47a). Immunofluorescence of cells cultured with 
osteogenic medium showed that OPN levels didn’t significantly change throughout the 
experiment in any of the conditions (Figure 46). Quantification by ELISA revealed OPN 
levels in cells cultured in osteogenic medium also decreasing along the experiment in all 
the conditions (Figure 47b). High expression levels at day 3 in cells cultured in osteogenic 
medium containing 0 mM and 0.75 mM were due to one of the replicates being discarded.  
 CHAPTER 4 
 
123 
 
4.2.1.5 OCN expression 
OCN expression was assessed by ELISA. Similar to the OPN case, OCN was found to 
decrease along the experiment in all the conditions either in complete (Figure 48a) or 
osteogenic media (Figure 48b). No statistically significant differences were found in any 
case. 
 
Figure 48. OCN expression in hMSCs cultured in culture medium containing citric acid. 
hMSCs were cultured either a) complete medium or b) osteogenic medium. 
4.2.1.6 Mineralization 
Mineralization was assessed by staining calcium deposits with Alizarin red, which was 
subsequently quantified. Alizarin red staining revealed that low calcium deposition 
occurred in all the conditions at all time points, either in complete or osteogenic media 
(Figure 49a-x); in the case of osteogenic medium, slightly darker staining was observed in 
cells cultured with 0.15 mM and 0.75 mM citric acid. These results were confirmed by 
quantification of bound alizarin red, which showed low calcium deposition in all the 
conditions at all time points and slightly increased calcium levels in cells cultured with 
osteogenic medium plus 0.15 mM and 0.75 mM citric acid, although differences were not 
significant (Figure 49y and z).  
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Figure 49. Mineralization expression in hMSCs cultured in culture medium containing 
citric acid. Alizarin red staining was performed on hMSCs cultured with 0 mM (a,e,i,m,q,u), 
0.15 mM (b,f,j,n,r,v), 0.75 mM (c,g,k,o,s,w) or 1.25 mM (d,h,l,p,t,x) for 3 (upper row), 14 (mid 
row) or 21 days (lower row). Bound alizarin red in complete (y) or osteogenic media (z) was 
quantified. *p value≤0.05. 
4.2.2 Tailored hydrogels 
4.2.2.1 In vitro biological characterization 
4.2.2.1.1 Cytotoxicity 
A cytotoxicity by indirect contact assay was performed to assess tailored hydrogels (E9C1 
54 mg/ml) for the release of toxic molecules. After a 42.5-h exposure period, cells were 
quantified with Alamar blue and subjected to live/dead staining. Alamar blue 
quantification showed that exposure to hydrogels led to a cell number reduced by 20% 
compared to that in control wells (TCPS; Figure 50a). Live/dead staining revealed almost 
no dead cells in control wells (Figure 50b) nor in those exposed to hydrogels (Figure 50c); 
in the latter case, this phenomenon was probably due to dead cells being removed during 
the wash step previous to staining.  
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Figure 50. Cytotoxicity of 54 mg/ml E9C1 hydrogels. a) Cell quantification after a 42.5-h 
exposure period. Live/dead staining of b) controls cells and c) cells exposed to 54 mg/ml E9C1 
hydrogels. Scale bar: 10 µm. *p value≤0.01. 
4.2.2.1.2 Proliferation 
The proliferation of hMSCs in 54 mg/ml and 40 mg/ml E9C1 hydrogels was quantified at 
days 3, 7, 14 and 21. As shown in Figure 51, cell numbers in hydrogels were significantly 
higher than those in TCPS at days 3 (4269.3 ± 697.8 in 54 mg/ml samples, 3610.7 ± 460 
in 40 mg/ml samples, and 289.3 ± 267.3 in TCPS), 7 (10633.3 ± 1037.3 in 54 mg/ml 
matrices, 10062.7 ± 575.1 in 40 mg/ml samples, and 458.7 ± 148 in TCPS)  and 14 
(29636.7 ± 7706.3 in 54 mg/ml hydrogels, 34040 ± 9127.5 in 40 mg/ml hydrogels, and 
11286.7 ± 993.2 in TCPS); by the end of the experiment, just RGD-C samples displayed 
cell numbers significantly higher than those in TCPS (71206.7 ± 25666.2 in 54 mg/ml 
hydrogels, 51953 ± 4437.7 in 40 mg/ml hydrogels, and 29120 ± 13286.96 in TCPS). No 
statistically significant differences between hydrogels were noticed at any time point.  
 
Figure 51. hMSCs proliferation on tailored and non-tailored hydrogels in complete 
medium. *p value≤0.05. 
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Figure 52. Qualitative assessment of hMSCs proliferation seeded on hydrogels in i) 
complete and ii) osteogenic media. Scale bar: 50 µm. 
 
Figure 53. Detailed view of hydrogels surface by SEM. a) Surface of a 54 mg/ml E9C1 
hydrogel containing a thin layer of polymer (black arrows). b-c) Surface of a 40 mg/ml E9C1 
hydrogel exposing the polymeric fiber-like structures (red arrows) in E9C1 hydrogels. Scale bar: 
50 µm. 
Cell proliferation in complete medium was qualitatively assessed by SEM, which 
confirmed that hMSCs are able to proliferate both in tailored and non-tailored hydrogels to 
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a similar extent (Figure 52,i). Additionally, the proliferation in hydrogels in osteogenic 
medium was qualitatively assessed by SEM. This test showed that cells behaved normally 
in differentiation medium, displaying a normal morphology (Figure 52,ii). No cells were 
observed inside hydrogels in any condition and at any time point. Interestingly, SEM 
observations revealed that most of the hydrogels displayed a thin layer on their surface 
(Figure 52 i) and ii), and Figure 53) assumed to be “collapsed polymer” and that was 
seemingly shielding hydrogels microarchitecture and hindering 3D cell colonization.  
 
Figure 54. Expression of osteogenic markers in hMSCs seeded in tailored and non-tailored 
hydrogels. *p value≤0.05; **p value≤0.01. 
4.2.2.1.3 In vitro osteogenic differentiation 
The expression of ALP, OPN and OCN in cells cultured in hydrogels was quantified and 
compared to that in cells cultured in TCPS. As shown in Figure 54a, ALP seemingly 
peaked at day 21, with cells cultured in TCPS expressing the higher amount of the marker. 
Globally, although it seemingly increased over time, ALP expression in cells cultured in 
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both hydrogels (and specially those seeded on 54 mg/ml) was consistently low. No 
statistically significant differences were observed between hydrogels.  
As for the expression of OPN (Figure 54b) and OCN (Figure 54c), levels of the markers 
were found to decrease along the experiment. No clear differences between hydrogels and 
TCPS were observed beyond OCN expression at day 3, when significantly increased 
levels were found in the case of cells seeded on hydrogels.  
4.2.2.2 In vivo biological characterization 
4.2.2.2.1 µCT 
µCT was performed to quantify bone within defects. Defects with 3.5-mm diameter were 
created in SCID mice calvaria and implanted with 40 mg/ml and 54 mg/ml E9C1 
hydrogels; control defects were left empty. Bone was quantified at 6 and 12 weeks after 
implantatation; empty defects at day 0 were used to determine the mean diameter of 
defects to create a VOI with a proper diameter, and to account for the initial amount of 
bone. A VOI with 3.51-mm diameter and 1.82-mm height was created; the VOI was 
allowed to possess a little excess in height to ensure that all the new tissue was enclosed 
within it. 3D reconstructions of all the defects at day 0, and 6 and 12 weeks after 
implantation used for quantification are shown in Figure 55; coronal and axial views of 
defects are presented to illustrate bone growth in diameter and thickness.  
Different parameters were quantified using non-defected areas of frontal bones at 12 
weeks post-implantation as a reference. First, bone volume was quantified. As shown in 
Figure 56a, bone wasn’t completely removed during surgery; thin pieces of bone were 
found in empty defects at day 0 (Figure 55a). Bone volume was found to increase to a 
similar extent in the three groups during the first 6 weeks of treatment (2.06 ± 0.20 mm3 in 
empty defects, and 2.42 ± 0.72 mm3 and 2.56 ± 0.37 mm3 in 54 mg/ml and 40 mg/ml 
hydrogel-treated defects). By the end of the experiment, defects treated with hydrogels 
displayed a bone volume (3.38 ± 0.48 mm3 in 54 mg/ml group and 3.47 ± 0.82 mm3 in 40 
mg/ml group) significantly higher than that in empty defects (1.92 ± 0.40 mm3), in which 
no differences between the two time points were observed. Interestingly, defects treated 
with 40 mg/m hydrogels displayed a bone volume significantly higher than that in frontal  
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Figure 55. 3D reconstructions of defects in SCID mice. Coronal and axial views of defects (a) 
at day 0, and after (b) 6 and (c) 12 weeks of implantation were generated. Scale bar: 1 mm. 
Apparent density in the 3D reconstructions is representative of bone thickness.  
bone (namely, calvaria; 2.71 ± 0.16 mm3). No statistically significant differences between 
hydrogels were found at any time point. 
 
Figure 56. Summary of µCT quantitative results. a) Bone volume, b) bone surface, c) 
surface/volume, d) volumetric BMD, and e) BMD were quantified. *p value≤0.05. 
Bone surface was also quantified (Figure 56b). Bone surface in empty defects was found 
to not significantly change along the experiment (26.96 ± 2.51 mm2 at day 0, 27.92 ± 1.89 
mm2 at 6 weeks, and 26.60 ± 6.29 mm2 at 12 weeks). Animals in the 40 mg/ml group were 
found to display a bone surface (33.75 ± 4.47 mm2) significantly higher than that in 
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control defects (27.92 ± 1.89 mm2) at week 6 and, by the end of the experiments, both 
hydrogels led to significantly increased bone surface (38.02 ± 5.48 mm2 in the 54 mg/ml 
group, and 38.76 ± 6.13 mm2 in the 40 mg/ml group). No differences between hydrogels 
were observed during the experiment. 
Bone in day 0 defects was found to possess a high surface/volume ratio (or surface 
density; 26.14 ± 2.51 mm-1; Figure 56c). Surface density was found to have decreased to a 
similar extent in all three groups at  week 6(13.63 ± 1.18 mm-1 in empty defects, 14.11 ± 
1.78 mm-1 in the 54 mg/ml group, and 13.42 ± 2.82 mm-1 in the 40 mg/ml group). This 
trend was kept during the rest of the experiment, by the end of which surface density of 
hydrogel-treated defects (11.30 ± 1.02 mm-1 in the 54 mg/ml group, and 11.36 ± 1.03 mm-
1 in the 40 mg/ml group) was significantly lower than that in empty defects (13.94 ± 1.60 
mm-1) and no significantly different from that in frontal bone (11.72 ± 0.41 mm-1).  
Two bone mineral density (BMD) calculations were performed. First, the volumetric 
BMD results are presented (Figure 56d). The volumetric BMD (namely, BMD VOI) 
results from calculating mean BMD in the whole VOI, considering both bone and void 
volume; results were normalized to that in un-defected frontal bone. This parameter was 
found to be similar for all three groups at week 6 (59.31 ± 23.61 % in empty defects, 74.18 
± 16.22 % in the 54 mg/ml group, and 82.56 ± 16.05 % in the 40 mg/ml group) and to be 
significantly higher in hydrogel-treated defects by 12 weeks (117.59 ± 11.05 % in the 54 
mg/ml group, and 122.96 ± 21.15 % in the 40 mg/ml group) when compared to that in 
empty defects (75.70 ± 15.57 %). No differences between hydrogels were found. 
Results of BMD calculations, corresponding just to the BMD of bone enclosed in the VOI 
normalized to that in frontal bone, are presented in Figure 56e. At a given time point and 
along the experiment, all groups were found to possess non-statistically different BMD 
values (6 weeks: 92.52 ± 4.65 % in empty defects, 87.95 ± 4.03 % in the 54 mg/ml group, 
and 91.14 ± 3.83 % in the 40 mg/ml group; 12 weeks: 96.18 ± 6.80 % in empty defects, 
96.79 ± 2.38 % in the 54 mg/ml group, 99.09 ± 5.78 % in the 40 mg/ml group). 
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4.2.2.2.2 Histology 
The tissue in treated and untreated defects was studied by histology. Hematoxylin and 
eosin (H&E), Goldner’s trichrome and alcian blue stainings were performed to assess cell 
infiltration into the defects/hydrogels, the formation of osteoid and mineralized bone, and 
the mode of osteogenesis, respectively. A general view of the three stainings in all 7 study 
groups can be found in Figure 57.  
As shown by µCT, thin pieces of bone remaining in the defects after surgery (namely, day 
0) were observed after H&E staining (Figure 57). Histological stainings showed that little 
regeneration occurred in empty defects, in which low amount of tissue was observed 
reconnecting defects ends at either 6 or 12 weeks (Figure 57, and Figure 58a and b). This 
connecting tissue was shown to contain both osteoid and mineralized bone (Figure 58c 
and d), with defects at 6 weeks containing more osteoid and less mineralized tissue than 
their 12 weeks counterparts. Alcian blue staining, here used to detect the presence of 
cartilage, wasn’t performed on empty defects as calvaria is naturally formed by 
intramembranous ossification [3]. 
40 mg/ml hydrogels were found to be partially degraded after 6 weeks of implantation 
(Figure 57). At this time point, cells had entered the scaffold (Figure 59d, e and f), which 
was found to be bound to native bone (Figure 59e). Additionally, cells entering the 
scaffold were seemingly undergoing osteogenic differentiation, as evidenced by the 
presence of osteoid (Figure 59f). Mineralized matrix, if present, couldn’t be detected given 
that the hydrogel strongly stained in green. 40 mg/ml scaffolds displayed higher 
degradation and cellularity (Figure 57 and Figure 59j) at 12 weeks post-implantation, 
when new bone was found to have formed within the hydrogel (Figure 59k and n). 
Interestingly, this new bone was seemingly undergoing remodeling as suggested by the 
presence of resorption sites and osteoclasts (Figure 59k and n); bone remodeling was 
parallel to bone formation, as evidenced by the presence of osteoid inside the hydrogel 
(Figure 59l). Alcian blue staining was negative (Figure 57), pointing out that bone 
formation occurred by intramembranous ossification. 
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bone; blue: cytoplasm, black: nuclei. Alcian blue) Blue: glycosaminoglycans; pink: cytoplasm; 
pink-red: nuclei. Scale bar: 0.5 mm. 
 
Figure 58. Detailed view of control defects. Empty defects at 6 (a,c) and 12 weeks (b,d) were 
subjected to hematoxylin & eosin (a-b), and Goldner’s trichrome stainings (c-d). a-b) Purple: 
nuclei; pink: cytoplasm; orange: mineralized bone. c-d) Due to the strong greenish staining of 
mineralized collagen masking osteoid, overexposed pictures are shown. Light blue: mineralized 
bone; red-purple: osteoid. Scale bar: 50 µm.  
54 mg/ml hydrogels were found to be barely degraded (Figure 57) and invaded by cells at 
6 weeks (Figure 59a); cells were mainly found in the outer part of scaffolds, with cell 
invasion occurring at discrete places. Degradation and invasion were found to be increased 
at 12 weeks (Figure 57 and Figure 59g); although increased, cell invasion was also found 
to be discrete. Despite low cell invasion, osteoid was found at both time points (Figure 59c 
and i); mineralized matrix couldn’t be detected at any time point due to hydrogels getting 
strongly stained in green. Hydrogels were found to be discretely bound to bone by week 6 
(Figure 57 and Figure 59b) and to be integrated into the tissue at 12 weeks post-
implantation (Figure 59g and h), time at which blood vessels were noticed in the bone-
hydrogel interface (Figure 59h and m). As in the case of 40 mg/ml hydrogels, alcian blue 
staining was negative (Figure 57), suggesting that bone formation took place by 
intramembranous ossification.  
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Figure 59. Detailed view of hydrogel-treated defects. Defects treated with 54 mg/ml (a-c, g-i, 
m) or 40 mg/ml (d-f, j-l,n) hydrogels at 6 (a-f) and 12 (g-n) weeks post-implantation were 
stained with H&E (a,b,d,e,g,h,j,k,m,n) and Goldner’s trichrome (c,f,i,l). H&E) Purple: nuclei; 
pink: cytoplasm; orange: mineralized bone. Goldner’s trichrome) Green: mineralized bone; blue: 
cytoplasm; black: nuclei; red: osteoid. Overexposed pictures of Goldner’s trichrome) light blue: 
mineralized bone; red-purple: osteoid. H: hydrogels; C: calvaria; O: osteoid; NB: new bone. 
Arrows: cells invading 54 mg/ml hydrogels; hash: blood vessels in the hydrogel-bone interface; 
asterisk: osteoclast. Scale bar: 50 µm. 
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4.3 DISCUSSION 
Citrate has been known to have bone as its main deposit since the early 40s [370,372]. 
Despite the fact that such a localized citrate accumulation was likely to be a reflection of 
its pivotal role in bone biology, important questions as to its origin and function have been 
left unattended for decades.  
Citric acid in bone has been long assumed to be incorporated from blood through the 
sodium-citrate transporter, which is seemingly not expressed in osteoblasts [524]; instead, 
citric acid seems to be locally overexpressed and secreted by osteoblasts [32,524]. Once 
secreted, it has been hypothesized to bind to hydroxyapatite to control the size [6] and 
crystallinity [525] of the mineral phase in concert with NCPs [25] and, thus, to be essential 
for an optimum mechanical performance of the tissue.  
Citric acid has been shown to be essential for the adipogenic differentiation of pre-
adipocytes [526]. During adipogenic differentiation, mitochondria-to-cytosol transported 
citrate is seemingly used for the synthesis of fatty acids. Interestingly, when this transport 
is abrogated, not only fat accumulation is reduced but the expression of PPARγ 
(Peroxisome proliferation-activated receptor gamma), a master regulator of adipogenic 
differentiation [527], is abolished [526]. Lipogenesis is not just essential in the case of fat-
accumulating phenotypes, but is also involved in general eukaryotic processes such as 
membranogenesis (i.e. synthesis of plasma membrane). Membranogenesis is especially 
active during cell proliferation and it’s related to high bioenergetic and synthetic 
requirements. In this context, it has been hypothesized that extracellular citrate could be 
transported into the cytosol, where it would be used to produce acetyl-CoA and thus to 
synthetize fatty acids [520]. This transport would be carried out by the sodium-coupled 
citrate transporter (NaCT), as demonstrated in human colon carcinoma cells [528] and 
cells from rat liver [529]. Despite this seems not to be a common metabolic route, we 
asked ourselves whether citrate being released during the in vivo degradation of our citric-
acid crosslinked hydrogels could have an effect on hMSCs metabolism and thus affect 
their proliferation and/or differentiation. To perform this study, three citrate concentrations 
were selected: 0.15 mM, 0.75 mM and 1.25 mM. 0.15 mM corresponds to the lower citric 
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acid levels in plasma, which are in the 0.15 mM-0.25 mM range (Dr. Costello, personal 
communication). 1.25 mM corresponds to the complete release of citric acid from 54 
mg/ml HRGD6 hydrogels in a volume of 200 µl (volume of medium used to perform cell 
culture on our hydrogels) assuming that citric acid used to produce aforesaid hydrogels is 
completely incorporated into the network. 0.75 mM was selected as an intermediate 
concentration.  
Prior to testing their effect on hMSCs proliferation and osteogenic differentiation, the 
three selected concentrations were assessed for cytotoxicity using supplemented complete 
medium. Cytotoxicity has been reported after exposing osteoblasts [530] and fibroblasts 
[531] to culture medium supplemented with citric acid at concentrations higher than 11.9 
mM. In these studies, the pH of supplemented media was left unadjusted, rendering 
impossible to clearly attribute the cytotoxic effect to citric acid itself rather than to the 
acidic pH of supplemented media. As shown in Figure 42, our selected concentrations, 
well below the reported cytotoxic values, were 100% cytocompatible, leading to 
unaffected cell number and morphology. When hMSCs were cultured with supplemented 
medium, a concentration-dependent increase in cell adhesion was observed, with the 1.25 
mM concentration leading to a significantly increased cell number at days 1 and 3 (Figure 
43). However, cell numbers in citric acid-treated wells equaled those in control wells 
along the experiment, suggesting that herein used concentrations were safe for hMSCs and 
thus feasible to be used to test the effect of the tricarboxylic acid on hMSCs osteogenic 
differentiation.  
The effect of citric acid on hMSCs differentiation was studied by quantifying calcium 
deposition and the expression of ALP, OCN and OPN, which are routinely used to assess 
osteogenic differentiation. Both complete and osteogenic culture media were 
supplemented with citric acid to investigate whether the tricarboxylic acid can either 
induce osteogenic differentiation or potentiate the effect of osteogenic supplements, 
respectively. Calcium deposition was found to increase over time in both cases; slightly 
higher values were obtained when osteogenic medium was used, with an apparent 
concentration-dependent increase in calcium deposition (although not statistically 
significant) for concentrations up to 0.75 mM by day 21 (Figure 49).  
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ALP expression in complete medium increased along the experiment, but overall values 
were low in all cases (Figure 44a), suggesting that none of the concentrations induced 
osteogenic differentiation. When osteogenic medium was used, ALP expression 
dramatically increased from day 3 to day 7, at which expression peaked in cells cultured 
with 0 mM and 0.75 mM citric acid (Figure 44b). From day 7 on, ALP expression slightly 
decreased in all conditions and a second peak at day 21 was observed in cells cultured 
with 0.75 mM citric acid for 21 days (although the peak was lower than that at day 7). 
ALP, an early marker of osteogenic differentiation, is involved in mineralization [532] and 
its expression precedes the formation of mineral deposits. Herein, despite ALP expression 
seemingly peaked at day 7 in cells cultured in osteogenic medium and reached values ca. 
10 times higher than those reached when using complete medium, calcium deposition in 
osteogenic medium was barely higher than that in complete medium. In order to rule out 
abnormal cell behavior as a reason for reduced mineralization, calcium deposition should 
have been measured beyond day 21, given that herein used cells may take longer to 
mineralize.  
The quantification of OPN (Figure 47) and OCN (Figure 48) expression revealed high 
expression of the late markers at day 3 and expression returning to basal levels throughout 
the experiment. Stem cells are well known to undergo spontaneous differentiation upon 
physical contact with neighboring cells, so culturing them to high confluence can lead to 
pre-commitment, an undesirable outcome if differentiation experiments are to be 
performed. Despite herein used hMSCs were cultured avoiding confluence, primary cells 
can undergo culture-induced alterations (reduced migration, proliferation, differentiation 
potential and trophic activity among others [61,143–149]) that, together with donor-related 
variability [533], can result in unforeseen behavior. Thus, it is hypothesized that hMSCs 
might have pre-committed during expansion culture and once exposed to osteogenic 
medium they would have had to readjust the machinery to undergo osteogenic 
differentiation, taking longer times to reach osteogenic phenotypes. Again, in order to rule 
out altered cell behavior as a reason for the apparent lack of differentiation, the expression 
of OCN and OPN should have been quantified beyond day 21. Globally, citric acid at 
herein used concentrations, which are much higher than those expected upon in vivo 
degradation, seems not to affect hMSCs behavior (i.e. it seems not to affect proliferation 
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nor to induce differentiation/potentiate the effect of osteogenic supplements), suggesting 
that the degradation products of our hydrogels (i.e. citric acid and amino acids) are 
biocompatible. 
Having shown that citrate can be used as a non-toxic crosslinker, mechanically-tailored 
hydrogels were tested for biological performance. Cytotoxicity studies revealed cell 
number reduced by 20% but normal cell morphology (Figure 50) after indirect exposure to 
54 mg/ml E9C1 hydrogels. According to ISO 10993-5:2009, these hydrogels would be 
slightly cytotoxic, which might be solved by subjecting samples to more extensive 
washing protocols to completely remove toxic by-products generated during crosslinking. 
hMSCs were able to proliferate both in 40 mg/ml and 54 mg/ml E9C1 hydrogels (Figure 
51 and Figure 52), which points out that –COOH groups from aspartic acid’s side chain is 
not involved in the crosslinking reaction, preserving the integrity of RGD sequences. 
Higher cell numbers were consistently obtained in hydrogels in comparison to TCPS, 
suggesting that hydrogels provide at least a 2.5D (since most hydrogels displayed a thin 
layer of polymer on the surface, which would explain why cells weren’t found within 
hydrogels; Figure 52 and Figure 53) environment for cell (in)growth. Interestingly, no 
significant differences between hydrogels were observed at any time point; however, 54 
mg/ml hydrogels led to significantly increased cell number by day 21 when compared to 
that in TCPS.   
A delayed expression of ALP was observed in all conditions, with the expression in cells 
cultured in TCPS seemingly peaking and being significantly higher than that in hydrogels 
at day 21 (Figure 55a). No differences were observed between hydrogels, the expression 
in which was consistently low. This phenomenon, given the proliferation results (Figure 
51) and the presence of the polymeric layer on surface, could be due to (i) most of the cells 
in hydrogels being in a proliferative state while some of them would have activated the 
differentiation machinery, or to (ii) hydrogels containing a high cell density, shown to lead 
to reduced ALP expression [532]. As shown in the study of citric acid as a soluble factor, 
the expression of both OCN and OPN was found to decrease along the experiment (Figure 
54 b and c). Despite the high levels at day 3, the low expression levels of OPN and OCN 
by the end of the experiment could be due to delayed differentiation, as suggested by 
observed delayed ALP expression.  
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The in vivo performance of 54 mg/ml and 40 mg/ml hydrogels was tested using a critical 
size defect model in SCID mice calvariae. Two critical size defects [534] were generated 
in the parietal bone of female SCID mice and treated with hydrogels; control defects were 
left empty. Bone regeneration was assessed by µCT and histology at 6 and 12 weeks post-
implantation. µCT revealed that higher bone formation had occurred at 12 weeks in 
hydrogel-treated defects in comparison to those left untreated, as evidenced by bone 
volume (Figure 56a) and surface (Figure 56b) calculations. Interestingly, bone fragments 
in hydrogel-treated defects were bigger (i.e. they possessed lower surface-to-volume 
values) than those in empty defects, as demonstrated by surface density calculations 
(Figure 56c). It is noteworthy to mention that the density of bone fragments in all 
conditions was essentially the same (Figure 56c), pointing out that differences between 
hydrogel-treated and non-treated defects regarding volumetric BMD (Figure 56e) are due 
to differences in bone volume rather than to differences in the density of bone fragments.  
Histology was performed to study the tissue in both untreated and hydrogel-treated 
defects. Defects were found to not spontaneously heal (Figure 57), although some bone 
was formed, as revealed by the presence of osteoid and mineralized tissue at both 6 and 12 
weeks post-implantation (Figure 58). Regarding hydrogels, higher cell invasion was 
observed in samples prepared at 40 mg/ml polymer concentration (Figure 57 and Figure 
59) when compared to their 54 mg/ml counterparts at both time points and, subsequently, 
scaffold degradation was found to be also higher in those hydrogels prepared at a lower 
polymer concentration. Despite low cell invasion, osteoid within 54 mg/ml hydrogels, as 
well as in 40 mg/ml ones, was noticed at both time points (Figure 59); bone formation in 
both cases seems to proceed through intramembranous ossification, as suggested by 
negative Alcian blue staining. The presence of mineralized tissue within hydrogels could 
not be observed due to strong staining of the polymer when performing Goldner’s 
trichrome staining (Figure 57 and Figure 59), but H&E staining revealed that bone 
formation occurred in the interface of the native tissue with either one of the hydrogels and 
inside 40 mg/ml samples at 12 weeks (Figure 59h,k,m and n). Interestingly, both 
hydrogels were found to be biodegradable, with 40 mg/ml being already partially 
degraded by week 6 (Figure 57); degradation of 54 mg/ml was initially noticed at week 
12. 
 CHAPTER 4 
 
141 
 
Despite 54 mg/ml hydrogels were designed to possess target mechanical properties to 
induce osteogenic differentiation [242], histology results suggest cell invasion and bone 
formation to be higher in non-tailored 40 mg/ml samples and µCT results show that no 
differences exist between hydrogels regarding the amount and properties of dense 
material. First, this phenomenon could be due to cell-independent mineralization of 54 
mg/ml due to calcium and phosphate ions diffusing through hydrogels and binding to 
dangling –COOH groups from citric acid, which would act as nucleation sites for HA. 
Second, it could be due to 54 mg/ml hydrogels seemingly possessing a density hindering 
cell infiltration which would result in delayed bone formation and thus lower amount of 
bone in comparison to that in 40 mg/ml counterparts. This apparent high density would 
not only hinder cell infiltration, but also prevent the tailored mechanical properties on 
exerting their potential osteoinductive effect. A third possibility would be that the 
mechanical properties of 54 mg/ml hydrogels, found to be osteoinductive in 
polyacrylamide hydrogels [242], wouldn’t be so in our ELRs hydrogels. Different authors 
have pointed out that cell behavior depends on the synergistic effect of matrix properties 
[246–248] in such a way that the Young’s modulus required to induce osteogenic 
differentiation might depend on scaffold chemical properties [245]. In order to find out if 
that’s the case, it would have been interesting to test hydrogels with several Young’s 
modulus values in vivo to find the best one given the chemistry of our matrices. It may 
well be that 40 mg/ml samples are the ones possessing a combination of chemical and 
mechanical properties feasible to induce osteogenic differentiation. Despite bone in 40 
mg/ml hydrogels-treated defects was mainly found in the tissue-material interface at 
herein analyzed time points (and thus, samples would be ostoconductive rather than 
osteoinductive) longer implantation times would be required to rule out osteoinduction. In 
any case, both hydrogels seem to be biodegradable and at least osteoconductive, as 
suggested by the presence of bone in the bone-scaffold interface, where the presence of 
blood vessels (Figure 59h and m) and resorption cavities and osteoclasts (Figure 59k and 
n) was noticed; once again, longer implantation times might help finding differences 
between hydrogels as to the amount and quality of new bone. 
These results evidence that more data are required in order to achieve the design of 
hydrogels with multiple tailored properties able to recreate the complex in vivo cell 
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microenvironment. Additionally, they suggest that, although functional studies on 2D may 
serve as a proof of concept, the conclusions drawn may not be valid when moving to a 3D 
environment. Thus, combinatorial studies assessing the synergistic effect of 3D scaffolds 
properties are required to achieve osteoinductive hydrogels. 
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PREFACE 
The present chapter represents our efforts to obtain active lysyl oxidase for the production 
of biomimetic hydrogels for tissue engineering. Water-soluble and urea-soluble versions 
of LOX were overexpressed using transformed bacteria. Purified LOX was characterized 
and a systematic study was performed to optimize the overexpression/purification system 
in order to obtain LOX with improved copper content and activity.    
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5.1 MATERIALS AND METHODS 
5.1.1 Production and purification of chimeric water-soluble LOX 
5.1.1.1 Amplification of the LOX gene 
The human aorta LOX gene was amplified from vector pLOX01 [535], which was 
provided by Dr. Karlo M. Lopez, from California State University Bakersfield. The 
polymerase chain reaction (PCR) was performed in 25 cycles by using LOXTAGF and 
MLOXR primers (Midland Certified Reagent Company, Inc.; Table 12) and Herculase 
Hotstart DNA polymerase (Agilent Technologies). The PCR program consisted on 
denaturing DNA at 94ºC for 1 minute, primer-DNA annealing at 62ºC for 1 minute and 
extension for 5 minutes at 72ºC. The proper amplification of the gene was confirmed by 
performing a 0.8% agarose gel electrophoresis at 100 V for 45 minutes by using a 1Kb 
DNA ladder (New England Biolabs).  
Primer Sequence 
LOXTAGF 5’-AAGGGGCCCGGGACGACCCTTACAACCCC-3’ 
MLOXR 5’-AAGGGGCTCGAGATACGGTGAAATTGTGCAGCC-3’ 
Table 12. Primers for the amplification of the LOX gene from human aorta. LOXTAGF 
and MLOXR introduce a SmaI and XhoI restriction sites for DNA ligation. 
5.1.1.2 Washing and concentration of the LOX gene 
The amplified gene was purified by using a DNA Clean & Concentrator-5 kit (Zymo 
Research). Briefly, DNA binding buffer was added to the mix resulting from PCR at a 9:1 
volume ratio, and the mixture was transferred to a Zymo-Spin column and centrifuged at 
10,000 g for 30s. The flow-through was discarded and 200 µl Wash buffer were added to 
the column, which was centrifuged at 10,000 g for 30 s. 10 µl PCR grade water were 
added to the column, and DNA was eluted by centrifugation 10,000 g for 30 s after a 1 
minute incubation at RT.  
5.1.1.3 Generation of the pLOX09 construct 
The LOX gene and pET-43.1a(+) (Novagen) vector were doubly digested with SmaI and 
XhoI (New England Biolabs) in NEB buffer 4 supplemented with BSA (New England 
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Biolabs) for 45 minutes at 37ºC. After digestion, DNA binding buffer was added to LOX 
and vector digestion mixes at 5:1 and 2:1 volume ratio, respectively. The LOX gene and 
the vector were then washed and concentrated as abovementioned. Ligation was carried 
out by incubating gene and vector with T4 DNA ligase (New England Biolabs) for 5 
minutes at RT. 
5.1.1.4 Transformation of competent NEB 10β Escherichia coli with the pLOX09 
construct 
3, 7 or 10 µl of the ligated plasmid (pLOX09; Figure 60) were added to competent 10β 
Escherichia coli (New England Biolabs) aliquots and the mixtures were incubated for 30 
minutes on ice. Bacteria were heat-shocked at 37ºC for 1 minute and 250 µl S.O.C. 
medium (Super optimal broth with catabolite repression; New England Biolabs) were 
added. The mixture was incubated at 37ºC for 2 hours at 200 rpm. Transformed bacteria 
were plated on Luria Broth (LB; Melford) agar plates (one plate for each amount of 
ligated plasmid) containing 100 µg/ml ampicillin (Melford) and incubated overnight at 
37ºC.  
 
Figure 60. pLOX09 map. The plasmid contains ampicillin resistance (yellow) for the selection 
of transformed cells; a lacI repressor (green) for the selective expression of recombinant proteins 
upon induction; the LOX gene (red) and a Nus-A Tag (violet) to increase the solubility of 
chimeric proteins; and polyhistidine tags (His tags; pink) for protein purification.  
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5.1.1.5 Purification of the pLOX09 construct 
One colony from each plate was transferred to 15-ml tubes containing 10 ml LB medium 
supplemented with 100 µg/ml ampicillin and incubated overnight at 37ºC and 200 rpm. 
The pLOX09 plasmid was independently purified from the three overnight cultures by 
using a QIAprep Spin Miniprep kit (QIAGEN). Briefly, bacteria were centrifuged at 8,000 
g for 3 minutes, resuspended in 250 µl buffer P1 and transferred to 1.5-ml tubes. 250 µl 
buffer P2 were added and the mixtures were homogenized by inverting the tubes; cell lysis 
was allowed to proceed for 5 minutes. 350 µl buffer N3 were added, and the mixtures 
were homogenized and centrifuged at 13,000 rpm for 10 minutes. Supernatants were 
transferred to spin columns and centrifuged at 13,000 rpm for 60 s; flow-throughs were 
discarded. The columns were washed by adding 750 µl buffer PE and by centrifugation at 
13,000 rpm for 60 s; a second centrifugation step was applied to completely remove PE 
buffer. The spin columns were placed in new 1.5-ml tubes and 50 µl ultrapure water were 
added; after a 2-minute incubation at RT, DNA was eluted by centrifugation at 13,000 
rpm for 1 minute. Purified pLOX09 from the three different colonies was doubly digested 
with SmaI and XhoI in NEB buffer 4 for 2 h at 37ºC. A DNA electrophoresis in 0.8% 
agarose was performed to select the purified fraction containing the construct. 
5.1.1.6 Transformation of competent SHuffle T7 E.coli with the pLOX09 construct 
2 µl of properly ligated pLOX09 were added to a Shuffle T7 E.coli (New England 
Biolabs) aliquot and the mixture was incubated on ice for 30 minutes. Bacteria were heat-
shocked at 37ºC for 1 minute and 250 µl S.O.C. medium were added. The mixture was 
incubated at 37ºC for 2 hours at 200 rpm and transformed bacteria were plated in LB agar 
with ampicillin and incubated overnight at 37º. After bacterial growth, plates were stored 
at 4ºC and used as a stock of transformed bacteria for protein overexpression. Plates were 
discarded 3 weeks after plating. 
5.1.1.7 LOX09 overexpression 
One colony of transformed SHuffle T7 E.coli was transferred to 15-ml tubes containing 10 
ml LB medium containing 100 µg/ml ampicillin and incubated overnight at 37ºC and 200 
rpm. Eight 1-ml aliquots of overnight culture were transferred to sterile 1.5-ml tubes and 
bacteria were centrifuged at 13,000 rpm for 2 minutes; supernatants were discarded to 
remove lactamases. Each pellet was resuspended in 1 ml of terrific broth (TB; Melford) 
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containing 100 µg/ml ampicillin. 500 ml TB supplemented with ampicillin were 
inoculated with 2 ml of resuspended bacteria and incubated at 37ºC and 200 rpm until the 
optical density (O.D.) was in the 0.6-0.8 range. At this point, the overexpression of 
recombinant LOX was induced by adding Isopropyl β-D-1-thiogalactopyranoside (IPTG; 
Melford) to a working concentration of 1 mM to induce protein overexpression. 
Additionally, CuSO4 was added to a final concentration of 1 µM to provide the enzyme 
with Cu+2. Bacteria were incubated overnight at RT and 200 rpm for LOX09 
overexpression. 
5.1.1.8 LOX09 purification 
Bacteria were centrifuged at 4,000 g for 20 minutes and the supernatant was discarded. 
Pelleted bacteria were resuspended in non-urea lysis buffer (15 mM imidazole and 0.3 M 
NaCl in 50 mM Tris-HCl, pH 7.8) and sonicated. Sonication was performed on ice at a 30-
35% amplitude in 15 s on – 45 s off (total time of effective sonication: 8 minutes) to avoid 
sample overheating. After sonication, cell debris were pelleted by centrifugation at 8500 
rpm for 20 minutes and discarded. Supernatants were collected and incubated overnight at 
4ºC with Ni-NTA (Nickel-nitriloacetic acid) agarose (QIAGEN) in an orbital shaker to 
allow the binding of the His-tagged enzyme to the resin.  
The lysate-resin mixture was centrifuged for 20 minutes at 8,500 rpm at 4ºC. The 
supernatant was discarded and the resin pellet was resuspended with non-urea lysis buffer. 
The centrifugation-resuspension steps were repeated 11 times to completely remove cell 
debris. Non-urea elution buffer (250 mM imidazole and 0.3 M NaCl in 50 mM Tris-
HCl,pH 7.8) was added to the resin, and the mixture was incubated in an orbital shaker for 
1 h at 4ºC to maximize the release of LOX09 and centrifuged. Purified LOX09 was stored 
at 4ºC and protected from light until use. 
The purity of LOX09 was assessed by Sodium dodecyl sulfate-polyacrylamide gel (SDS-
PAGE) electrophoresis using a resolving gel prepared at a 12.5% polyacrylamide 
concentration. Samples were mixed 1:1 with loading buffer (0.23 M SDS, 4% glycerol, 
16.7% β-mercaptoethanol and 0.083% bromophenol blue in water) and denaturalized by 
exposure to boiling water for 5 minutes. 20 µl of samples were loaded in the gel and 
electrophoresis was performed at 200 V for 45 minutes; a broad range (2-212 kDa) protein 
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marker (New England Biolabs) was used. At electrophoresis completion, the gel was 
incubated overnight with staining solution (0.125% Coomassie brilliant blue R-250, 50% 
methanol and 10% glacial acetic acid in water). Excess staining was removed by 
sequentially incubating the gel overnight in de-stain solutions I (50% methanol and 10% 
glacial acetic acid in water) and II  (5% methanol and 7% glacial acetic acid in water) at 
4ºC.  
5.1.1.9 Protein quantification 
The amount of purified protein was quantified by using the bicinchoninic acid (BCA) 
assay kit (Pierce). Briefly, reagents A and B were mixed at a 50:1 volume ratio and 
thoroughly homogenized. Samples were mixed with the working solution at a 1:20 
volume ratio and incubated at RT for 2 hours. At the end of the incubation, absorbance 
was read at 562 nm; non-urea elution buffer was used as a blank to account for the 
contribution of the components in the buffer to absorbance.  
5.1.2 Production and purification of native urea-soluble LOX 
5.1.2.1 Generation of the pLOX02 construct 
The LOX gene from human aorta was amplified from vector pLOX01 [535]. The PCR 
was performed in 25 cycles by using MLOXF and MLOXR primers (Table 13) and 
Herculase Hotstart DNA polymerase. The amplified gene was washed and concentrated as 
previously stated, and both LOX gene and pET-21b vector (Novagen) were doubly 
digested with NdeI (New England Biolabs) and XhoI restriction enzymes for 45 minutes 
at 37ºC. The washing and ligation of digested gene and vector were performed as 
previously mentioned, leading to obtaining the plasmid pLOX02 (Figure 61). 
Primer Sequence 
MLOXF 5’-AAGGGGCATATGGACGACCCTTACAACCCC -3’ 
MLOXR 5’-AAGGGGCTCGAGATACGGTGAAATTGTGCAGCC-3’ 
Table 13. Primers for the amplification of the LOX gene from human aorta. MLOXF and 
MLOXR introduce a NdeI and XhoI restriction sites for DNA ligation. 
To make sure that the generated plasmid contained the LOX gene, pLOX02 was 
transformed into competent 10β E. coli as abovementioned. Cells were plated into LB agar 
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plates containing 100 µg/ml ampicillin and incubated overnight at 37ºC. Three colonies 
were independently inoculated into 10-ml LB medium + ampicillin and cultured overnight 
at 37ºC and 200 rpm. pLOX02 was purified and digested with NdeI and XhoI as 
previously stated, and a DNA electrophoresis in 0.8% agarose was performed. Digested 
LOX gene and pET-21b vector were used as controls. 
 
Figure 61. pLOX02 map. The plasmid contains ampicillin resistance (blue) for the selection of 
transformed cells; a lacI repressor (green) for the selective expression of recombinant proteins 
after induction; and the LOX gene (red) fused with a His-tag (yellow) for its purification. 
Purified pLOX02 was transformed into SHuffle T7 E.coli as previously stated. 
Transformed bacteria were cultured overnight in LB media and plated in LB + ampicillin 
agar. LB agar plates were used as a source of transformed bacteria for protein 
overexpression and discarded three weeks after plating. 
5.1.2.2 LOX02 overexpression 
Several tests were performed to optimize the overexpression system for soluble LOX02; a 
summary of these tests can be found in Table 34, Supplementary data. Tests number 1, 
and 3 aimed the maximization of protein yield and purity; tests number 1, 6 and 7 aimed 
the maximization of the percentage of enzyme molecules containing the copper cofactor. 
Briefly, a colony of transformed Shuffle T7 E. coli was used to prepare an overnight 
culture in LB medium. Bacteria from the overnight were used to inoculate TB 
supplemented with 100 µg/ml ampicillin, and 500-ml cultures were performed at either 
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30ºC or 37ºC. When the O.D. reached values of 0.6-0.8, the overexpression was induced 
with 0.5 mM, 1 mM, 1.5 mM, 2 mM or 5 mM IPTG and CuSO4 was added to 1 µM, 2 
µM, 5 µM, 10 µM or 20 µM final concentrations. Overexpression was performed at 250 
rpm and either 16ºC or 22ºC, and let to proceed overnight, for 24 h or for 48 h; in the latter 
case, extra ampicillin was added to the cultures at 24 h at a 100 µg/ml concentration to 
keep the selection pressure and prevent bacteria from getting rid of the pLOX02 plasmid. 
The expression of LOX02 in inclusion bodies was also explored. Briefly, bacteria in 500-
ml TB cultures were grown at 37ºC and overexpression was induced at an O.D. of 0.6-0.8 
with IPTG at a final concentration of 1.5 mM; CuSO4 was added at a 1 µM concentration. 
Overexpression was performed at 250 rpm and 37ºC for 4 hours. 
5.1.2.3 LOX02 purification  
The purification system was also optimized for soluble LOX02. Tests number 1, 2 and 4 
(Table 34, Supplementary data) were performed to maximixe protein yield and purity 
and/or the percentage of enzyme molecules containing the copper cofactor. 
For the purification of soluble LOX02, bacteria were centrifuged at 8,500 rpm at 4ºC for 
15 minutes and resuspended in urea lysis buffer (0.2 M NaCl, 6 M urea and 10 mM 
imidazole in 16 mM phosphate buffer, pH 7.8). Sonication was performed as previously 
mentioned and lysates were incubated with TALON cobalt resin (Clontech) or Copper 
chelating resin (G Biosciences) at 4ºC overnight or 15 min RT + 4ºC overnight, and 
subjected to four different purification methods (Table 14); in all cases, the purification 
was performed in urea lysis buffer at 4ºC, and LOX02 was recovered in urea elution 
buffer (0.2 M NaCl, 6 M urea and 250 mM imidazole in 16 mM phosphate buffer, pH 
7.8). Eluted protein was stored in aluminium foil-wrapped tubes at 4ºC until use. 
Method Purification method Steps Speed Time, T 
1 Centrifugation in tube 11 3,000-4,500 rpm 15 min, 4ºC 
2 Centrifugation in spin column 5 250 g 15 min, 4ºC 
3 Centrifugation in tube  
Centrifugation in spin colum 
5 
5 
3,000-4,500 rpm 
250 g 
15 min, 4ºC 
15 min, 4ºC 
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4 Centrifugation in tube  
Gravity-flow in spin column 
5 
5 
3,000-4,500 rpm 
- 
15 min, 4ºC 
- 
Table 14. Summary of methods used to purify soluble LOX02. 
For the purification of LOX02 from inclusion bodies, bacteria were centrifuged at 8,500 
rpm at 4ºC for 15 minutes and resuspended in lysis buffer (50 mM NaCl, 1 mM EDTA, 
0.02% sodium azide and 1% Triton X-100 in 50 mM Tris-HCl, pH 8). Sonication was 
performed as abovementioned and lysates were centrifuged at 18,000 rpm at 4ºC for 10 
minutes. Supernatants were discarded and pellets were resuspended in urea wash buffer 
(0.5 M NaCl and 2 M urea in 50 mM Tris-HCl, pH 8) and centrifuged at 15,000 rpm for 
10 minutes at 4ºC. Supernatants were discarded and pellets were resuspended in 
solubilization buffer (8 M urea, 2 mM β-mercaptoethanol, 50 mM imidazole and NaCl 0.5 
M in phosphate buffer 16 mM) and incubated overnight at 4ºC under magnetic stirring. 
Tubes were then centrifuged at 15,000 rpm at 4ºC for 10 minutes, and supernatants were 
recovered and transferred to disposable columns containing copper chelating resin. Five 
washing steps with urea lysis buffer were performed by gravity flow. For the elution of 
LOX02 from inclusion bodies, the resin was incubated with urea elution buffer at 4ºC for 
15 minutes under agitation and the protein was eluted by gravity flow. A second elution 
was performed in the same conditions. 
The purity of LOX02, either soluble or from inclusion bodies, was assessed by SDS-
PAGE using a resolving gel prepared at 12.5% polyacrylamide and a ColorPlus prestained 
broad range (7-175 kDa) protein marker (New England Biolabs). The electrophoresis gels 
were stained and washed as previously stated. 
5.1.2.4 Dialysis 
The usefulness of dialysis to maximize the percentage of soluble LOX02 molecules 
containing the copper cofactor was investigated. The dialysis step was performed in 3 ml 
Slide-A-Lyzer G2 cassettes (Thermo Scientific) with a 10 kDa molecular weight cut-off 
(MWCO). The dialysis protocol was based on that in [536] and consisted on: (i) 
incubation in 0.15 M NaCl, 6 M urea and 10 mM 2,2′-dipyridine in 16 mM phosphate 
buffer, pH 7.8 for 48 h, (ii) incubation in 0.15 M NaCl, 6 M urea and 0.5 mM CuSO4  in 
16 mM phosphate buffer, pH 7.8 for 48 h, (iii) incubation in 0.15 M NaCl, 6 M urea, 10 
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mM EDTA  in 16 mM phosphate buffer, pH 7.8 overnight, and (iv) two incubations in 
0.15 M NaCl and 6 M urea in 16 mM phosphate buffer, pH 7.8 overday/overnight. All 
incubations were performed at 4ºC with gentle stirring and using a dialysis 
solution:sample volume ratio of 200:1. Dialyzed samples were concentrated using Amicon 
Ultra-4 devices with a 10 kDa MWCO (Millipore) by centrifugation at 3,000 rpm at 4ºC 
for 10 minutes. Dialyzed and concentrated protein was stored in aluminium foil-wrapped 
tubes at 4ºC until use.  
In the case of LOX02 from inclusion bodies, dialysis was performed in order to refold the 
protein, which was diluted to ca. 100µg/ml. Briefly, the enzyme was dialyzed against (i) 
dialysis buffer (6 M urea and 0.15 M NaCl in 16 mM phosphate buffer, pH 8) overnight, 
(ii) refolding buffer (6 M urea, 0.15 M NaCl, 200 µM CuSO4 and 2% N-
lauroylsarcosinate (Sigma) in 16 mM phosphate buffer, pH 8) for 24 h, and (iii) dialysis 
buffer twice overday/overnight. Refolding was carried out in 3 ml Slide-A-Lyzer G2 
cassettes using a buffer:sample volume ratio of 200:1. All steps were performed at 4ºC. 
5.1.2.5 LOX02 quantification  
LOX02 was quantified by the BCA assay. The working solution was prepared as 
previously stated and mixed with samples at a 8:1 volume ration in 96-well plates. 
Absorbance was read at 562 nm. 
5.1.2.6 Cu+2 quantification  
Solutions containing purified LOX were mixed with 1.84 M trichloroacetic acid (Sigma) 
in water at a 3:1 volume ratio. The resulting solution was mixed with 1.94 mM ascorbic 
acid (Sigma) in water and a 0.9375 M NaOH, 0.68 M HEPES and 2.67% BCA reagent A 
solution at a 1:0.2:0.8 volume ratio. The resulting solution was transferred to 96-well 
plates and absorbance was read at 360 nm. CuSO4 was used to prepare a Cu+2 standard 
curve.  
5.1.2.7 Detection of the LTQ cofactor  
The presence of the LTQ cofactor in soluble LOX purified with the copper resin from test 
1 (Table 34, Supplementary data) was assessed by spectrophotometry and Western Blot. 
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Spectrophotometry. A 0.13 M phenylhydrazine in 1 M Tris-HCl, pH 7 solution was 
prepared and mixed with purified LOXO2 at a 1:100 volume ratio. The mixture was 
incubated overnight at RT and the absorbance sprectrum (200-800 nm) was recorded. 
Urea elution buffer was used to substract background signal. 
Western blot. Two SDS-PAGE gels with resolving gel prepared at a 12.5% 
polyacrylamide concentration were prepared. Samples were mixed with loading buffer at a 
1:1 volume ratio and boiled for 5 minutes. SDS-PAGE was run at 200 V for 45 minutes 
using Precision plus protein dual color standards (Bio-rad). One of the gels was stained 
with Coomassie blue as previously stated and the other was used for Western blot. Briefly, 
the gel was sandwiched with fiber pads, filter paper and a nitrocellulose membrane and the 
sandwich was transferred to an electrophoresis cuvette filled with transfer buffer (25 mM 
Tris-HCl, 192 mM glycine and 10 % methanol in water). The transference was run at 100 
V for 1 hour under mild stirring. The nitrocellulose membrane was removed from the 
sandwich and stained overnight in the dark at RT with 0.24 mM nitroblue tetrazolium 
(Sigma) and 2 M glycine in water solution (pH 10). The membrane was then washed with 
water and dried. In order to stain proteins, the membrane was incubated with 1.31 mM 
Ponceau S (Sigma) in 5% acetic acid for 1 h at RT and washed to remove excess staining.  
5.1.2.8 Activity assays 
The activity of LOX02 was assessed in 50 mM borate buffer pH 8.2 containing 1.2 M 
urea, 50 µM 10-Acetyl-3,7-dihydroxyphe-noxazine (Cayman Chemical), 10 mM 
cadaverine (Sigma) and 10 U/ml horseradish peroxidase (Sigma). The mixtures were 
prepared in 96-well plates and fluorescence evolution at 37ºC was recorded in a pre-
warmed microplate reader. The activity was calculated from the slope of the fluorescence 
curve during the first five minutes; elution buffer instead of LOX02 was used to set 
background slope. 30% H2O2 was used to prepare a standard curve; activity is expressed 
as U/mg, where U = nmol H2O2/min. 
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5.2 RESULTS 
5.2.1 Production and purification of chimeric water-soluble LOX 
5.2.1.1 Amplification of the LOX gene 
The human LOX gene was amplified from the pLOX01 plasmid. The use of LOXTAGF 
and MLOXR allowed the proper amplification of the gene, which had an expected length 
of 745 bp (Figure 62).  
 
Figure 62. Amplification of the LOX gene from human aorta. 
5.2.1.2 Generation of the pLOX09 construct 
 
Figure 63. DNA electrophoresis of plasmids from cells transformed with 3 (lane 3), 7 (lane 
4) or 10 µl (lane 5) ligation product. MW: 1 kb DNA ladder; lane 1: doubly digested LOX 
gene; lane 2: doubly digested pET-43.1a(+) vector. 
10β E. coli cells were transformed with 3, 7 or 10 µl of the ligation product. After 
independently culturing cells transformed using the three ligation products, plasmids were 
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purified to select those cells containing the plasmid properly ligated. As shown in Figure 
63, just those cells transformed with 7 µl ligation product contained the pLOX09 plasmid. 
5.2.1.3 LOX09 purification 
SHuffle T7 E.coli cells transformed with the properly ligated pLOX09 plasmid were used 
for LOX09 overexpression.LOX09 was expressed at an average yield of 1379.69 ± 379.63 
µg/l of culture (Table 15) and was eluted to high purity (Figure 64).  
 [LOX09] (µg/ml) Yield (µg/l of culture) 
287,04 ± 65,11 1379,63 ± 379,63 
Table 15. Average protein concentration in the eluted fraction and yield of the overexpres-
sion system in the production of LOX09. 
Despite highly pure LOX09 was obtained, three main bands were consistently observed 
when running SDS-PAGE (Figure 64). These bands were assumed to correspond to the 
LOX09 fusion protein (upper band), Nus-A tag (58 kDa; mid band) and LOX (32 kDa; 
lower band), respectively, and to be the result of partial proteolysis.  
5.2.2 Production and purification of native urea-soluble LOX 
5.2.2.1 Generation of the pLOX02 construct 
The human LOX gene was amplified from pLOX01 and ligated with the pET-21b vector. 
Three colonies of transformed 10β E.coli were assessed for the presence of the properly 
ligated pLOX02 plasmid. As shown in Figure 65, all three selected colonies contained the 
pLOX02 plasmid, pointing out that any of them could be used to prepare cultures for the 
overexpression of LOX02. 
5.2.2.2 LOX02 quantification 
Several tests were performed in an effort to maximize the overexpression yield and the 
protein concentration in the eluted fraction. Affinity resins coordinated with either copper 
or cobalt were tested. In this study, cobalt-loaded resin led to a higher yield and to 
obtaining eluted solutions with higher protein concentration, although both yield and 
concentration were low in both cases (Table 16). Copper-loaded resin was used from then 
on. 
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Figure 64. SDS-PAGE of purified LOX09. MW: protein ladder; lane 1: LOX09 elution 
fraction. 
 
Figure 65. DNA electrophoresis of plasmids from three independent colonies of 
transformed 10β E.coli cells. MW: ladder; lane 1: doubly digested LOX gene; lane 2: doubly 
digested pET-21b vector; lanes 3-5: digested plasmids from colonies number 1, 2 and 3, 
respectively. 
Copper resin Cobalt resin 
[LOX02] (µg/ml) 
250.33 ± 5.77 318.58 ± 11.79 
Yield (µg/l of culture) 
2503.33 3185.83 
Table 16. Effect of metal-loaded resin on eluted protein concentration and yield. 
Available protocols for protein purification recommend performing the protein-resin 
binding step at either RT or 4ºC. To test the influence of the binding temperature, cell 
lysates were incubated with copper-loaded resin at 4ºC overnight, with or without a pre-
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incubation step at RT. As shown in Table 17, pre-incubating lysate and resin at RT led to 
reduced binding and thus to lower elution concentration and yield. An overnight 
incubation at 4ºC was used ever since. 
4ºC RT 
[LOX02] (µg/ml) 
875.58 ± 7.14 581.92 ± 12.78 
Yield (µg/l of culture) 
8755.33 5819.17 
Table 17. Effect of resin binding temperature on eluted protein concentration and yield 
using copper-loaded resin. 
A 1 mM IPTG concentration is routinely used to induce the expression of LOX in 
transformed E.coli [483,485]. A test was performed to assess whether the higher 
overexpression yields could be achieved by using higher [IPTG]. As shown in Table 18, 
the overexpression yield peaked at a 1.5 mM IPTG concentration, which was selected to 
be used from then on. 
Table 18. Effect of [IPTG] on overexpression yield and elution concentration. 
A test was perfomed in order to assess whether extending the overexpression time leads to 
increased yield. Table 19 shows that good elution concentrations were obtained when 
performing overexpression either overnight or for 24 h, with the latter leading to increased 
yield. 
Overnight 24 h 48 h 
[LOX02] (µg/ml) 
2403.71 ± 1098.17 2502.917 ± 47.86 1474.67 ± 23.78 
0.5 mM 1 mM 1.5 mM 2 mM 5 mM 
[LOX02] (µg/ml) 
323.50 ± 5.77 250.33 ± 5.77 1007.17 ± 8.47 612.75 ± 19.18 904.42 ± 9.89 
Yield (µg/l of culture) 
3235 2503.33 10071.67 6127.5 9044.167 
 CHAPTER 4 
 
159 
 
Total yield (µg/l of culture) 
7641.67 ± 1112.5 12514.58 7370.83 
Table 19. Effect of overexpression time on yield and elution concentration. 
In an effort to maximize the percentage of enzymes molecules incorporating a copper 
atom, CuSO4 was added to induced cultures at 1, 2, 5, 10 and 20 µM final concentrations. 
As shown in Table 20, all CuSO4 concentrations led to good elution concentrations and 
yield, with the latter peaking at a 20 µM CuSO4 concentration.  
Table 20. Effect on [CuSO4] on protein yield and elution concentration in overnight 
overex-pression cultures. 
Four different purification protocols were used during the optimization of the 
overexpression and purification of LOX02. All four methods led to acceptable yields 
(Table 21), but method 4 allowed obtaining purified fractions at higher protein 
concentrations (up to 3.5 mg/ml). Thus, method 4 was established as the protocol for the 
purification of soluble LOX02.  
Method 1 Method 2 Method 3 Method 4 
[LOX02] (µg/ml) 
1007.17 ± 8.47 1800.92 ± 937.48 1938.29 ± 732.70 2403.75 ± 1098.17 
Yield (µg/l of culture) 
10071.67 5595.93 ± 1268.51 6357.29 ± 311.04 7641.67 ± 1112.5 
Table 21. Effect of the protein purification protocol on elution concentration and yield. 
Although impurities were detected in the eluted fractions coming from all four methods 
(Figure 66), the intensity of unspecific bands is remarkably lower compared to that of the 
LOX02 band, suggesting that impurities would represent a low percentage of total protein.  
1 µM 2 µM 5 µM 10 µM 20 µM 
[LOX02] (µg/ml) 
1878.83 ± 68.59 1323 ± 123.18 1167.67 ± 45.67 1346.67 ± 42.74 1746 ± 17.36 
Yield (µg/l of culture) 
9394.167 13230 11676.67 13466.67 17460 
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Figure 66. SDS-PAGE of eluted fractions obtained by means of four different purification 
methods. Lane 1: Centrifugation in tube; lane 2: centrifugation in spin column; lane 3: 
centrifugation in tube + centrifugation in spin column; lane 4: centrifugation in tube + gravity 
flow. 
The purification of LOX02 from inclusion bodies was explored. Two eluted fractions were 
obtained for each purification to assess whether all the protein bound to the resin was 
effectively released during the one-step elution protocol used in the case of soluble 
LOX02. As shown in Table 22, most of the protein was recovered in the first elution step, 
while ca. 1/6 of the total amount of protein was released during the second elution step. 
Elution 1 Elution 2 
[LOX02] (µg/ml) 
1968.81 ± 1014.95 393.70 ± 165.05 
Total yield (µg/l of culture) 
7087.537 ± 3366.63 
Table 22. Protein concentration and yield after the purification of LOX02 from inclusion 
bodies. Total yield represents the sum of LOX02 from both elutions. 
5.2.2.3 Cu+2 quantification 
Several tests were also performed in order to maximize the percentage of enzyme 
molecules incorporating the Cu+2 cofactor, essential for LOX activity. LOX02 purified 
with either copper or cobalt-loaded resins was subjected to copper quantification. Copper-
loaded resin led to a remarkably higher copper content in eluted fractions (Table 23) and 
was thus selected to be used in further studies. 
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Copper resin Cobalt resin 
10.38 ± 2.95 % 1.75 ± 0.35 % 
Table 23. Copper content of soluble LOX02 purified with copper or cobalt-loaded resins. 
A test was performed to assess whether longer overexpression times would lead to higher 
copper incorporation into enzyme molecules. For this study, overexpression was let to 
proceed either overnight, for 24 h or for 48 h. As shown in Table 24, the percentage of 
enzyme molecules containing a copper atom decreased as overexpression time increased. 
Overnight overexpression was selected to be used in further experiments.  
Overnight 24 h 48 h 
29.07 ± 8.30 % 10.04 ± 4.11 % 4.50 ± 0.44 % 
Table 24. Effect of overexpression time on soluble LOX02 copper content. 
Given the low copper content of LOX02 purified from cultures with 1 µM CuSO4, the 
effect of adding higher CuSO4 concentrations after induction was studied. As shown in 
Table 25, CuSO4 concentrations beyond 1 µM led to reduced copper content.  
Table 25. Effect of CuSO4 concentration on soluble LOX02 copper content. 
Given that adding extra copper right after induction is not useful to increase copper 
incorporation into the enzyme, a dialysis step involving the removal of copper atoms from 
purified soluble LOX02 followed by adding CuSO4 was performed. As shown in Table 
26, dialysis was not effective and indeed it led to a decreased percentage of enzyme 
molecules with a copper atom. 
Non-dialyzed    Dialyzed 
%Cu+2 
22.88 ± 7.04 % 11.07 ± 3.40 % 
Average fold decrease 
2.26 ± 0.20 
Table 26. Effect of dialysis on soluble LOX02 copper content. 
1 µM 2 µM 5 µM 10 µM 20 µM 
29.07 ± 8.30 % 14.23 ± 1.98 % 12.81 ± 0.96 % 12.48 ± 2.85 % 8.02 ± 3.55 % 
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Two elution steps were performed when purifying LOX02 from inclusion bodies. 
Surprisingly, the enzyme in the second elution contained a considerably increased copper 
content when compared to that in LOX02 from the first elution (Table 27).  
Elution 1  Elution 2 
%Cu+2 
10.05 ± 3.58 % 35.22 ± 5.46 % 
Average fold increase 
4.11 ± 1.25  
Table 27. Copper content in LOX02 purified from inclusion bodies. 
LOX02 from inclusion bodies in the second elution was subjected to refolding by dialysis 
at a protein concentration of 100 µg/ml. As shown in Table 28, refolding led to an 
increased copper content, with enzyme molecules containing ca. 2 copper atoms on 
average.  
LOX02  Refolded LOX02 
%Cu+2 
36.84 ± 4.78 % 212.59 ± 18.50 % 
Fold increase 
5.77  
Table 28. Copper content in LOX02 from inclusion bodies before and after refolding. 
5.2.2.4 Detection of the LTQ cofactor 
The presence of the LTQ cofactor was assessed by spectrophotometry and Western Blot. 
First, for its detection by spectrophotometry, soluble LOX02 was incubated with 
phenylhydrazine. Phenylhydrazine binds to LTQ, producing an adduct with an absorption 
maximum at λ= 454 nm [536]. As shown in Figure 67, the adduct peak was not observed 
upon incubation of soluble LOX02 purified by method 1 with phenylhydrazine. 
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Figure 67. Detection of the LTQ cofactor by absorbance. Buffer (grey) and purified soluble 
LOX02 (black) were incubated with phenylhydrazine and the absorbance spectra were recorded 
in the 200 nm – 800 nm range. Inset: Detail on the 200 nm – 500 nm region. 
 
Figure 68. Detection of the LTQ cofactor by Western Blot. Four batches of LOX02 purified 
by means of method 1 were used. a) SDS-PAGE gel stained with Coomassie blue; b) 
nitrocellulose membrane stained with nitroblue tetrazolium; c) nitrocellulose membrane stained 
with Ponceau S. MW: ladder; lanes 1-4: LOX02 batches 1-4. Lightly stained bands in b) and c) 
have been contoured for clarity. 
For the detection of LTQ by Western Blot, a double SDS-PAGE was performed. One of 
the gels was stained with Coomassie blue (Figure 68a) and the other one was used for 
Western Blot. Soluble LOX02 transferred to nitrocellulose membranes was stained with 
nitroblue tetrazolium (Figure 68b), which stains quinones with redox activity [537], and 
 CHAPTER 4 
 
164 
 
Ponceau S for protein detection (Figure 68c). As shown in Figure 68b, slightly stained 
bands appeared after incubation with nitroblue tetrazolium in batches number 1, 3 and 4, 
and these bands corresponded to LOX02 in Coomassie blue-stained gels and Ponceau S-
stained membranes. These results suggest that a low percentage of soluble LOX02 
molecules contain the LTQ cofactor. 
5.2.2.5 LOX02 activity 
LOX02 purified from tests aiming to increase the percentage of enzyme molecules 
containing the copper cofactor was assessed for activity in order to assess whether 
increases in copper content result in boosted activity. First, the effect of overexpression 
time on soluble lysyl oxidase activity was tested in order to determine whether extending 
the time the enzyme has to incorporate copper and develop the LTQ cofactor results in 
increased activity. As shown in Table 29, the highest mean activity was achieved for 
overnight overexpression, while longer times led to reduced catalytic potential. 
Overnight 24 h 48 h 
Activity (U/mg) 
0.16 ± 0.10 0.047 ± 0.012 0.064 ± 0.013 
Table 29. Effect of overexpression time on soluble LOX02 activity. 
Adding extra CuSO4 at the moment of induction didn’t seem to be beneficial. While 
adding CuSO4 at 2, 5 and 10 µM led to reduced activity compared to that when 1 µM was 
added, a 20 µM concentration didn’t essentially affect activity (Table 30).  
Table 30. Effect of CuSO4 concentration on soluble LOX02 activity. 
Performing a dialysis involving the chelation of bound metallic atoms and subsequently 
adding copper led to reduced activity in dialyzed soluble LOX02 (Table 31). 
 
1 µM 2 µM 5 µM 10 µM 20 µM 
Activity (U/mg) 
0.16 ± 0.10  0.05 ± 0.017 0.034 ± 0.025 0.035 ± 0.031 0.11 ± 0.012 
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Non-dialyzed    Dialyzed 
Activity (U/mg) 
0.22 ± 0.11 0.106 ± 0.004 
Fold decrease 
2.09 
Table 31. Effect of dialysis on soluble LOX02 activity. 
The first two elutions performed to purify LOX02 from inclusion bodies were assayed for 
LOX activity. As shown in Table 32, second elutions were consistently more active (up to 
ca. 5.5 times) that first ones. 
Elution 1  Elution 2 
Activity (U/mg) 
0.13 ± 0.07 0.64 ± 0.15 
Average fold increase 
4.95 ± 0.68  
Table 32. LOX02 activity in fractions purified from inclusion bodies. 
Second elutions from the purification of LOX02 from inclusion bodies were subjected to a 
refolding protocol, which didn’t seemingly have an effect on the catalytic potential of the 
enzyme (Table 33). 
LOX02  Refolded LOX02 
Activity (U/mg) 
0.58 ± 0.14 0.62 ± 0.17 
Table 33. Activity of LOX02 from inclusion bodies before and after refolding. 
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5.3 DISCUSSION 
Lysyl oxidase catalyzes the in vivo oxidative deamination of ε-NH2 groups from lysine (or 
hydroxylysine) residues [424,425] to aldehyde groups that can condense with each other 
or react with primary amines to generate Schiff bases, being thus responsible for the 
crosslinking in collagen and elastin [24,454]. In vitro, LOX has proved able to oxidize 
both short [458,459] and long substrates [466]. Although the activity on the enzyme 
depends on substrate chemical parameters such as pI [458], and substrate sequence and 
length [459–461], a proper 3D conformation of the substrate is critical for the formation of 
LOX-catalyzed crosslinks [454] (i.e. for aldehyde groups and primary amines to be close 
enough to lead to aldol condensation products and Schiff bases). This has been 
demonstrated for collagen [425], tropoelastin [464] and for Urry’s ELPs, whose oxidation 
seemingly depends on their ability to coacervate, being the oxidation of VPGXG-based 
ELPs higher as their coacervation is more favored [466].  
LOX is commonly purified in buffers containing 4-6 M urea given its tendency to self-
aggregate [474]. However, although urea seems not to affect LOX activity when short 
substrates are used [538], it strongly inhibits the enzyme when long substrates such as 
aortic elastin are to be crosslinked (a urea concentration “as low” as 0.2 M can inhibit 
LOX activity by 25%; [474]). Urea is a well-known chaotropic agent, being able to 
denaturate proteins [539,540] or, in other words, to prevent them from folding into their 
natural 3D conformation. On one hand, urea is required for LOX to be soluble; on the 
other hand, urea prevents LOX natural substrates from coacervating, thus hindering their 
crosslinking. In light of these conflicting facts, strategies aiming the production of 
biomimetic LOX-crosslinked hydrogels may rely on (i) modifying the enzyme to make it 
water-soluble or on (ii) optimizing the purification protocol to achieve highly concentrated 
LOX solutions to minimize the amount of urea the substrates are exposed to.  
As previously mentioned, active LOX doesn’t possess any post-translational modification 
other than proteolysis. This makes LOX a feasible protein to be produced in a recombinant 
form in E. coli. In this study, LOX from human aorta was fused with a Nus-A tag, 
commonly used to increase the solubility of recombinant proteins [541], by inserting the 
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LOX gene into a pET-43.1a(+) vector to generate the so-called pLOX09 plasmid (Figure 
60). Properly ligated pLOX09 (Figure 63) was employed to transform SHuffle T7 E.coli 
cells, which were cultured and induced to overexpress the water-soluble version of LOX, 
LOX09. The fusion protein was expressed at low yield (Table 15) and recovered by 
affinity chromatography to high purity (Figure 64). However, SDS-PAGE revealed that 
LOX09 had undergone partial proteolysis resulting in the scission of the solubility tag, as 
evidenced by the presence of three bands (Figure 64). SHuffle T7 E.coli cells are deficient 
in proteases, so the proteolysis is likely to occur during purification. Given that all the 
batches of purified LOX09 showed signs of proteolysis, the use of the fusion protein was 
discarded.  
As an alternative, native LOX (namely LOX02) from human aorta was produced. The 
LOX gene was properly inserted into a pET-21b vector to generate the pLOX02 plasmid 
(Figure 61 and Figure 65), which was used to transform SHuffle T7 E. coli cells for its 
overexpression either in soluble or insoluble forms. Several tests were performed to 
establish a protocol for the production soluble LOX02 at a high yield and to purify the 
enzyme in an active form and at a high concentration (Table 34, Supplementary data). 
Despite leading to a lower yield (Table 16), a copper-loaded resin was selected to purify 
the enzyme given that it allowed the retrieval of soluble LOX02 with higher copper 
content compared to that in LOX02 purified with cobalt-loaded resin (Table 23). Although 
manufacturers recommend performing the protein-binding step at RT, higher binding and 
thus higher yield and LOX02 concentration were achieved by performing binding at 4ºC 
(Table 17). Despite the expression of recombinant LOX is commonly achieved by 
induction with 1 mM IPTG [427,485], a 1.5 mM concentration was selected given that it 
led to a higher soluble LOX02 yield compared to 0.5, 1, 2 and 5 mM concentrations 
(Table 18). Following, an optimization of the purification protocol was performed and 
method 4 (Table 14) was selected on the basis of mean protein concentration on purified 
fractions (Table 21). Although fractions purified by means of the selected method 
contained impurities, purity was assumed to be high given the apparent relative abundance 
of soluble LOX02 and impurities (Figure 66). 
The overexpression of soluble LOX02 was performed overnight, and for 24 and 48 h to 
assess whether longer overexpression times allowed the retrieval of higher amounts of 
 CHAPTER 4 
 
168 
 
protein and a higher copper incorporation. Although extending the overexpression time to 
24 h led to increased yield (Table 19), copper incorporation and activity were found to be 
lower as longer overexpressions were performed (Table 24 and Table 29), so overnight 
overexpression was selected. After inducing soluble LOX02 expression, CuSO4 was 
added as a source of Cu+2 to be incorporated into the enzyme structure. Given that low 
copper incorporation was achieved when working at 1 µM CuSO4 concentrations (Table 
24), the use of higher amounts of CuSO4 was explored. Despite copper is known to be 
toxic for bacteria [542–544], herein used concentrations were seemingly non- toxic and, 
indeed, higher yields were achieved when the highest CuSO4 concentrations were used 
(Table 20). However, adding extra copper didn’t improve copper incorporation and, in 
fact, led to lower percentage of enzyme molecules including the metallic cofactor (Table 
25) and, subsequently to lower activity (Table 30). This could be due to the presence of 
impurities containing divalent cations in CuSO4 preparations that could prevent copper 
atoms from binding to the protein. In case that was the case, a dialysis was performed 
involving the removal of metallic atoms with 2,2′-dipyridine and addition of CuSO4 to 
reload the protein with copper. Unfortunately, dialysis was not effective, leading to a 
reduced percentage of enzyme molecules loaded with the metallic cofactor (Table 26) and 
to reduced lysyl oxidase activity (Table 31). This could be due to an improper folding of 
the protein during dialysis, thus hindering the incorporation of the metal. 
Given that the activity of soluble LOX02 was low in all cases, the purification of the 
enzyme from inclusion bodies was explored. Overexpressed proteins are commonly 
accumulated in the form of inclusion bodies, insoluble aggregates of misfolded or 
partially-folded proteins [545,546]. Despite improper protein folding and the need to 
perform time-consuming refolding protocols, inclusion bodies are actually a tool for 
obtaining recombinant proteins at high purity [546]. LOX02 from inclusion bodies was 
purified in two elutions in order to maximize the amount of recovered protein (Table 22). 
Both fractions were independently characterized and the second elution was consistently 
found to contain more copper (Table 27) and to be more active (Table 32) than elution 1. 
Refolding of LOX02 in second elutions led to a striking increase in copper content (Table 
28) but didn’t lead to an improvement regarding protein activity (Table 33).  
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The presence of the LTQ cofactor in soluble LOX02 was assessed by spectrophotometry 
and Western Blot. Although LTQ couldn’t be detected by spectrophotometry (Figure 67), 
Western Blot revealed weak staining for quinones (Figure 68a), suggesting that a low 
percentage of the enzyme molecules developed the LTQ cofactor, the active site of the 
enzyme [336,453]. LTQ is formed by autocatalysis upon a copper atom is properly 
incorporated into the enzyme [452,536]. A low copper content is then likely to result in 
low abundance of LTQ and thus low activity.  
In vivo, LOX binds copper through specific histidine residues [451,536]. Free histidine 
has been shown to bind copper with high affinity, competing with proteins like albumin, 
which plays a role in copper transport [547], for the incorporation of the metallic atom 
[548], being histidine even able to remove copper bound to albumin [549]. It is feasible to 
think, then, that histidine residues in the His-tag would compete with those in LOX 
sequence for copper binding. Thus, it is hypothesized that the copper content quantified 
for LOX02 would correspond both to those copper ions bound to LOX02 specific residues 
and to those bound to the His-tag, with the latter not contributing to the development of 
LTQ . This would explain why soluble LOX02 produced with 1 µM CuSO4 (Table 25 and 
Table 30) and LOX02 from inclusion bodies in second elutions (Table 27 and Table 32) 
contain similar amounts of copper but possess clearly differing levels of activity, or why 
refolding LOX02 results in a mean copper content above 200% (Table 28) and in an 
unmodified enzymatic activity (Table 33). A copper content-activity correlation couldn’t 
be established. This might be due (i) to batch-to-batch differences, and (ii) to copper 
randomly binding to histidines either in the specific binding sites or in the His-tag, the 
presence of which may additionally lead to protein misfolding [550], which in turn may 
hinder specific copper incorporation. The removal of the polyhistidine tag by enzymatic 
proteolysis [551] seems an appealing approach to determine whether limited copper 
incorporation is related to the tag or to the expression/purification system itself. 
This chapter illustrates our efforts to obtain active lysyl oxidase for the production of 
highly biomimetic hydrogels. Despite we achieved the production and purification of 
recombinant human LOX with a copper content and activity higher than those found in the 
literature [483,485], the insolubilization of ELRs was never achieved. Further work is 
required to yield a more efficient system (hundreds of mg/l of culture are commonly 
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achieved for recombinant proteins) allowing the production of highly active LOX feasible 
to be used to produce scaffolds for tissue engineering. 
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5.4 SUPPLEMENTARY DATA 
 
          
Table 34. Summary of the tests performed to adjust protein overexpression and 
purification conditions. C.T.: culture temperature; O.T.: overexpression temperature; O.N.: 
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overnight; O.t.: overexpression time; R.B.T.: resin binding temperature. Purification method 1: 
centrifugation in tube; 2: centrifugation in spin column; 3: centrifugation in tube + centrifugation 
in spin column; 4: centrifugation in tube + gravity-flow in spin column. 
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Conclusions 
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6.1 CONCLUSIONS 
1. The production of hydrogels by EDC-mediated catalysis can be successfully achieved 
through a single-step reaction in mild conditions without the need of using NHS as a 
stabilizing agent. 
2. Citric acid can be used both as a biocompatible crosslinker and a bioactive molecule 
providing hydrogels with calcium phosphate nucleation capacity.  
3. Herein developed reaction can be used to produce hydrogels as long as polymers to be 
crosslinked possess –NH2 groups and a low –COOH/-NH2 ratio.  
4. EDC-catalyzed crosslinking with citric acid can be used to control polymer aggregation 
and thus to tailor the architecture of so-produced hydrogels, while polymer concentration 
is useful to their mechanical properties.  
5. EDC-catalyzed crosslinking with citric acid seems not to involve –COOH groups from 
aspartic acid in RGD tripeptides, thus preserving the integrity of cell adhesion motifs. 
6. The degradation products of citric acid-crosslinked hydrogels are biocompatible, thus 
not altering MSCs behavior upon in vivo degradation. 
7. Both mechanically-tailored and non-tailored hydrogels are biocompatible and able to 
integrate into native bone in vivo and to be at least osteoconductive, allowing bone 
formation by intramembranous ossification. 
8. Mechanically-tailored hydrogels seem not to be superior to their non-tailored 
counterparts as to osteogenic potential in vivo, probably due to hindered cell invasion or to 
a non-osteogenic combination of chemical and physical signals. 
9. The effect of single scaffold signals, either in 2D or 3D, on cell behavior needs to be 
considered a proof of concept given the complex and synergistic nature of ECM signals in 
vivo. 
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10. Despite having obtained recombinant human LOX with improved copper content and 
activity, it was not enough to achieve the insolubilization of ELRs. Thus, novel 
overexpression and purification systems are required to achieve highly active LOX to be 
used to produce scaffolds for in situ bone tissue engineering. 
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